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ABSTRACT OF THE DISSERTATION
Anti-Inflammatory Effects of Adipose-Derived Mesenchymal Stem Cells
for Flexor Tendon Healing
by
Cionne N. Manning
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2013
Professor Stavros Thomopoulos, Chairperson

Despite advances in surgical techniques over the past three decades, tendon repairs remain prone
to poor clinical outcomes. While previous attempts to improve flexor tendon healing have
focused on the later stages of healing (i.e., proliferation and matrix synthesis), the early
inflammatory phase of tendon healing remains poorly understood and its modulation during
healing has not yet been studied. The overall goal of this work is therefore to determine whether
flexor tendon healing can be enhanced through modulation of the inflammatory environment
after surgical repair.

To meet this objective, the inflammatory response after flexor tendon injury and repair was first
characterized to help identify inflammation-related targets for future treatments.

Temporal

changes in immune cell population and gene expression of inflammation-, matrix degradation-,
and extracellular matrix-related factors were examined. Of the observed changes, the most
dramatic effect was the greater than 4000-fold up-regulation in the expression of the pro-

xi

inflammatory factor IL-1β. While some inflammation is essential for healing to occur, such high
levels of pro-inflammatory cytokines may result in collateral tissue damage and impair tendon
healing.

To examine the effect of inflammatory cytokines on tendon fibroblasts, the native cell type that
must eventually re-build the injured tendon, we established two in vitro models of inflammation:
one induced by exogenous IL-1β and one induced by macrophages (the primary cellular source
of IL-1β). We found that IL-1β and other pro-inflammatory cytokines secreted by macrophages
induce further up-regulation of pro-inflammatory factors by tendon fibroblasts. Furthermore,
exposure of tendon fibroblasts to an inflammatory environment led to up-regulation of factors
related to matrix degradation and down-regulation of factors related to extracellular matrix
formation. These changes in expression are likely detrimental to tendon healing in vivo.

In an effort to reduce the negative effects of inflammatory cytokines on tendon fibroblasts,
adipose-derived mesenchymal stem cells (ASCs) were incorporated into the two in vitro models
and their ability to modulate inflammation was investigated.

While ASCs were unable to

counteract the effects of IL-1β directly, ASC co-culture with macrophages successfully
suppressed the negative effects of macrophages on tendon fibroblasts. FACS analysis revealed
that ASCs induced a phenotypic switch from a pro-inflammatory macrophage phenotype to an
anti-inflammatory macrophage phenotype, thus resulting in exposure of tendon fibroblasts to
fewer pro-inflammatory cytokines.

xii

In order to translate these in vitro findings in vivo, a surgically manageable scaffold capable of
delivering and retaining ASCs at the repair site was developed. The fibrin/nanofiber scaffolds
were well-tolerated in the in vivo flexor tendon repair setting and successful delivery of ASCs
was achieved. Pilot data demonstrated promise with this approach, as demonstrated by downregulation of IL-1β and MMP1 in the ASC treated animals. However, the pilot study was
underpowered, and additional animals and assays are required to fully evaluate the effect of
ASCs in vivo.

xiii

Chapter 1 - Introduction
1.1

Intrasynovial flexor tendon healing

Extensive surgical repair is commonly required to treat flexor tendon injuries. These repairs are
frequently associated with poor clinical outcomes1–4. One of the major causes leading to loss of
hand function after injury and repair is the development of repair-site elongation and rupture5,6.
Failure of the repair site to accrue strength within the first three weeks after surgery is the major
factor leading to rupture4,6–11. It has been reported that 13% of flexor tendon repairs rupture
completely and another 48% of repairs develop repair-site elongation or gapping5. Gaps greater
than 3 mm are directly correlated with decreased structural properties of the repair site5.
Moreover, adhesion formation within the digital sheath is another major factor leading to loss of
hand function5,6,10,12–15. Thus, efforts to improve flexor tendon healing aim to address two
contrasting goals: 1) reduction of adhesions, and 2) increased ECM synthesis at the repair site.

Despite advances in surgical techniques over the past three decades, tendon repairs remain prone
to poor clinical outcomes16.

Previous attempts to improve tendon repair have focused on

inhibiting adhesion formation within the digital sheath and accelerating cell proliferation and
matrix production at the repair.

While rehabilitation protocols1–4,17–30 and surface

modifications9,31–57 have successfully reduced adhesion formation and improved tendon gliding
within the sheath, tendon repairs remain prone to rupture due to failure of the tendons to accrue
strength within the first 3 weeks post-operatively. In an attempt to accelerate cellular activity
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and matrix synthesis, growth factors have also been utilized7,8,15,23,27,28,58–89. This approach,
however, has only had limited success.

These prior attempts at improving tendon healing have focused on the later stages of healing.
The early inflammatory phase of tendon healing (i.e., the first week after repair) is poorly
understood and its modulation during healing has not yet been studied. While it is clear that
some inflammation is essential for proper healing90,91, excessive levels of pro-inflammatory
cytokines may result in collateral tissue damage and, thus, may be detrimental to tendon
healing92–96. Studies of tendon-to-bone healing suggest that altering the inflammatory response
either through direct blockade of specific pro-inflammatory factors94 or by fine modulation of the
immune cell population92,93,97 may be advantageous to tendon healing.

1.2

Natural course of tendon healing

Wound healing is classically characterized as four overlapping, yet distinct, phases: haemostasis,
inflammation, proliferation, and remodeling. Immediately upon repair, fibrin and inflammatory
cells fill the repair site98–111. Within the first 2-3 days, the epitenon cells (i.e., fibroblastic cells
on the tendon surface) begin to proliferate, resulting in a thickening of the epitenon layer.
Erythrocytes, macrophages, and other inflammation-related cells remain at the repair site 3 days
post-operatively6 and granulation tissue begins to form as early as day 4 post-operatively98–111
(Figure 1.1).
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Figure 1.1:

Pictorial of the haemostasis/inflammatory phase of cutaneous wound healing.

Tendon repair during this phase of healing is similar. Reproduced with permission by Reinke et
al.112

Between days 7 and 9, extrinsic fibroblasts from the surface of the tendon begin to migrate into
the repair site and deposit small diameter collagen fibers, forming a callus between the tendon
stumps98–111. The collagen fibers are initially oriented perpendicular to the longitudinal axis of
the tendon, implying an origin from the surface of the tendon98–111. At this point (days 7-14)
early indications of vascularization are evident103. Tendon fibroblasts (TFs) from within the
tendon proper begin to proliferate between days 14-21 and extend into the callus by the fourth
post-operative week (Figure 1.2).

3

Figure 1.2: Pictorial of the proliferative phase of cutaneous wound healing. Tendon repair
during this phase of healing is similar. Reproduced with permission by Reinke et al.112

Fibroblasts within the gap re-align by days 21-28 and become oriented in the longitudinal axis of
the tendon and newly synthesized collagen is laid down longitudinally98–111. Newly formed
collagen continues to mature, cross-links form and mature, and the repair begins to accrue
strength by 9 weeks113 (Figure 1.3). By 12 weeks, repaired tendons regain approximately one
third of their original ultimate tensile load113.

4

Figure 1.3: Pictorial of the remodeling phase of cutaneous wound healing. Tendon repair
during this phase of healing is similar. Reproduced with permission by Reinke et al.112

1.3

Previous efforts to improve flexor tendon healing

1.3.1 Rehabilitation protocols for improved range of motion
Extensive research supports the concept that manipulation of the mechanical environment (i.e.
rehabilitation) post flexor tendon repair can enhance the healing process. Mechanical load may
enhance tendon healing through two mechanisms: (1) direct stimulation of TFs and (2) motion of
the tendon, preventing accrual of adhesions between the tendon and its sheath. It is well
established, both in vitro and in vivo, that TFs are responsive to mechanical load. Both static and
cyclic load have been shown to promote cellular activity. Additionally, Hannafin et al. used
stress-deprived tendon explants to illustrate the necessity of load for normal tendon mechanics
and morphology. A gradual decline in tensile modulus was observed in stress deprived tendons
compared to loaded controls. Cellularity, cell morphology, and collagen alignment were also
5

significantly affected by stress deprivation17. Furthermore, Slack et al. demonstrated increased
protein and DNA synthesis in loaded tendon explants compared to unloaded18.

Thus,

manipulation of the mechanical loading environment during healing may improve tendon healing
by stimulating cellular activity during the early post-operative period. Several groups have
applied this concept in experimental and clinical studies1–3,19–24 by employing one of two distinct
rehabilitation protocols – active and passive motion rehabilitation. In both regimes, cyclic
excursion of the tendon through the sheath inhibited the formation of adhesions between the
tendon and its sheath, leading to improved gliding of the tendon and enhanced range of motion
of the repaired digit. The key difference between these two types of rehabilitation regimens,
however, is the amount of load exerted across the repair during the exercises.

During active

motion rehabilitation, the patient performs the exercises unassisted, which requires muscle
activation and, thus, produces high loads across the repair. During passive motion rehabilitation
(Figure 1.4), on the other hand, a physical therapist manipulates the digit through flexion and
extension. Since this does not require muscle activation, the loads applied across the repair are
much lower.

Figure 1.4: Schematic of post-operative rehabilitation in the canine animal model. A) The
operated-on forelimb is immobilized in a spica cast. B) The wrist of the forelimb is accessed by
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a removable portion of the cast.

C) Rehabilitation consisted of repetitive digital flexion-

extension with the wrist flexed. Reproduced with permission by Silva et al.24

While both passive and active motion rehabilitation protocols have been successful in
stimulating adhesion-free healing3,19,20211,2,22,23, there appears to be an increased risk of repair site
gapping or rupture during active motion rehabilitation. One study showed improved clinical
outcomes with active motion rehabilitation. However, due to the variability that is introduced
with active motion, high rupture rates have been reported.

Gelberman and Woo showed that timing of rehabilitation is critical. They found that early
passive mobilization led to enhanced tensile properties and range of motion compared to delayed
mobilization or immobilized digits22,23. Takai et al. found that frequency of mobilization also
plays a key role. Tendons that received the high-frequency protocol (i.e. 12 cycles/min of
controlled passive motion for 5 min/day) showed significantly higher tensile properties than
those that received the low-frequency protocol (i.e. 1 cycle/min for 60 min/day)21.

Based on these studies, early mobilization regimens that emphasize high frequency, cyclic
excursion of at least 1.7mm within the sheath at low-loads (i.e. passive motion) are
recommended1,21–24.

Although recent modifications in rehabilitation protocols have proven

highly effective in reducing adhesion formation, due to a lack of strength at the repair site, the
tendons remain susceptible to ruptures1–4,22,24,25. As mechanical (rehabilitation) approaches for
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improving the repair have been exhausted, clinical and experimental studies suggest that future
strategies be aimed at accelerating the repair process by altering the biological environment26–30.

1.3.2 Surface modifications for enhanced tendon gliding
Digital function relies heavily on the ability of the tendon to glide within its sheath. Adhesion
formation between the repaired tendon and its sheath effectively limits tendon excursion within
the sheath and, thus, greatly hinders the range of motion of the repaired digit. Although proper
rehabilitation can significantly reduce adhesion formation, increased gliding resistance remains a
major concern after tendon repair.

Uchiyama and Sun both showed that uninjured tendons are able to glide smoothly within the
digital sheath due to a low-friction contact that is created in part by hyaluronic acid (HA). They
found that hyaluronidase treatment, which effectively strips away all HA from the tendon
surface, led to increased gliding resistance of the tendon within the sheath41,42. Based on this and
other studies, treatment of injured tendons with HA has been extensively investigated9,31–45,47–49.
Nishida et al. soaked tendon grafts in hyaluronic acid prior to in vivo implantation and
demonstrated enhanced gliding properties compared to untreated controls34. Similarly, Amiel et
al. demonstrated positive effects of HA treatment49.

While most initial studies showed some beneficial effect of HA on tendon gliding, some studies
were difficult to interpret49,51–55. These inconsistent results may be attributed to the insufficient
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coating method. Simply soaking the tendons in HA may lead to rapid clearance of the lubricant
from the tendon surface. Thus, several groups have used carbodiimide derivatization to modify
hyaluronic acid (cd-HA) so that the HA can be chemically bound to the tendon surface35,38,43–47
and provide a more long-term gliding surface38,56. Yang et al. found that ex vivo tendons treated
with cd-HA-gelatin displayed enhanced gliding ability after the 50th loading cycle compared to a
simple-HA treatment (i.e. unmodified hyaluronic acid) and compared to control. Zhao et al.
found similar results in vivo using autologous tendon grafts38. Lubricin, another key component
of flexor tendon lubrication has also been shown to play an important role in minimizing
adhesion formation36,37,39,40 (Figure 1.5).

Figure 1.5: Gliding resistance for the peroneus longus tendons after 1000 cycles was decreased
with various surface modifications: cd-gelatin, cd-HA-gelatin, and cd-gelatin+lubricin
treatments. Reproduced with permission by Taguchi et al.39
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Through the implementation of both natural and synthetic surface modifications31–49, significant
improvements in gliding function of the tendon within its sheath has been achieved. However,
due to failure of the tendons to accrue strength during the first 3 weeks post-operatively, repaired
tendons remain at risk for gap formation and rupture.

1.3.3 Growth factor-based therapies for enhanced tendon healing
Rehabilitation and tendon surface coating methods have led to significant improvements in postrepair range of motion. However, they have not let to improvements in repair site strength.
Recent attempts to improve tendon healing have therefore focused on biological manipulation of
the wound environment via the use of growth factors. Growth factors are powerful regulators of
biological activity that are naturally synthesized and released into the wound environment
following injury and repair58–62. However, the naturally synthesized growth factors appear to be
insufficient to restore the tendon to its pre-injury status in terms of strength and stiffness.
Therefore, in an effort to promote cellular activity and matrix synthesis and, thus, enhance the
strength of the healing tendon, researchers have attempted to deliver exogenous growth factors,
namely, platelet derived growth factor BB (PDGF-BB), basic fibroblast growth factor (bFGF),
and transforming growth factor beta (TGF-β) to the repair site in order.

Due to the ability of PDGF-BB to promote cell proliferation in vitro23,62, PDGF-BB has been a
popular growth factor for tendon and ligament healing therapies.

Several investigators report

increased fibroblast proliferation in vivo when stimulated with PDGF-BB63,64.
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In addition,

PDGF-BB delivery to injured tissues in both ligament and skin wounding models led to
substantial improvements in enhanced tensile properties60,63–65.

Similarly, bFGF has also been effective in promoting cell proliferation27,28,62 and collagen
production27,28. In one study, canine anterior cruciate ligaments (ACLs) were injured using a
biopsy punch and bFGF-impregnated pellets were sutured into the defects. After 6-24 weeks of
healing, the ACLs that were treated with bFGF exhibited enhanced healing potential. bFGF
treatment led to neovascularization and improved collagen fiber orientation at the repair site66.

Investigators have also extensively researched TGF-β for enhanced tendon healing. TGF-β1 has
been shown to effectively promote cell proliferation and ECM synthesis as well as increase the
strength and stiffness of the repair site in medial lateral ligament and skin wounding models60–65.
However, TGF-β1 has also been implicated in adhesion formation67.

Taken together, these studies suggest that the use of specific growth factors may be beneficial for
tendon and ligament healing. However, the use of growth factors is complicated. Woo et al.60
and Chan et al.27,28 highlight the importance of dosage, while others indicate that the residence
time of the growth factors is also a mitigating factor68–70. Bolus application of growth factors
typically leads to clearance of the growth factor from the wound site within 48 hours68. Since
tendons are pauci-cellular, they rely on the migration of fibroblasts from surrounding tissue,
which typically takes 2-3 days. Thus, growth factors delivered by a bolus injection at the time of

11

surgical repair may be cleared before they are able to stimulate the cells of interest and, thus,
may have limited effectiveness.

To prolong the residence time of the growth factors, a variety of different biomaterials that bind
the cytokines of interest to a biocompatible matrix have been utilized66,69–83. For example, a
novel growth factor delivery system developed by Sakiyama-Elbert and colleagues has been
shown to significantly prolong the release of heparin-binding growth factors86,87,114,115. Using
this delivery system, both PDGF and bFGF were successful in stimulating TFs to proliferate and
produce collagen in vitro86–89. In vivo, sustained delivery of PDGF-BB via a heparin/fibrin based
delivery system (HBDS) led to enhanced biological activity (as demonstrated by increases in
total DNA, collagen crosslinks, and gene expression related to tendon regeneration and
remodeling) and improved range of motion and excursion of the treated tendons compared to
controls (i.e., tendons that received the HBDS alone)7,8,86 (Figure 1.6). However, sustained
delivery of PDGF-BB was unsuccessful in increasing the structural properties of the tendon (e.g.,
strength and stiffness). On the other hand, bFGF was actually detrimental to tendon healing15.
Sustained delivery of bFGF to healing tendons led to increased scar formation and, thus, led to
inferior range of motion compared to controls. Furthermore, while TGF-β3 improved healing in
a rotator cuff model (Appendix)116, it has been shown to be detrimental in the context of flexor
tendon healing. Specifically, suppression or deletion of TGF-β led to increased range of motion
in the flexor tendon repair model29,117.

Thus, despite some promising results, it is clear that

these growth factors are not sufficient to enhance the strength of flexor tendon repair.
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Figure 1.6: Delivery of PDGF-BB via a heparin-binding delivery system at the time of flexor
tendon injury and repair significantly enhanced range of motion and tendon excursion of the
repaired tendon. CTL: Control/Repair-only; DS: Delivery System; PDGF: DS + PDGF; NORM:
normal/uninjured. Reproduced with permission by Thomopoulos et al.118

1.4

The role of inflammation in chronic and acute tendon injuries

Previous attempts to improve tendon healing have focused on the later stages of tendon
healing98–111,113,119–121. The early inflammatory phase (i.e., the first week after repair) of tendon
healing is poorly understood and its modulation during healing has not yet been studied. Classic
flexor tendon repair studies by Potenza and Gelberman in the 1960s and the 1980s, respectively,
described inflammatory cells at the site of repair as early as 1 day post-operatively. However,
the details of the cell types present and the temporal changes in those cell populations were not
described98,102.
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1.4.1 The role of inflammation in chronic tendinopathies
Recent results in a variety of tendon models indicate that the predominant cell types that
infiltrate injured tendons within the first 24 hours are macrophages, monocytes, and
neutrophils97,122–129.

Millar et al. collected biopsy samples of pathologic subscapularis and

supraspinatus tendons from human patients undergoing arthroscopic shoulder surgery and
evaluated the samples immunohistochemically to identify the cell populations present.
Macrophages (positive for the cell markers CD68 and CD206), T cells (positive for the cell
marker CD3), mast cells (positive for mast cell tryptase), and endothelial cells (positive for the
cell marker CD34) were quantified. The authors found significantly greater macrophage, mast
cell, and T-cell expression in both torn supraspinatus tendons and matched subscapularis tendons
compared to normal controls. The authors also found that the extent of inflammatory cell
infiltration was inversely correlated to the size of the rotator cuff tear (i.e., smaller tears had
more cell infiltration than larger tears), indicating that the infiltration of inflammatory cells
occurs early in human tendinopathies130. Studies by Schubert et al.131 and Scott et al.132 provide
additional evidence for early inflammatory cell infiltration in tendinopathies. Schubert et al.
found increased numbers of macrophages and lymphocytes in samples collected from patients
presenting with Achilles tendinosis for several months131. Scott et al., however, examined
tissues from patients presenting with Achilles pain and tenderness for an average of 22 months
and did not identify many macrophages or lymphocytes. Instead, the authors reported mast cells
as the predominant cell type132.

Taken together, these studies provide further evidence that macrophages and lymphocytes
predominate in early human tendinopathies. Furthermore, Millar et al. identified a significant
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up-regulation of pro-inflammatory cytokines and apoptotic genes associated human rotator cuff
tendinopathies126. Tendon biopsies were collected from patients at the time of surgery and were
analyzed for gene expression using semi-quantitative reverse transcription polymerase chainreaction. The authors observed increased expression of tumor necrosis factor alpha (TNFα),
macrophage inhibitory factor, and interleukins 18, 15, and 6 in tendinopathic samples compared
to controls.

The subsequent secretion of these cytokines was confirmed using

immunohistochemistry. Significant up-regulation of the apoptotic mediators caspase 3 and 8
also was observed. This increased expression of pro-inflammatory cytokines and apoptotic
genes is associated with the large influx of inflammatory cells reported in early human
tendinopathies.

Pro-inflammatory cytokines have also been reported in inflamed equine tendons. Hosaka et al.
found significant up-regulation of interleukin-1 alpha, interleukin-1 beta (IL-1β), TNFα and
interferon gamma (IFNγ) in equine tendinosis133. Unlike human models, animal models allow
for a time course of cell infiltration to be determined. Using a rodent Achilles tendon model of
tendinopathy, Marsolais et al. report a 46- and 18-fold increase in neutrophils and proinflammatory macrophages, respectively, 24 hours after collagenase-induced tendinopathy. By
day 3, the number of neutrophils decreased by 70%, whereas the number of macrophages
remained constant. Neutrophils returned to control levels by day 7, while macrophages did not
return to normal levels until day 14124.
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1.4.2 The role of inflammation in acute tendon repairs
Neutrophils and macrophages have also been identified as the predominant inflammatory cells
types after tendon-to-bone repair97,125. Macrophages in particular have been implicated in the
early healing process.

Classical macrophages, also called M1 or type 1 macrophages are

recruited from circulating blood monocytes and are activated by IFNγ and/or lipopolysaccharides
(LPS) (Figure 1.7). Upon activation, they secrete other pro-inflammatory cytokines such as IL1β, TNFα, interleukin-12 (IL-12), and nitric oxide (NO).

A second type of macrophage, called

M2 or type 2, is activated by interleukin-4 (IL-4) and/or interleukin-13 (IL-13) and, as such, is
also termed “alternatively activated macrophage” (Figure 1.8).

M2 macrophages play a

distinctly different role than M1 macrophages. M2 macrophages secrete the anti-inflammatory
factor IL-10 and are involved in the regeneration of damaged tissues124,134–151. Macrophages can
be identified by the expression of certain surface markers (e.g., CD11b, CD14, F4/80 (in mice),
EMR1 (in humans)) using flow cytometry or immunohistochemical staining.

CD206 and

CD301, however, are specific to M2 macrophages and, thus, are generally used to differentiate
between M1 and M2 macrophages.

The ED1 and ED2 antigens are also widely used to

differentiate between the two phenotypes.

Type 1 macrophages are ED1+ and type 2

macrophages are ED2+92,93,97,124,152–155.
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Figure 1.7: Classically- vs. alternatively-activated macrophages.

Classically activated

macrophages or M1 macrophages are generated by activating circulating blood monocytes with
IFNγ and/or LPS. They secrete IL-1β, TNFα, IL-6, and NO and are ED1+ and are generally
considered pro-inflammatory. Alternatively activated macrophages or M2 macrophages are
activated by IL-4 and/or IL-13 and secrete IL-10. They can be identified as CD206+, CD301+,
or ED2+ and are considered to be anti-inflammatory and pro-regenerative.

Additional studies in an ACL tendon-to-bone repair model suggest that excessive inflammation
may be a key factor leading to poor clinical outcomes and that inhibition of the naturally
occurring inflammatory response may be beneficial for healing92,93,97. Based on the observations
that a large influx of M1 macrophages occurs in the bone tunnel during the early stages of ACL
healing97,128, Hayes et al. hypothesized that the macrophages may contribute to the formation of
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scar tissue following ACL reconstruction. To test this hypothesis, the authors treated rats with
clodronate (a bisphosphonate that selectively induces macrophage apoptosis) after ACL
reconstruction. The animals were sacrificed 7, 14, 28, and 42 days post-operatively and tissues
were analyzed histologically and biomechanically. The authors reported a significant reduction
in the number of macrophages and the amount of TFG-β at the repair site in the samples that
received the clodronate treatment. Macrophage-depleted samples also exhibited reduced scar
tissue formation and increased collagen fiber organization, osteoid formation, and mineral
apposition rate compared to controls at all timepoints. Furthermore, the specimens treated with
clodronate displayed significant improvements in biomechanical properties.

The authors

concluded that macrophages can inhibit the healing potential of ACL repairs and that modulating
inflammation may prove beneficial for tendon-to-bone healing92.

Other studies found that immobilization of the knee after ACL reconstruction led to improved
mechanical properties via a shift in macrophage phenotype. Dagher et al. hypothesized that
immobilization of the ACL after repair would accelerate resolution of acute inflammation and
enhance the healing process. An external fixation device was used to immobilize the knees of
rats after ACL reconstruction. A mobilized group was used as control. The animals were
allowed 2-4 weeks of healing before sacrifice. Analysis of the ACL tendon-to-bone insertion
sites showed a switch in macrophage phenotype due to immobilization.

Whereas the

macrophages found at the repair site of mobilized rats were of the pro-inflammatory M1
phenotype, immobilization led to a decrease in M1 macrophages and an increase in antiinflammatory, pro-regenerative M2 macrophages (Figure 1.8). The phenotype switch led to
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improved tendon-to-bone integration, as evidenced by reduced scar tissue formation, increased
collagen fiber organization, and enhanced biomechanical properties93.

Figure 1.8: Immobilization of knees after ACL repair led to decreased levels of ED1+ cells (i.e.,
M1 macrophages) and an increase in ED2+ cells (i.e., M2 macrophages) compared to controls.
Reproduced with permission by Dagher et al.93

Lastly, Gulotta et al. found that suppression of the pro-inflammatory cytokine TNFα in a rat
rotator cuff model led to improved tendon-to-bone healing at the early post-operative
timepoints94. Upon surgical repair of the supraspinatus tendon, experimental groups received 3.0
mg/kg of pegylated soluble tumor necrosis factor receptor type I every other day for a total of 3
doses. The control group received saline solution using the same dosing schedule. Animals were
sacrificed 2, 4, and 8 weeks post-operatively and histologic and biomechanical assessments were
performed. Immunohistochemical staining verified the efficacy of the TNFα blockade. The
authors reported decreased TNFα staining in the experimental group at 4 and 8 weeks. Fewer
M1 macrophages were evident at 4 weeks compared to controls and enhanced biomechanical
properties were observed at both 2 and 4 weeks post-operatively. No differences were noted in
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biomechanical or histologic properties by 8 weeks. This study suggests that TNF-α blockade
may enhance tendon-to-bone healing at the early post-operative timepoints, potentially through
the suppression of M1 macrophages94.

Taken together, these results suggest that classically activated macrophages (M1 macrophages)
may impede tendon healing. While some inflammation is critical for clearance of dead cells and
tissues from the wound and for chemotaxis of fibroblasts to the repair site,112,156–162 excessive
levels of macrophage-secreted pro-inflammatory cytokines, such as IL-1β and TNFα, may be
detrimental to tendon healing, as they induce matrix metalloproteinase (MMP)-mediated
catabolism of healthy tendon ECM surrounding the wound144,163–165. Thus, modulating the
inflammatory environment (e.g., by reducing the number of M1 macrophages and increasing the
number of M2 macrophages) may be advantageous for tendon healing.

1.5

Mesenchymal stem cell-based therapies to enhance tendon healing

1.5.1 Mesenchymal stem cells for promoting ECM synthesis
Previous growth factor-based efforts were insufficient to significantly improve flexor tendon
healing due to the paucity of cells in intrasynovial flexor tendons. Thus, recent focus has shifted
toward cell-based therapies for tendon repair166–174. For such therapies, mesenchymal stem cells
(MSCs) are a particularly attractive cell type for a variety of reasons. MSCs are multipotent
stromal cells and, thus, have the capability to differentiate along multiple different cell lineages,
including tenogenic, osteogenic, chondrogenic, and adipogenic lineages166,167,169,175–180 (Figure
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1.9). MSCs transplanted at the time of tendon repair could theoretically differentiate into TFs
and produce the ECM needed to enhance repair-site strength and stiffness.

Figure 1.9: Schematic demonstrating the pluripotency of mesenchymal stems cells (MSCs).
MSCs can differentiate along multiple different cell lineages, including tenogenic (tendon),
chondrogenic (cartilage), adipogenic (fat), osteogenic (bone), and myogenic (muscle) lineages.
Reproduced with permission by Uccelli et al.171

Indeed, several recent studies have shown that administration of undifferentiated or predifferentiated MSCs improved histological and biomechanical outcomes in a variety of softtissue repair models84,85,181–199. Young et al. incorporated bone marrow derived MSCs in a type 1
collagen gel that was then contracted onto a biodegradable suture that was used to repair gap
defects in rabbit Achilles tendons. After four weeks of healing, tendons treated with the MSCtreated sutures were two times as strong and stiff as contralateral controls that were repaired with
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unmodified sutures. Increases in cross sectional area and collagen fiber alignment were also
observed84. Similar results were observed by Awad et al. in a rabbit patellar tendon model85,200.
In one study, autologous MSCs delivered in a collagen composite led to an 18-26% increase in
modulus and maximum stress 4 weeks after surgery200. Similar results were observed in a
second study by the same group in which larger patellar tendon defects were created. Although
improved biomechanics were observed, after 26 weeks of healing, the MSC-treated repairs were
still 75% weaker than normal/uninjured tendons. Similarly, Gulotta et al. labeled bone marrowderived MSCs by transducing the cells with adenovirus-mediated LacZ (Ad-LacZ) and delivered
the transduced cells via a fibrin carrier to injured rat rotator cuffs. Although tendons treated with
Ad-LacZ-transduced MSCs exhibited greater β-galactosidase activity at the repair site
(indicating that the MSCs were present and metabolically active), no histological or
biomechanical differences were observed compared to carrier-alone and repair-only controls181.
Based on these disappointing results, subsequent approaches by Gulotta et al. involved
genetically modifying the MSCs to over-express factors believed to be important in the
development of the tendon-to-bone insertion site183,201.

In separate studies, MSCs were

transduced with adenovirus-mediated membrane type 1 metalloprotease (Ad-MT1-MMP)182 and
scleraxis (Ad-Scx)183. In both studies, the authors reported enhanced biomechanical and
histological properties after 4 weeks of healing182,183.

1.5.2 Mesenchymal stem cells for modulating inflammatory environment
Studies have demonstrated that MSCs exhibit potent anti-inflammatory and immunosuppressive
properties. In vivo, MSC delivery has been shown to enhance skin graft survival202–206 and
prevent graft versus host disease (GVHD) after bone marrow transplantation207–209 in various
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animal models. Clinical studies indicate that MSCs may play a role in preventing and treating
chronic GVHD in human patients, but these results have not yet been confirmed by large clinical
trials207,210.

Numerous in vitro studies have helped elucidate the mechanisms behind MSC-derived
immunomodulation170,203,208,211–242.

These studies indicated that MSCs are capable of

suppressing the adaptive immune response via direct suppression of T and B lymphocyte
proliferation (i.e., T and B cells)170,203,208,211–242 (Figure 1.10). Direct co-culture of MSCs with T
cells or B cells has been shown to significantly inhibit the proliferation of the lymphocytes (and
subsequent secretion of pro-inflammatory cytokines) by arresting them in the G1 phase of the
cell cycle222. Indirect co-culture, using transwell plates (i.e., plates that separate the two cell
types with a porous membrane, inhibiting cell-cell contact, but allowing for the diffusion of
soluble factors) revealed similar findings173,203,213,215–219,222,225,226,228,233,234,236,237,239,243–247. MSCconditioned supernatants were also able to inhibit the proliferation of mixed lymphocyte
reactions172,173,217,219,220,227,236,248.

These results indicate that soluble factors secreted by the

MSCs are responsible for the inhibition of lymphocyte proliferation.
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MSC

Figure 1.10: Schematic demonstrating the ability of MSCs to inhibit T and B lymphocytes (i.e.,
T and B cells) via the secretion of various soluble factors (e.g., PGE2, IDO, TGFβ1).
Reproduced with permission by Uccelli et al.171

While it is widely accepted that soluble factors secreted by MSCs are responsible for the
inhibition of T and B cell proliferation, the precise mechanism remains unclear. The factors
most commonly cited include indoleamine 2,3-dioxygenase (IDO)217,220,224,225,248, NO225,226,234,237,
and prostaglandin E2 (PGE2)216,244.

DelaRosa et al. suggested that secretion of IDO (an

intracellular enzyme that catalyzes tryptophan into kynurenine249) by stem cells is required for
the inhibition of immune cells. Using human adipose-derived MSCs (hASCs), the authors
showed inhibition of mixed lymphocyte reactions when in direct or indirect contact with MSCs
and observed a significant decrease in the production of IFNγ, TNFα, and interleukins 2 and 5.
To determine whether IDO was essential, the authors applied 1-methyl-DL-tryptophan (1-MT), a
pharmacological inhibitor of IDO.

They found that hASCs failed to inhibit lymphocyte

proliferation in the absence of IDO. Similarly, the authors used genetically modified hASCs
with silenced IDO enzymes to demonstrate the need for IDO in the suppression of
lymphocytes217. Maby-El Hajjami et al. found similar results using MSCs electroporated with
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IDO-small interfering RNA248. Further investigations by Meisel et al. showed that the depletion
of tryptophan by IDO was the underlying cause of IDO-mediated immunosuppression. The
authors found that T-cell proliferation was restored when tryptophan was added to the mixed
lymphocyte/MSC co-culture224. Ren et al. also verified the need for IDO in human and monkey
MSC-mediated immunosuppression. However, the authors found that IDO was not necessary for
MSC-mediated immunosuppression in cells derived from mice. Rather, the authors reported
nitric oxide (NO) to be the key mediator of MSC-mediated immunosuppression in mice. The
authors used pharmacological inhibitors and neutralizing antibodies against a variety of possible
factors and found that NG-monomethyl-L-arginine (an inhibitor of nitric oxide) restored
lymphocyte proliferation, suggesting that NO was essential for suppression225. Moreover, MSCs
from mice lacking the gene for inducible nitric oxide synthase (iNOS-/- mice), had a reduced
ability to suppress T-cell proliferation234,237. Prostaglandin E2 (PGE2) has also been cited as key
to the immunosuppressive activity of human MSCs211,250–253. Aggarwal et al. found that the
secretion of PGE2 was significantly up-regulated when immune cells were co-cultured with
MSCs.

To determine if PGE2 had a significant role in immunosuppression, the authors

employed two different PGE2 inhibitors (NS-398 and indomethacin). They found that PGE2
inhibition led to a 70% restoration of immune cell proliferation, as well as a significant increase
in the production of pro-inflammatory cytokines TNFα and IFNγ211. Other studies reported
heme oxygenase, hepatic growth factor, and TGF-β as key mediators of MSC-mediated
immunosuppression218,221,232. These results suggest that multiple factors are likely involved in
the immunosuppressive activity of MSCs.

25

Recent evidence suggests that MSCs can also modulate the innate immune response. MSCs
appear capable of reprogramming inflammatory macrophages into an anti-inflammatory
macrophage phenotype136,140,141,244,254–256. In vivo, MSC delivery has been shown to enhance
healing in a variety of injury and disease models where inflammation plays a critical
role140,244,254.

These improvements have been attributed to a shift in the local cellular

environment. Transplanted MSCs appear to reprogram inflammatory M1 macrophages into antiinflammatory pro-regenerative M2 macrophages, leading to a decrease in pro-inflammatory
cytokines (e.g. TNFα, IL-12) and an increase in anti-inflammatory cytokines (e.g. IL-4, IL13)140,244,254. Significant increases in the survival rate of septic mice treated with the MSCs have
been reported216. MSCs have also been shown to enhance healing of spinal cord injuries225 and
dermal wounds226. The beneficial effects of MSCs in these models, however, were eliminated in
the absence of monocytes and macrophages (i.e., macrophage depletion by clondronate).

In vitro, Kim et al. have recently shown that M2 macrophages can be generated by co-culturing
immature (non-polarized) macrophages with MSCs in vitro255,257. Monocytes were isolated from
human blood and bone marrow and cultured with 10% human serum blood for 7 days (without
addition of any cytokines) to generate macrophages. 2x105 MSCs were then added either
directly on top of the monocyte-derived macrophages or in a transwell insert that prevented
direct cell-cell contact, but allowed soluble factors to diffuse through the porous membrane. The
cells were then incubated for an additional 3 to 4 days. Using flow cytometry, the authors
demonstrated a shift toward a M2 phenotype when the monocyte-derived macrophages were cocultured (either directly or indirectly) with MSCs.

Macrophages co-cultured with MSCs

exhibited high-levels of CD206 expression, a marker of alternatively activated macrophages.
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Co-cultured macrophages also expressed high levels of the anti-inflammatory cytokine
interleukin-10 (IL-10) and low levels of the pro-inflammatory cytokine TNF-α compared to
controls.
While several recent studies indicate that the beneficial effects of MSCs on a variety of healing
models can be attributed to the ability of MSCs to reduce inflammation through the recruitment
of M2 macrophages140,244,254,255,257–260, the mechanisms of action remain unclear. Francois et al.
suggested that MSC-secreted IDO is responsible for this phenomenon220 (Figure 1.11).

The

authors found that co-culture of naïve or IFNγ pre-stimulated MSCs with monocyte-derived
macrophages led to a significant increases in the production of IL-10138 (a feature of
M2macrophages). Further analysis showed that the macrophage population became CD206+
after co-culture with MSCs.

These results support the notion that MSCs can reprogram

inflammatory, M1 macrophages into anti-inflammatory, IL-10 producing, M2 macrophages.
Addition of 1-MT (a pharmacological inhibitor of IDO) to the MSC/macrophage co-culture
significantly reduced the amount of IL-10 produced, indicating a possible involvement of IDO in
the differentiation of monocytes into M2, immunosuppressive macrophages220,261.
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Figure 1.11: Proposed mechanism for MSC-mediated monocyte differentiation into M2
macrophages. MSCs, when activated by IFNγ, secrete IDO, which catalyzes the degradation of
tryptophan (TRP) into kynurenine (KYN). Tryptophan depletion and/or metabolites of the
kynurenine pathway mediate the differentiation of monocytes into IL-10 secreting, CD206+
immunosuppressive M2 macrophages. Reproduced with permission by Francois et al.220

Nemeth et al., on the other hand, suggested that PGE2 secretion by MSCs is responsible for
monocyte differentiation into M2 macrophages244. The authors reported increased levels of
cyclooxygenase 2 (COX2, also known as PGE2 synthase) after MSC/macrophage co-culture. To
determine if COX2 played a key role in the shift of macrophages from the M1 to the M2
phenotype, MSCs from Ptgs2−/− mice (i.e., mice lacking PGE2 synthase/COX2) were tested. Coculture of macrophages with MSCs from these mice was unable to produce IL-10. The authors
concluded that activated MSCs produced PGE, which acted to reprogram M1 macrophages into
M2, IL-10 secreting, immunosuppressive macrophages. Nemeth et al. suggest a possible role for
NO in this phenomenon. They showed that when the MSCs and macrophages isolated from
mice lacking the gene for nitric oxide (Nos2-/- mice) were co-cultured, IL-10 production was not
induced. However, the addition of S-nitroso-N-acetylpenicillamine, a nitrosothiol derivative
that releases nitric oxide, was able to restore the ability of Nos2−/− cells to produce IL-10244.
While no clear consensus exists as to the mechanism of action, it is well reported that MSCs are
capable of reprogramming inflammatory M1 macrophages into anti-inflammatory, IL-10
secreting, M2 macrophages.
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1.6

Scope and Procedure of the Dissertation

Studies in tendon-to-bone models suggest that altering the early inflammatory response either
through direct blockade of specific pro-inflammatory factors94 or by fine modulation of the
immune cell population92,93,97 may be advantageous to tendon healing. Based on these studies
and the potential for MSCs to regulate those processes140,244,254,255,257, the overall goal of this
dissertation was to investigate the role of inflammation on flexor tendon healing and the ability
of mesenchymal stem cells to modulate this process. The inflammatory phase of flexor tendon
healing was first characterized using an animal model in order to establish the cytokine profile
time course and to help identify targets for future treatments.

Next, a series of in vitro

experiments were performed to determine whether the high levels of pro-inflammatory cytokines
seen in vivo are detrimental to the native TFs.

Two models of inflammation were developed for

this purpose: one induced by exogenous delivery of the pro-inflammatory factor, IL-1β, and one
induced by M1 macrophages (the primary cellular source of IL-1β in vivo). ASCs were then
incorporated into the two models to explore the ability of ASCs to modulate the inflammatory
environments. The central hypothesis of this dissertation is that ASCs will protect TFs via the
modulation of macrophage phenotypes. It is hypothesized that ASCs co-cultured with proinflammatory macrophages (i.e., M1 macrophages) will prompt the macrophages toward an antiinflammatory phenotype (i.e., M2 macrophages), resulting in fewer pro-inflammatory cytokines,
thus lessening their negative effects on TFs. Finally, a tendon-specific scaffold was developed
for the delivery of ASCs in vivo. The scaffold was used in a pilot study to investigate the ability
of ASCs to enhance flexor tendon healing via modulation of the early inflammatory phase of
flexor tendon healing.
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1.6.1 Specific Aims
Aim 1: Characterize the early inflammatory response after flexor tendon injury and repair and
identify targets for future treatments.
Hypothesis:

Gene expression levels will coincide with the temporal changes in the cell

populations (i.e., TFs vs. inflammatory cells).
Anticipated results: The early post-operative healing response after tendon repair will mirror
that of dermal wound healing in terms of hemostasis and immune cell recruitment.

Pro-

inflammatory factors will be up-regulated during the early stages when immune cells
predominate at the repair site, while ECM genes will be up-regulated at the later timepoints when
fibroblasts infiltrate the wound. MMPs will be up-regulated throughout the course of healing,
but will increase over time as the remodeling phase approaches.
Study Design: Flexor tendon injuries will be created and immediately repaired using repair
techniques identical to those used clinically. Animals will be sacrificed at 1, 3 and 9 days for
gene expression and histologic assessments.

Aim 2: Examine the effects of inflammation on native TFs using in vitro models: (1) induced by
exogenous IL-1β and (2) induced by co-culture with pro-inflammatory macrophages.
Hypothesis: Pro-inflammatory factors, either delivered directly or secreted by macrophages, will
negatively impact TF behavior.
Anticipated results:

IL-1β will induce up-regulation of pro-inflammatory and matrix

metalloproteinase genes and a down-regulation of tendon-specific and ECM genes by TFs.
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Since M1 macrophages are the primary cellular source of IL-1β, co-culture with macrophages
will induce similar changes.
Study Design: TFs will be exposed to exogenous IL-1β and various macrophage phenotypes and
the effect will be examined via gene and protein expression.

Aim 3: Investigate the ability of ASCs to modulate inflammation and its effects on TFs either by
acting directly on the inflammatory cytokine, IL-1β, or indirectly by eliciting phenotypic changes
in macrophage populations.
Hypothesis: ASCs will suppress the negative effects of pro-inflammatory factors (exogenous or
macrophage-mediated) on TFs.
Anticipated results: ASCs co-cultured with TFs in an inflammatory environment induced by IL1β, will either take up IL-1β, effectively reducing the amount of IL-1β in the media, or secrete
anti-inflammatory factors that counteract the effects of IL-1β.

ASCs in co-culture with

inflammation-inducing macrophages will promote a phenotypic switch towards an antiinflammatory, M2 macrophage phenotype, resulting in decreased levels of pro-inflammatory
factors and suppression of the negative effects of M1 macrophages on TFs.
Study Design ASCs will be incorporated into the two in vitro models of inflammation and their
effect on TF gene expression and protein expression will be assessed.
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Aim 4: Develop a tendon-specific scaffold to deliver ASCs in vivo at the time of tendon repair
and investigate the ability of ASCs to enhance flexor tendon healing via the modulation of the
early inflammatory phase of flexor tendon healing.
Hypotheses: ASCs will improve flexor tendon repair by modulating the early inflammatory
phase of healing.
Anticipated results: ASCs delivered at the time of flexor tendon injury and repair will suppress
the early inflammatory response via the recruitment of anti-inflammatory, M2 macrophages as
opposed to pro-inflammatory, M1 macrophages. As a result, genes related to inflammation and
matrix degradation will be decreased in the ASC-treated groups compared to untreated controls.
Study Design: Fibrin/nanofiber scaffolds, either acellular or cellular (i.e., containing 1 million
ASCs) will be implanted at the site of flexor tendon injury and repair in a clinically relevant
canine model. Animals will be sacrificed at 3 and 9 days for gene expression and histologic
assessments.
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Chapter 2 - The Early Inflammatory Response after Flexor
Tendon Healing
2.1

Introduction

Despite improved surgical techniques and rehabilitation protocols over the past few decades,
flexor tendon repairs remain prone to poor clinical outcomes1–4,16, including development of
repair-site elongation and rupture4–11 and adhesion formation within the digital sheath5,6,10,12–15.
Wound healing is classically divided into four overlapping phases: haemostasis (day 0),
inflammation (day 1-7), proliferation (day 3-14), and remodeling (day 7-several weeks)112,156–160.
The first stage, haemostasis, occurs immediately following injury. Vasoconstriction and clotting
factors released by injured cells initiate the formation of a fibrin clot, which serves as a
temporary seal over the injury site. Chemoattractants secreted by injured cells, and activated
platelets within the fibrin clot, initiate the beginning of the inflammation phase112,156–160.
Polymorphonuclear cells (PMNs) are recruited to the wound site within hours of injury to clear
the wound of debris and bacteria.

After 48-72 hours, monocytes infiltrate the wound,

differentiate into macrophages, and control the clearance of dead cells and tissues through
phagocytosis and the production of metalloproteinase proteolytic enzymes (i.e., MMPs), such as
collagenase112,156–160. The third stage, proliferation, is characterized by fibroblast migration,
proliferation, and deposition of extracellular matrix to form granulation tissue112,156–160. During
the fourth and final stage, remodeling, a careful balance between MMP-mediated collagen
degradation and continued synthesis of collagen by fibroblasts, results in reorganization of the
extracellular matrix. The maturation and alignment of collagen fibers during this phase leads to
increased tensile strength of the healing tissue112,156–160.
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Previous attempts to improve tendon repair have focused on the later stages of healing.
Rehabilitation protocols have successfully reduced adhesion formation within the digital sheath
during the proliferative/matrix synthesis phase1–4,17–30 (see Chapter 1, section 1.3.1). Natural and
synthetic surface modifications also have been utilized to enhance tendon gliding and to inhibit
adhesion formation during the proliferative/matrix synthesis phase9,31–57 (see Chapter 1, section
1.3.2). However, due to failure of the healing tendons to accrue strength during the first 3 weeks
post-operatively, the repair remains at risk for gap formation and rupture. Thus, focus has
recently shifted to biological manipulation of the proliferative/matrix synthesis stage to promote
cellular activity and matrix synthesis7,8,15,23,27,28,58–89. Stimulation of cells using growth factors,
however, has had limited success. While platelet-derived growth factor BB (PDGF-BB) and
basic fibroblast growth factor (bFGF) were successful in stimulating tendon fibroblasts (TFs) to
proliferate and to produce collagen in vitro86–89, neither were able to enhance the structural
properties of the tendon when delivered in vivo7,8,15,86. Furthermore, the enhanced cellular
activity stimulated by bFGF led to increased scar formation that was detrimental to tendon
healing15 (see Chapter 1, section 1.3.34). While the later stages of flexor tendon healing have
been previously targeted, the early inflammatory phase (i.e., first week) of tendon healing is
poorly understood and its modulation during healing has not yet been attempted.

The purpose of this study was to characterize the early inflammatory response after flexor tendon
injury and repair in order to help identify targets for future treatments. Using a clinically
relevant large animal model of flexor tendon injury and repair, temporal changes in immune cell
population and gene expression of inflammation-, matrix remodeling-, extracellular matrix-
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(ECM), and differentiation-related factors were examined during the early post-operative period
up to 9 days.

We expect that the early post-operative healing response after tendon repair will mirror that of
dermal wound healing in terms of hemostasis, cell recruitment, matrix deposition and
remodeling112,156–160.

Specifically, we predict that inflammatory cells (i.e., PMNs and

monocytes/macrophages) will dominate the repair in the first few days after repair, with a
corresponding increase in the gene expression of pro-inflammatory factors161,262.

As the

inflammatory cells diminish and fibroblasts begin to infiltrate the wound, we expect that the
expression of pro-inflammatory genes will decrease towards baseline, while the extracellular
matrix- and matrix degradation-related genes will increase.

2.2

Methods

Flexor tendon animal model: All procedures were approved by the Washington University
Animal Studies Committee. Flexor tendon injury and repair was performed in the clinically
relevant canine animal model (N=11)7,8,15,86,99,263. The sheaths of the second and fifth digits of the
right forelimb in the region between the annular pulleys proximal and distal to the proximal
interphalangeal joint were exposed through midlateral incisions. The sheaths were entered and
the flexor digitorum profundus tendons were transected sharply. The tendons were repaired
using surgical techniques identical to those used in humans (4-0 Supramid core suture, 6-0
Proline running epitenon suture). Both the second and fifth digits of the right forelimb were
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repaired. After surgery, the operative limb was immobilized using a fiberglass shoulder spica
cast with the elbow flexed to 90° and the wrist flexed to 70° and a controlled passive motion
rehabilitation protocol, similar to that used clinically, was applied. The protocol consists of two
five-minute rehabilitation sessions performed five days a week starting on the first postoperative
day3,25 The dogs were euthanized on days 1, 3 or 9 post-operatively and the operated tendons
were removed by dissection and prepped for either gene expression analysis (N=3) or histologic
analysis (N=5).

Tendons from the contralateral paw were also dissected to serve as

normal/uninjured controls.

Histology: Upon dissection, tendons allocated for histology were fixed in 4% paraformaldehyde
overnight, embedded in paraffin, and cut into 5 µm sections. To examine the immune response,
sections were stained with hematoxylin and eosin (H&E) and assessed for various immune cells
(i.e., PMNs, monocytes, macrophages) by an independent certified pathologist (Necat
Havlioglu), blinded to group. Fibroblasts were characterized as spindle-shaped cells with an
elliptic nucleus and thin cytoplasm. PMNs were identified as cells containing nuclei with two to
four lobules and a granulated cytoplasm, while cells with a single-lobed or kidney-shaped
nucleus were classified as monocytes/macrophages. A standard scoring system was used to
determine the levels of each outcome (- no prevalence, + mild prevalence, ++ moderate
prevalence, +++ marked prevalence). For overall cellularity and the prevalence of certain cell
types, the number of cells per high powered field (HPF, 20x) was counted and assigned a score
as follows: + <50 per HPF, ++ 51-100 per HPF, +++ 101-150 per HPF, ++++ >150 per HPF.
Vascularity was measured on the following scale: + <5 per HPF, ++ 6-10 per HPF, +++ > 10 per
HPF. All assessments were done using a 20x objective and 12-21 fields of view were averaged.
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The percentage of fibroblasts compared to overall cellularity was also assessed and scored as
follows: + = less than 5%, ++ = 5-50%, +++ > 50%. Sections were also viewed under polarized
light for the assessment of collagen alignment.

Proliferating cell nuclear antigen (PCNA)

staining (Invitrogen, NY) was performed according to the manufacturers’ protocols to access cell
proliferation and apoptosis, respectively.

Gene expression: Tendons allocated for gene expression were dissected and 10 mm sections (5
mm on each side of the repair) were isolated and immediately flash frozen in liquid nitrogen.
RNA was extracted from the tendons using the RNeasy mini kit (Qiagen, CA) following the
manufacturer’s protocol. RNA yield was quantified using a NanoDrop spectrophotometer
(Thermo Scientific, DE) and 500 ng of RNA was reverse transcribed to cDNA using the
Superscript VILO cDNA synthesis kit (Invitrogen Corporation, CA) following manufacturer’s
instructions. Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR)
was performed using SYBR Green chemistry on a StepOnePlus Real-Time PCR System
(Applied Biosystems, CA). All primers for real-time PCR were purchased (Qiagen, CA). Gene
expression changes were measured for genes related to inflammation (IL-1β, TNFα, COX2),
matrix degradation (MMP1a, 1b, 3, 13), extracellular matrix (collagen type 1 (COL1), collagen
type 3 (COL3), lysol oxidase (LOX), decorin (DCN)), and differentiation (scleraxis (SCX),
tenomodulin (TNMD), lubricin (LUB), and vascular endothelial growth factor (VEGF)). Data
was analyzed using the delta delta Ct method.

The results were first normalized to a

housekeeping gene (glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) and then again to
normal/uninjured group. The delta Ct values were compared using a 2-way ANOVA (for
treatment and time), followed by a Fisher’s post-hoc test. Significance was set to p < 0.05.

37

2.3

Results

Inflammation: Overall cellularity at the repair site was significantly increased 1 day postoperatively (Table 2.1). The dominant cell type contributing to this increase in cellularity was
the PMN (Figures 2.1, 2.2, Table 2.1). The majority of the PMNs were within the fibrin clot at
the entrance to the repair. PMNs were also present in the tendon tissue near the surface of the
repair (Figures 2.1, 2.2).

Cellularity

PMN

Mono

Fibro %

Vascularity

Day 1

++

++

-

+

-/+

Day 3

+

+

+

+

-/+

Day 9

+

+

+

++/+++

++

Table 2.1: Histological analysis of the early inflammatory response 1, 3, and 9 days postoperatively. The prevalence and type of immune cells at the repair site was assessed over time.
A standard scoring system was used to determine the levels of each outcome.
Cellularity/PMN/Mono: + <50 per HPF, ++ 51-100 per HPF, +++ 101-150 per HPF, ++++ >150
per HPF. Vascularity: + <5 per HPF, ++ 6-10 per HPF, +++ > 10 per HPF.

Fibroblast

percentage: + = less than 5%, ++ = 5-50%, +++ > 50%. PMN = Polymorphonuclear cells, Mono
= monocytes/macrophages, Fibro% = fibroblast percent compared to overall cellularity, HPF =
High powered field (20x), (N=3-5).
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Repair Surface

Tendon Surface

Repair Center

Tendon Substance

Day 9

Day 3

Day 1

Normal

Overview

Figure 2.1: Representative histologic sections of normal and repaired tendons 1, 3, and 9 days
post-operatively.

The sections were stained with H&E and viewed under brightfield for cell

identification. An overview of a representative section from each timepoint is shown to the left
(4x objective, 2 mm scale bar). Colored squares indicate the regions of interest (repair surface,
tendon surface, repair center, tendon substance) on the overview images and corresponding high
magnification images (20x objective, 200 µm scale bar) are shown to the right with
corresponding border colors.
tendon surface on day 1.

Inflammatory cells are seen infiltrating the repair site via the
The Inflammatory response decreases over time and fibroblasts

invaginate and fill the repair by day 9. New blood vessel formation on the tendon surface is
evident on day 9.
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PMNs

Vascularity

Day 9

Day 3

Day 1

PCNA

Figure 2.2: Representative histologic sections of repaired tendons 1, 3, and 9 days postoperatively. The sections were stained with either H&E or PCNA and viewed under brightfield
for identification of immune cells (PMN), vascularity, and cell proliferation (PCNA). Changes in
cell proliferation were most evident near the surface of the tendon. PMNs (black arrows)
infiltrated the repair site on day 1, but decreased over time. New blood vessel formation was
evident on the surface of the tendon away from the repair site by day 9. Images for PMNs and
vascularity are the same regions as those presented in Figure 2.1 (see border color for region of
image). 40x objective, 200 µm scale bar, (N=3-5).

A corresponding spike in pro-inflammatory genes (TNFα, IL-1β, COX2) was evident. TNFα
was up-regulated 10.6-fold compared to normal, while IL-1β and COX2 were up-regulated a
remarkable 4403- and 837-fold (Figure 2.3).
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Figure 2.3: Fold changes in gene expression of pro-inflammation- and matrix degradationrelated factors relative to normal 1, 3, and 9 days post-operatively. * p < 0.05, † p <0.10, 2-way
ANOVA, significant effect of time (except for TNFα), bars signify Fisher’s post-hoc
comparisons, * by x-axis signifies a significant difference compared to normal tendons, (N=3).

On day 3, overall cellularity remained higher than in normal/uninjured tendon, but was decreased
compared to day 1. A shift in the immune cell population was noted at this timepoint, with fewer
PMNs evident at the repair site compared to day 1 (Figures 2.1, 2.2, Table 2.1). Presumably, this
is why the expression of pro-inflammatory factors, IL-1β and COX2, were down-regulated 2.541

and 4.9-fold, respectively, compared to day 1. TNFα remained up-regulated 6.78-fold. The
most prominent immune cell type by day 3 was from the monocyte/macrophage lineage (Figures
2.1, 2.2, Table 2.1). Macrophages are known to be a major source of IL-1β during wound
healing156,161. Consistent with this, expression levels of pro-inflammatory genes remained
significantly elevated at day 3 compared to normal/uninjured control tendon (IL-1β, COX2, and
TNFα were up-regulated 1743-, 170.52-, and 6.78-fold, respectively, compared to
normal/uninjured tendons) (Figure 2.3). The number of monocytes/macrophages at the repair
site remained stable through day 9 (Figures 2.1, 2.2, Table 2.1); however, IL-1β and COX2
expression continued to decrease, but remained significantly up-regulated compared to
normal/uninjured tendons (924.5- and 26.3-fold for IL-1β and COX2, respectively). TNFα
levels remained relatively constant at this timepoint (8.57-fold greater than normal) (Figure 2.3).
While the expression of inflammatory factors decreased over time, expression levels remained
significantly higher than normal, even 9 days post-repair.

Proliferation: PCNA staining showed proliferation of epitenon cells (i.e., tendon surface cells) as
early as day 1 (Figure 2.2). By day 3, the epitenon was thickened and the tendon surface cells
continued to proliferate. Proliferation of cells deeper in the tendon substance (i.e., endotenon
cells) was also observed on day 3 and continued through day 9 (Figure 2.2).

By day 9,

fibroblasts infiltrated the repair site and filled the gap between the tendon stumps (Figure 2.1,
Table 2.1). Expression of tendon-specific and extracellular matrix genes was significantly downregulated 1 day post-operatively (27.0-, 14.9-, 35.6-, and 24.5-fold for COL1, COL3, SCX, and
TNMD, respectively). As the cellular environment shifted from immune cell-dominant on day 1

42

to fibroblast-dominant on day 9 (Table 2.1), the expression of tendon-specific and tendon
extracellular matrix genes returned to baseline, with the exception of TNMD (Figure 2.5).

Remodeling:

Matrix degradation, as evidenced by MMP expression and polarized light

microscopy, was seen as early as day 1. MMPs 1, 3, and 13 were up-regulated 1634-, 14.7-, and
102.1-fold, respectively, compared to normal/uninjured tendons (Figure 2.3). Polarized light
microscopy revealed rapid loss of collagen fiber organization that was likely related to the upregulation in MMP expression (Figure 2.4).

Normal

Day 1

Day 3

Day 9

Figure 2.4: Representative histologic sections of normal and repaired tendons 1, 3, and 9 days
post-operatively. The sections were stained with H&E and viewed with polarized light to assess
collagen fiber alignment. White regions indicate fiber alignment along the long axis of the
tendon. Dark regions indicate a loss of fiber alignment. Some collagen fiber alignment was lost
as early as 1 day post-operatively. Alignment was further disrupted by day 3 and remained
steady through day 9. 4x objective, 2 mm scale bar, (N=3-5).
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MMPs involved in the degradation of collagen types 1 and 3 (MMP1, MMP13) were further upregulated on day 3 (Figure 2.3) and collagen fiber alignment was further disrupted (Figure 2.4).
By day 9, the expression of MMPs 1 and 13 continued to rise, reaching 24,158- and 493.5-fold
increases compared to normal/uninjured tendon (Figure 2.3). Collagen fiber alignment remained
similar to that of day 3 (Figure 2.4). On day 9, newly formed blood vessels were observed
(Figures 2.1-2.2, Table 2.1). Few (if any) vessels were evident on days 1 and 3 (Figures 2.1-2.2,
Table 2.1). Therefore, the new vessels seen at day 9 were likely a result of the up-regulation of
vascular endothelial growth factor (VEGF, 17.9-fold) observed on day 1 (Figure 2.5).
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Figure 2.5: Fold changes in gene expression of tendon ECM and tendon-specific factors relative
to normal 1, 3, and 9 days post-operatively. * p < 0.05, † p <0.10, 2-way ANOVA, significant
effect of time (except for LOX and TNMD), bars signify Fisher’s post-hoc comparisons, * by xaxis signifies a significant difference compared to normal tendons, (N=3).
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2.4

Discussion

While the proliferation and remodeling stages of flexor tendon healing have been studied in
detail98–111,113,119–121 and subsequently targeted to enhance flexor tendon healing1–4,7,8,15,17–30,58–89,
the early inflammatory phase of tendon healing is poorly understood and its modulation during
healing has not yet been investigated. This study characterized the early inflammatory response
following flexor tendon injury and repair. We examined temporal changes in the cell population
and gene expression of inflammation-, matrix remodeling-, extracellular matrix-, and
differentiation-related factors and found that flexor tendon healing mimics that of dermal wound
healing

in

terms

of

haemostasis

and

the

sequential

recruitment

of

PMNs

and

monocytes/macrophages112,156–160. PMNs infiltrated the repaired tendon as early as one day postoperatively, but were replaced by monocytes/macrophages as the dominant immune cell type by
day 3. By day 9, tendon fibroblasts appeared at the repair site in large numbers. As noted by
others98–101,104–110,120,121, the source of the fibroblasts appeared to be the epitenon cells. The
epitenon cells began to proliferate as early as 1 day post-operatively. By day 3, the epitenon
thickened and the cell proliferation continued. By day 9, fibroblasts invaginated the repair via the
surface of the tendon and filled the gap between the tendon stumps. During this process,
expression of pro-inflammatory and matrix remodeling genes were significantly up-regulated.
TNFα, IL-1β, and COX2 levels spiked as early as day 1, but decreased over time as the cell
population changed from immune cell dominant to tendon fibroblast dominant. In contrast,
extracellular matrix- and differentiation-related genes were significantly down-regulated on day
1, when immune cells dominated the repair, but increased towards baseline values as PMNs
underwent apoptosis and fibroblasts were recruited to the repair site. Finally, MMPs were
significantly up-regulated upon injury and steadily rose over time as macrophages cleared the
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wound of debris and dead tissue and as fibroblasts filled the repair and initiated the remodeling
phase of healing. As expected, the temporal increase in MMP expression coincided with a
decrease in collagen fiber alignment.

Previous characterizations of flexor tendon healing focused on: (1) describing the morphological
changes at the repair site98–111, (2) identifying the cellular source that contributes to tendon
healing98–101,104–110,120,121, and (3) examining the effect of rehabilitation on adhesion
formation113,119. While these studies have been instrumental in informing surgical techniques
and rehabilitation protocols, the early inflammatory process was not carefully characterized.
Potenza merely described the inflammatory response as “red and white blood cells” filling the
repair, but did not provide a detailed description of the exact types of immune cells present or
any temporal changes in the immune cell population98. Gelberman et al. described fibrinous
bridges overlying a “mesh of erythrocytes, macrophages, and other inflammatory-type cells” on
day 3, but earlier timepoints were not investigated102. The expression of inflammatory and
catabolic factors was not described until the past decade. Berglund et al. revealed a significant
spike in the expression of pro-inflammatory factors (IL-1β and COX2) 3 days post-operatively,
but no earlier timepoints were examined264. IL-1β and COX2 levels remained elevated through
day 6, but returned to baseline by day 12. Similarly, the matrix degradation factor, MMP13, was
significantly up-regulated on day 3 and remained elevated through day 24 (with no temporal
changes)264. These results are generally in agreement with the current study; however, they were
obtained in a rabbit flexor tendon-healing model, which is less clinically relevant than the canine
model due to the smaller size of the tendons and the inability to perform passive motion
rehabilitation. In contrast, canine flexor tendons are similar in size to those of humans and a
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passive motion rehabilitation protocol, similar to that used clinically, was applied in the current
study. Furthermore, the current study combined the use of histology and gene expression to
elucidate the cellular source of the gene expression changes.

Regardless, there were a number of limitations to the current study. First, additional timepoints
could be used to better determine when some of these temporal changes occurred, as there
appeared to be a dramatic transition sometime between days 3 and 9. Second, the cellular source
contributing to the gene expression results was a combination of inflammatory cells and
fibroblasts. Therefore, the specific expression patterns for individual cell types remain unknown.
However, histological assessment of the various cell types partly addresses this limitation. The
percentage of fibroblasts (compared to overall cellularity) was estimated based on a
morphological assessment and quantification. Given the high cellularity and the low fibroblast
percentage on day 1, we can postulate that the up-regulation of pro-inflammatory factors at this
early timepoint was primarily due to infiltration of immune cells (i.e., PMNs and
moncoytes/macrophages). Similarly, the initial down-regulation of tendon-specific and tendon
ECM genes is likely due to a diluted fibroblast population.

RNA extracted from

normal/uninjured tendons was mainly from fibroblasts. These cells express SCX, TNMD, COL1,
and COL3. On the other hand, RNA extracted from the repaired tendons on day 1 was mainly
derived from inflammatory cells, which do not express those genes. As the cell population
shifted from immune cell-dominant to fibroblast-dominant, the expression of tendon-specific and
tendon ECM-related factors returned to baseline levels. While the histological assessment of
fibroblast percentage helped to interpret the gene expression data, immunohistochemical
analyses would further elucidate the cellular source of the differential gene expression seen over
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time. Immunohistochemistry also would help verify the translation of these genes into protein.
However, the appropriate canine antibodies are not yet commercially available.

A third

limitation is the lack of protein-level assessment, which does not always parallel transcription.
Protein expression could be assessed by Western immunoblot analysis; however, this approach
also requires canine-specific antibodies and additional animals. Finally, the animal model used
was an acute injury model, in which the injury is created and surgically repaired immediately.
Clinically, a delay of days to weeks often occurs between injury and repair. This has important
implications for the inflammatory process, which only dominates in the first 3 days after surgical
repair.

While some inflammation is critical for tissue healing90,91,162, excessive levels of proinflammatory cytokines (e.g. IL-1β, TNFα, and NO) that are secreted by macrophages may, in
fact, be detrimental to tissue healing by causing MMP-mediated catabolism of healthy tendon
ECM surrounding the wound144,163–165.

In vitro studies have shown that pro-inflammatory

factors, such as IL-1β and TNFα, induce TFs to up-regulate their own expression of
inflammatory and catabolic mediators (i.e., MMPs),163,164,265,266 while down-regulating their
expression of type 1 collagen164,267. Similarly, at the tissue level, IL-1β exposure leads to upregulation of MMPs and down-regulation of type 1 collagen expression, resulting in reduction of
the ultimate tensile strength and elastic modulus of the tendons and an increase in maximum
strain268.

In a tendon-to-bone model, TNFα-blockade led to fewer pro-inflammatory

macrophages and improved structural properties at the early post-operative timepoints94. Other
studies suggest that modulating the immune cell population itself may improve tendon healing92–
96

.

Hayes et al. found that selectively inducing macrophage apoptosis via the use of a
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bisphosphonate (i.e., clodronate), led to reduced scar tissue formation, increased collagen fiber
organization, and improved structural properties (i.e., load to failure and stiffness) in a tendon-tobone healing model92. Similarly, Dagher et al. found that immobilization of the knee after ACL
reconstruction led to improved mechanical properties via a shift in macrophage phenotype.
Whereas the macrophages found at the repair site of mobilized rats were of the pro-inflammatory
phenotype (i.e., M1 macrophages), immobilization led to a decrease in M1 macrophages and an
increase in anti-inflammatory, pro-regenerative macrophages (i.e., M2 macrophages). Improved
tendon-to-bone integration was noted, as evidenced by reduced scar tissue formation, increased
collagen fiber organization, and enhanced biomechanical properties (e.g. failure load and
stiffness)93. Taken together, these results suggest that M1 macrophages (which secrete IL-1β)
may impede tendon healing and, thus, modulation of the early inflammatory phase of tendon
healing may prove beneficial.

While the pro-inflammatory factors (such as IL-1β) and cytotoxic mediators secreted by
macrophages may result in excessive matrix degradation269, macrophages also play a pivotal role
in fibroblast chemo-attraction. Synthesis of numerous potent growth factors, such as TGF-β,
bFGF, and PDGF, by macrophages promote cell proliferation and synthesis of extracellular
matrix112,156–162. Macrophages also play an important role in angiogenesis through the secretion
of VEGF112,156–161112,156–162.

Indeed, several studies have shown that global depletion of

macrophages during wound healing leads to retarded wound repair90,91,162,270. One such study
showed that ablation of macrophages in the wound resulted in decreased expression of TGF-β,
reduced fibroblast proliferation, and a reduction in extracellular matrix synthesis162.
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Based on these studies, fine modulation of the inflammatory environment might enhance tendon
healing. This approach may be more effective than a global IL-1β blockade or macrophage
depletion. Future studies could aim to reduce IL-1β production during the early post-operative
period via control of macrophage phenotype, promoting a switch from pro-inflammatory M1
macrophages to anti-inflammatory M2 macrophages.

Upon recruitment to the wound,

monocytes differentiate into macrophages. The functional phenotype of the macrophages is
dependent on the wound environment. Bacterial products (such as lipopolysaccharide, LPS) and
inflammatory cytokines (such as interferon gamma, IFNγ), which are typically present during the
early stages of wound healing, promote differentiation of monocytes into pro-inflammatory M1
macrophages (also known as classically activated macrophages or CAMs)136,138,139,141,156,271.
Recent studies suggest that mesenchymal stem cells (MSCs) can induce a phenotype switch from
pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages139,140,245,255,272. Thus,
we hypothesize that MSC-mediated modulation of the macrophage population during the early
inflammatory phase of tendon healing may prove beneficial to the healing process by reducing
the levels of pro-inflammatory factors (such as IL-1β), which in turn will enhance tendon
fibroblast viability and reduce collateral damage of healthy tendon tissue.

The next two chapters (Chapters 3-4) will investigate 1) the effects of IL-1β on native tendon
fibroblasts to determine whether the high levels of IL-1β observed in vivo may be detrimental to
the native TFs and whether this might be a future target for enhanced healing; and 2) the effects
of various macrophage phenotypes on native tendon fibroblasts to determine whether a shift
from a M1 macrophage phenotype to an M2 macrophage phenotype would be beneficial to
tendon healing.
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Chapter 3 - The Effects of the Pro-Inflammatory Cytokine,
Interleukin 1β, on Tendon Fibroblasts: An In Vitro Model of
Inflammation
3.1

Introduction

In the previous chapter, we demonstrated that intrasynovial flexor tendon injuries induce a rapid
local inflammatory response characterized by early infiltration of inflammatory cells (e.g.,
macrophages, polymorphonuclear cells) and a significant up-regulation of pro-inflammatory
(e.g., IL-1β, TNFα, and COX2 and matrix degradation genes (e.g., MMP-1, -3, -13) within the
first 9 days post injury and repair. In addition, we observed significant down-regulation of genes
related to flexor tendon ECM (collagen type I (COL1), collagen type III (COL3), lubricin
(LUB)) and tendon fibroblast differentiation (e.g., SCX, TNMD). Remarkably, IL-1β gene
expression increased 4000-fold within 3 days post-operatively.

Similar results have been

reported in a rabbit flexor tendon model of acute injury and repair. Berglund et al. observed
significant up-regulation of IL-1β, COX2, and MMP-13 gene expression 3 days after flexor
tendon injury and repair. As with our study, the most striking outcome was the increase in IL-1β
expression (1600-fold increase)273. IL-1β has also been implicated in a variety of tendinopathy
models both in animals and in human patients126,133.

In vitro studies by other investigators have shown that human tendon fibroblasts (TFs) exposed
to pro-inflammatory cytokines (i.e., IL-1β, TNFα, IL-6) further up-regulate their expression of
inflammatory cytokines and matrix metalloproteinases123,155,163,164,265–268,273–278.
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Moreover,

exposure of bioartificial tendons to IL-1β ex vivo has been shown to cause down-regulation of
type 1 collagen expression and an up-regulation of MMPs, resulting in a reduction in the ultimate
tensile strength and elastic modulus of the tendon analogues and an increase in maximum
strain268.

Based on these studies, our objective in the current study was to examine the effect of IL-1β on
TFs to determine whether the high levels of IL-1β observed in vivo might be detrimental to the
native TFs. Based on previous studies6–13, we hypothesize that IL-1β will induce up-regulation
of pro-inflammatory and matrix metalloproteinase genes by canine TFs. In addition to upregulation of inflammation and matrix degradation genes, however, we also expect a downregulation of genes related to tendon extracellular matrix and fibroblast differentiation. To test
these hypotheses, an in vitro model of inflammation was used in which exogenous IL-1β was
delivered to TFs in culture. The response of TFs to IL-1β was determined by monitoring the
expression of genes and proteins related to inflammation and matrix remodeling. Understanding
these cellular responses will allow for subsequent experiments targeting the inflammatory
process during tendon healing.
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3.2

Methods

Tendon Fibroblast Cell Isolation and Culture: TFs were isolated from the tail of adult Sprague
Dawley rats (N=4). The tissue was minced and digested in 0.2% Collagenase Type IA in
Phosphate Buffered Saline for 1-2 hours. The digested tissue was collected by centrifugation
and incubated in alpha-modified eagles medium (Alpha-MEM) with 10% Fetal Bovine Serum
(FBS) and 1% Penicillin/Streptomycin (P/S) (37°C, 5% CO2, 95% humidity). The cells were
used on passage 4.

Dose-response study: Prior to IL-1β treatment, the amount of FBS in the tendon fibroblast
culture media was gradually reduced over time until only 1% FBS remained in order to reduce
the potential competing effects of the various factors in the FBS. All experiments were
performed using media containing minimal amounts of FBS (i.e., 1% FBS). To determine the
effect of IL-1β on TFs, TFs (N=4 cell isolations) were plated at 5.2x104 cells/cm2 in 6 well plates
and treated with varying amounts of IL-1β (0 ng/ml, 0.01 ng/ml, 0.1 ng/ml, 1 ng/ml, 10 ng/ml,
100 ng/ml; rat-derived, R&D Systems, Minneapolis, MN). The cells were cultured for 1, 2, and
3 days before RNA was isolated and qRT-PCR was performed.

Gene Expression: Total RNA was isolated (RNEasy Minikit; Qiagen, Valencia, CA) from the
TFs on days 1, 2, and 3 after treatment with IL-1β. 500 ng RNA was reverse transcribed to
cDNA using the Superscript VILO cDNA synthesis kit (Invitrogen Corporation, CA). qRT-PCR
was performed to measure the gene expression levels of pro-inflammatory factors (IL-1β, TNFα,
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COX2) and matrix degradation factors (MMP1, 3, 13) for all dosages. Additional factors related
to ECM (collagen type 1 (COL1), collagen type 3 (COL3)) and TF differentiation (SCX,
TNMD) were only assessed for the 10 ng/ml group. All primers for qRT-PCR were purchased
(Qiagen, CA). The data was analyzed using the delta delta Ct method, in which the results were
normalized to a housekeeping gene (GAPDH) and then to the control group (i.e., untreated TFs).
The delta Ct values were compared using a multi-factor ANOVA (for the effects of IL-1β,
dosage, and time) followed by a Fisher’s post-hoc test. The delta Ct values for the additional
genes assessed only in the 10 ng/ml group were compared using a 2-way ANOVA (for the
effects of IL-1β and time). Significance was set to p < 0.05.

Protein Expression: Cell supernatants were collected on days 1, 2, and 3 from the 10 ng/ml
group. Samples were stored at -80°C until analysis. The levels of IL-1β, TNFα, and MMP3 were
assessed using commercially available kits (ELISAs, R&D Systems, Minneapolis, MN). Data
was normalized to control (TFs cultured alone). Group means were compared using a 2-way
ANOVA (for the effects of IL-1β and time). Significance was set to p < 0.05.
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Live/Dead Assay: A separate set of experiments was performed to assess the viability of the TFs
after IL-1β exposure. TFs were treated with 10 ng/ml of IL-1β or left untreated (control). 1, 2,
and 3 days after IL-1β treatment, the supernatant was removed and the cells were stained with a
commercially available Live/Dead Viability/Cytotoxicity kit according to the manufacturers
protocols (Invitrogen, NY).

Cells were imaged using a fluorescent microscope and the

percentage of live cells was calculated using ImageJ.

3.3

Results

IL-1β induced up-regulation of genes related to inflammation and matrix degradation by TFs:
Significant up-regulation of various inflammatory and matrix degradation genes (compared to
control, 0 ng/ml) were observed on days 1 and 3 when TFs were treated with IL-1β (Figures 3.13.2).

On day 1, the lowest dose, 0.01 ng/ml, was sufficient to significantly up-regulate

expression of COX2 and MMP3, while 0.10 ng/ml was sufficient to up-regulate MMP13. 1
ng/ml up-regulated IL-1β and MMP1, while 10 ng/ml was required to up-regulate TNFα. To
maintain these effects through day 3, higher dosages of IL-1β were often necessary. However,
10 ng/ml was sufficient to maintain up-regulation of all tested genes till day 3, with the exception
of TNFα, which required a dose of 100 ng/ml.
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Figure 3.1: IL-1β induced up-regulation of inflammation-related genes by TFs occurs in a dosedependent manner. Gene expression for each dosage is normalized to control (0 ng/ml).
* p < 0.05, multi-factor ANOVA. There was a significant effect of dosage and time for all genes.
There was a significant effect of IL-1β treatment for IL-1β and COX2 (TNFα, p= 0.08), (N=4,
except for IL-1β on day 1, N=3).
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Figure 3.2: IL-1β induced up-regulation of matrix degradation-related genes by TFs occurs in a
dose-dependent manner. Gene expression for each dosage is normalized to control (0 ng/ml).
* p < 0.05, multi-factor ANOVA. There were significant effects of IL-1β treatment, dosage, and
time for all genes. (N=4).

In contrast, 10 ng/ml of IL-1β significantly inhibited genes related to tendon extracellular matrix
(COL1, COL3) and differentiation (SCX, TNMD) (Figure 3.3).
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Figure 3.3: IL-1β induced down
down-regulation of tendon ECM- and differentiation-related
differentiation
by TFs.
Gene expression of tendon ECM (COL1, COL3) and
nd differentiation (SCX, TNMD) in control
TFs and in TFs treated with 10 ng/ml of IL
IL-1β for 1 or 3 days. * p < 0.05, two-way
two
ANOVA,
significant effect of IL-1β treatment (N=4).
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IL-1β induced secretion of matrix degradation enzymes by TFs: At the protein level, TFs
cultured alone did not secrete detectable levels of IL-1β, TNFα, or MMP3 (data not shown).
Treatment with 10 ng/ml IL-1β, however, significantly increased the amount of MMP-3 in the
cell supernatant in a time-dependent manner (Figure 3.4).

As expected, IL-1β levels also

significantly increased. As there were no time-dependent increases in the IL-1β levels, the spike
in IL-1β can be attributed to the exogenous addition of IL-1β to the media and not to the TFs
themselves (Figure 3.4). TNFα remained undetectable even after IL-1β treatment (data not
shown).

IL-1β

MMP3
35.00

50
40

pg/ml

20.00

TF

15.00

TF+IL1β

Day 1

Day 2

*

Day 3

0

Day 1

*

*

UND

UND

UND

UND

UND

10

UND

TF+IL1β
20

10.00

0.00

TF

30

UND

pg/ml

25.00

5.00

*

60

*

30.00

Day 2

*

Day 3

*

Figure 3.4: IL-1β induced MMP3 protein expression by TFs. Expression of MMP3 (left) and IL1β (right) from control TFs (white bars) and TFs treated with 10 ng/ml of IL-1β (grey bars) for 1,
2, and 3 days. UND = undetected. * p < 0.05, ANOVA, significant effect of IL-1β treatment and
time. There was a significant decrease in IL-1β protein between day 1 and 3 for the TF+IL-1β
group, (N=4).

60

IL-1β reduced TF cell viability: TF cultures exposed to 10 ng/ml of IL-1β exhibited decreased
numbers of viable cells (Figure 3.5). Whereas 96% and 99% percent of TFs remained viable in
the control group on days 1 and 3, respectively, only 14% and 22% were viable in the IL-1βtreated group.

B1

A

B2

Figure 3.5: IL-1β treatment led to decreased TF viability. TFs were either left untreated (white
bars in A and inset B1) or treated with 10 ng/ml of IL-1β (grey bars in A and inset B2). In panel
B, live cells appear green and dead cells appear red. Scale bar = 1 mm, * p < 0.05, 2-way
ANOVA, significant effect of IL-1β treatment, (N=3).
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3.4

Discussion

In the previous chapter, we demonstrated that tendon injuries induce a local inflammatory
response characterized by high levels of pro-inflammatory cytokines, such as IL-1β, TNFα, and
COX2, and simultaneous increases in the matrix-degradation factors MMP-1, -3, and -13. The
most dramatic change observed in vivo was the greater than 4,000-fold up-regulation of the gene
encoding for the pro-inflammatory cytokine, IL-1β. Using an in vitro model of inflammation via
exogenous delivery of IL-1β, we found that exposure of tendon fibroblasts to IL-1β caused
significant up-regulation of various genes related to inflammation (i.e., TNFα, IL-1β, COX2) and
matrix degradation (i.e., MMP 1, 3, 13) in a dose-dependent manner. To reproducibly induce
significant up-regulation of genes related to both inflammation and matrix degradation at days 1
and 3, and therefore replicate the gene expression profile we observed in the in vivo model,
10 ng/ml of IL-1β was required. At this established dose, exposure of tendon fibroblasts to IL1β led to significant down-regulation of factors related to tendon ECM (COL1, COL3) and
differentiation (SCX, TNMD).

These results are in agreement with those of other investigators. In previous in vitro reports,
exposure of human TFs to pro-inflammatory cytokines (i.e., IL-1β, TNFα, IL-6) led to further
up-regulation of inflammatory and matrix degradation genes by the TFs163,164,265,266,273–277.
Specifically, IL-1β induced up-regulation of IL-1β and other inflammatory and catabolic
mediators, including TNFα, COX2, IL-6, PGE2, and the MMPs 1, 3, and 13123,155,163,164,265–268,273–
279

. Furthermore, the MMP-mediated degradation of tendon ECM subsequently led to the loss of
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type 1 collagen164,267. These studies, however, only investigated a single dosage (i.e., 10 ng/ml)
and it is unclear how this dosage relates to the in vivo environment after tendon injury.

In the current study, the expression of IL-1β, TNFα, and MMP3 proteins released into the media
also were analyzed. As expected, IL-1β was significantly increased in the groups that received
IL-1β. However, the levels of IL-1β decreased over time, indicating that the detected IL-1β is
mainly from the exogenous delivery of the protein and not from synthesis by the TFs themselves.
The up-regulation of MMP3 observed at the gene expression level was translated into increased
levels of MMP3 protein, which increased over time. In contrast, the increase in TNFα at the
gene expression level was not observed at the protein level. In fact, at the protein level, TNFα
was undetectable in all groups.

While relative amounts of IL-1β protein can be assessed between the treated and non-treated
groups and over time, the absolute values may not be accurate as 10 ng/ml of IL-1β was added to
the treated groups, yet only 27 pg/ml was detected on average. In future studies, it would be
advisable to make a standard curve from the same IL-1β stock as used in the experiment instead
of using the IL-1β provided in the ELISA kit. This would allow for a better understanding of
how the levels of IL-1β observed compare to the amount of IL-1β delivered. Furthermore, the
assessment in this study of MMPs was limited. First, only MMP3 was assessed, as ELISA kits
were not available for the other MMPs. The MMP3 enzyme is involved in the degradation of
various collagen types; however, it is unable to degrade collagen type 1, which makes up more
than 90% of the collagen component of tendons. MMP1, the primary metalloproteinase that
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degrades collagen type 1, would be more relevant. Second, the activity of the MMP3 enzyme
was not assessed; to assess the activity of the enzyme, zymography could be performed.

The in vitro model suggests that the IL-1β produced in vivo after tendon injury and repair may, in
turn, increase expression of genes related to inflammation and matrix degradation, decrease
expression of genes involved in extracellular matrix production and tendon fibroblast
differentiation, and decrease cell viability. However, the amount of IL-1β produced in vivo after
tendon injury is unknown. Therefore, it is unclear whether the dosages examined in this study
are biologically relevant. Another limitation of this model is the use of only one exogenous
factor to simulate inflammation, whereas the in vivo environment includes a milieu of different
cytokines at the repair site. Due to these limitations, in the next chapter, we describe the
development of a more biologically relevant in vitro model of inflammation using macrophages,
a cell type found in a variety of different tendon injury and repair models, which secretes high
levels of pro-inflammatory factors, including IL-1β and TNFα92,93,97,122–124,130,280,281.
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Chapter 4 - The Effects of Macrophages on Tendon
Fibroblasts: A Co-culture Model of Inflammation
4.1

Introduction

In the previous chapter, we established an in vitro model of inflammation via exogenous delivery
of IL-1β. Addition of this cytokine reproduced the high levels of IL-1β seen in vivo after flexor
tendon injury and repair (see Chapter 2). Although this model demonstrated that exposure to IL1β may be detrimental to tendon healing, promoting increased expression of inflammatory and
matrix degradation genes and decreased expression of tendon ECM and TF-specific genes, it did
not recreate the complex in vivo inflammatory environment.

The primary source of IL-1β during the early period of in vivo tendon healing is produced by
cells of the monocyte/macrophage lineage280–292.

Following tissue damage, monocytes are

recruited to the site from circulating blood. These cells rapidly differentiate into macrophages in
response to extracellular molecular signals. Macrophages will adopt distinct activation states that
can be broadly classified into two subtypes: classically activated (M1) and alternatively activated
(M2) macrophages. M1 (or type 1) macrophages are activated by a combination of IFNγ and a
microbial stimulus, such as bacterial lipopolysaccharide96,124,134–151,293–297. Upon activation, M1
macrophages secrete IL-1β as well as other pro-inflammatory factors (e.g., TNFα, IL-12, and
NO) that aid in the removal of debris and pathogens from the wound96,124,134–151,293–297. M2, or
type 2, macrophages are activated by interleukin-4 and/or interleukin-13 and play a distinctly
different role than M1 macrophages96,124,134–151,293–297.
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M2 macrophages secrete the anti-

inflammatory factor IL-10 and are involved in the regeneration of damaged tissues96,124,134–151,293–
297

.

Cells of the monocyte/macrophage lineage were identified in vivo as early as 3 days after tendon
injury and repair (see Chapter 2). Moreover, macrophages have been identified in a variety of
tendinopathies and tendon repair models in both humans and in animals92,93,97,124,126,128,130.
Therefore, we sought to investigate the effect of macrophages on tendon fibroblasts. Since IL-1β
was shown in the previous chapter to induce the expression of inflammation- and matrix
degradation-related genes and since M1 macrophages are primary sources of IL-1β in vivo, it is
hypothesized that co-culture of TFs with M1 macrophages will yield similar results to those seen
with direct IL-1β application. Specifically, we expect TFs to up-regulate their expression of
inflammation- and matrix degradation-related genes and down-regulate their expression of
tendon ECM- and TF-specific genes. To test this hypothesis, we established an in vitro model of
inflammation via co-culture of TFs with macrophages of varying phenotypes (M0 (nonpolarized/immature), M1 (classically activated), or M2 (alternatively activated)). The effect of
soluble factors produced by macrophages on TFs was determined by monitoring the TF gene
expression and overall protein expression of factors related to inflammation, matrix production
and degradation, and TF differentiation.

66

4.2

Methods

Tendon fibroblast cell isolation and culture: TFs were isolated from the tail of male 6 week old
C57BL/6J mice (Jackson Laboratories, N=5). The tissue was minced and digested in 0.2%
Collagenase Type IA in Phosphate Buffered Saline for 1-2 hours. The digested tissue was
collected by centrifugation and incubated in alpha-modified eagles medium (Alpha-MEM) with
10% Fetal Bovine Serum (FBS) and 1% Penicillin/Streptomycin (P/S) (37°C, 5% CO2, 95%
humidity). Cells were used on passage 2-3.

Macrophage cell isolation and culture: 6 week old male C57BL/6J mice were purchased
from Jackson Laboratories (N=5). To generate macrophages, the femurs and tibiae of the mice
were flushed with RPMI-1640 to obtained total bone marrow. L929-conditioned medium was
used to generate bone marrow-derived macrophages over a 6-day culture period. L929 cells
secrete macrophage colony-stimulating factor (M-CSF), which is required to differentiate bone
marrow cells into macrophages. Thus, to obtain M-CSF, L929 cells were cultured and the
supernatant (containing M-CSF) was collected and added as a supplement to RPMI Complete
media. 1x106 L929 cells were plated in a 75-cm2 flask containing 25 mL RPMI Complete
Media (RPMI media + 10% FBS + 1% P/S) and cultured for 1 week without passage. The
supernatant was collected, sterile filtered, stored at -20⁰C, and replaced with fresh RPMI
Complete media. The cells were cultured for an additional week without passage and the
supernatant was again collected, sterile filtered, and pooled with the supernatant from the
previous week. The pooled supernatants were stored at -20⁰C until use. The supernatant was
used to make the L929-supplemented media (30% L929 Supernatant + 10% FBS + 1% P/S in
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RPMI media).

The bone marrow cells were cultured in the L929-supplemented media

(0.5x106/well, 6 well plates) to generate macrophages. After 1 week of culture, the macrophages
were then primed to become either M1 or M2 macrophages or left untreated (M0). To generate
M1 macrophages, cells were treated with 50 ng/ml IFNγ (R&D systems, Minneapolis, MN) and
100 ng/ml Escherichia coli LPS (Invivogen, San Diego, CA) in RPMI Complete media for 24
h. M2 macrophages were generated by treated the cells with 10 ng/ml IL-4 (R&D systems,
Minneapolis, MN) in RPMI Complete media for 24 h. Untreated macrophages (M0) received
RPMI Complete media only. All experiments were performed in duplicate.

Macrophage/tendon fibroblast co-culture: To determine the effects of macrophages on TFs, M0,
M1, or M2 macrophages were co-cultured with TFs using transwell plates. After 24 h of
priming, the media was replaced with fresh RPMI complete media and TFs were seeded in the
inserts of the transwell plates (2.6x104 cells/cm2). Macrophages and TFs were co-cultured for
24h before supernatant collection and RNA isolation was performed. Control groups consisted
of TFs alone, M0 macrophages alone, M1 macrophages alone, and M2 macrophages alone
(Figure 4.1).

68

A

C

B
TF

TF

TF

M0

M1

M2

E

D

F

TF

TF

TF

M0

M1

M2

G
TF

Figure 4.1: Schematic of experimental design. M0, M1, and M2 macrophages were cultured
alone (A-C) or in co-culture with TFs (D-F). TFs were also cultured alone as a control (G).

Flow cytometry: Cells were prepared for flow cytometry by staining with anti-F480 antibody
(eBiosciences clone BM8, San Diego, CA), CD11b (eBiosciences clone M1/70, San Diego, CA),
CD301 Alexa Fluor® 488 (AbD Serotec, Oxford, UK) and CD206 APC (AbD Serotec, Oxford,
UK). Data were acquired on a BD FACS Canto Flow Cytometer (BD Biosciences, San Jose,
CA) and analyzed with FlowJo software (Treestar, Ashland, OR). The gating strategy was
devised to select only live, singlet cells that stained positive for both F480 and CD11b (general
macrophage markers). The expression of M2 macrophage-specific markers (CD206 and CD301)
in the selected macrophage population was then assessed (Figure 4.2). Data are expressed as
geometric mean fluorescent intensity ± standard deviation. Statistical differences were assessed
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using a two-way ANOVA (for the effects of macrophage type and the presence of TFs) followed
by a Fisher’s post-hoc test. Significance was set to p < 0.05.

Figure 4.2: Representative figure describing the flow cytometry gating strategy. (A) Side scatter
area (SSC-A) and forward scatter area (FSC-A) were used to eliminate any dead cells from the
cell population examined. (B) Side scatter width (SSC-W) and forward scatter width (FSC-W)
were used to ensure that only singlets were analyzed. (C) Macrophage cell populations were
identified by F480 and CD11b staining. (D) Expression of CD206 (a marker specific to M2
macrophages) was assessed.

Gene expression: Total RNA was isolated (RNEasy Minikit; Qiagen, Valencia, CA) from the
TFs on day 1. 500 ng RNA was reverse transcribed to cDNA, using the Superscript VILO
cDNA synthesis kit (Invitrogen Corporation, CA). qRT-PCR was performed to measure the
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gene expression levels of pro-inflammatory factors (IL-1β, TNFα, COX2), matrix
metalloproteinases (MMP1a, 1b, 3, 13), and ECM-related factors (COL1, COL3, BGN, DCN),
and TF-specific factors (SCX and TNMD). All primers for qRT-PCR were predesigned (Qiagen,
CA).

The data was analyzed using the delta delta Ct method, in which the results were

normalized to the housekeeping gene (GAPDH) and then to the control group (i.e., untreated
TFs). The delta Ct values were compared using an ANOVA (for the effect of macrophage type),
followed by a Fisher’s post-hoc test. Significance was set to p < 0.05.

Protein expression: Cell supernatants were collected on day 1 and samples were stored at -80°C
until analysis. The levels of IL-1β, TNFα, NO and Prostaglandin E2 (PGE2) were assessed
using commercially available kits (IL-1β ELISA, R&D Systems, Minneapolis, MN; TNFα
ELISA, R&D Systems, Minneapolis, MN; Nitric Oxide Colorimetric Assay, EMD Millipore
Chemicals, Darmstadt, Germany; Prostaglandin E2 Parameter Assay Kit, R&D Systems,
Minneapolis, MN). Data was normalized to control; specifically, protein levels from the TFs
cultured alone were subtracted from their paired groups (i.e., groups containing TFs from the
same animal). Group means were compared using a 2-way ANOVA (for effect of macrophage
type and presence of TFs), followed by a Fisher’s post-hoc test. Significance was set to p < 0.05.
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4.3

Results

Verification of macrophage induction: Verification of the different macrophage phenotypes was
obtained by assessing surface marker and protein expression. Flow cytometry revealed that all
macrophages expressed high levels of CD11b and F480, and that macrophages treated with M2priming media also expressed high levels of CD206 and CD301 (Figure 4.3).

Geometric mean

fluorescent intensities (MFI) of CD206 and CD301 were 2.6- and 1.5-fold greater, respectively,
in the M2 macrophages compared to the M0 macrophages. Similarly, the MFIs of CD206 and
CD301 were 5.1- and 1.5-fold greater, respectively, in the M2 macrophages compared to the M1
macrophages.

The presence of TFs did not have a significant effect on surface marker

expression. To further evaluate macrophage phenotypes, protein expression was examined. M1
macrophages consistently secreted significantly greater amounts of inflammation-related proteins
(Figure 4.4). For example, M1 macrophages secreted approximately 3-, 8.8-, 17-, and 5.5- fold
more IL-1β, TNFα, PGE2, and NO, respectively, than did M0 and M2 macrophages. Secretion
of these proteins by M0 and M2 macrophages was not statistically different from each other
(Figure 4.4).
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Figure 4.3: Verification of macrophage phenotype using FACS analysis. Expression of surface
markers for mono-culture macrophages 1 day after addition of M1-priming media, M2-priming
media, or untreated (M0). Geometric mean fluorescent intensity of the M2 markers CD206 and
CD301 were significantly increased in the M2 group compared to the M0 and M1 groups.
* p < 0.05, ANOVA, significant effect of macrophage type for all protein assays, bars signify
Fisher’s post-hoc comparisons (N=5).
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Figure 4.4: M1 macrophages express high levels of pro-inflammatory factors.

Protein

expression of mono-culture macrophages 1 day after M1-priming media, M2-priming media, or
untreated (M0). UND = undetectable. * p < 0.05, ANOVA, significant effect of macrophage
type for all protein assays, bars signify Fisher’s post-hoc comparisons (N=5).
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M1 macrophages induce up-regulation of pro-inflammatory and matrix degradation factors by
TFs: The effect of macrophages on TFs was determined by co-culturing TFs with the various
macrophage types. Gene expression analysis of the TFs revealed significant up-regulation of
factors related to inflammation in all macrophage co-culture cases compared to TFs cultured
alone (Figure 4.5). M1 macrophages induced a significant up-regulation of TNFα, IL-1β, and
COX2 in co-cultured TFs compared to control (i.e., TFs cultured alone). Co-culture with M0
and M2 macrophages also led to a significant up-regulation of IL-1β in the TFs, but to a much
lesser extent than M1 macrophages. Co-culture with M0 and M2 macrophages led to 2.1- and
8.6-fold increases in IL-1β, respectively, whereas co-culture with M1 macrophages led to a
2800-fold increase in IL-1β.

Co-culture with M1 macrophages also led to significant up-

regulation of matrix-metalloproteinases (Figure 4.6).

M1 macrophages caused significant

increases in MMP-1a, -1b, -3, and -13 in TFs. M0 macrophages did not have any significant
effect on the expression of MMPs in the TFs, while M2 macrophages caused a significant upregulation of MMP-1a and -1b. However, as with IL-1β, the up-regulation caused by M2
macrophages compared to control was significantly less than that caused by M1 macrophages.
M1 macrophages led to 150- and 100-fold increases in MMP-1a and -1b, respectively, while M2
macrophages only led to 5.5- and 8.7-fold increases. Co-culture with M0, M1, or M2
macrophages led to a significant decrease in ECM production by TFs, as evidenced by downregulation of collagens (COL1, COL3) and biglycan (BGN) and up-regulation of decorin (DCN).
The main role of DCN is to regulate fibril diameter, so COL1 and DCN typically trend in
opposite directions298. As with inflammation-related genes, M1 macrophages had the largest
effect (Figure 4.7). M1 macrophages caused a 3.3- and 2.9-fold decrease in COL1 and COL3 by
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TFs, respectively. In addition, M1 macrophag
macrophages caused a significant up-regulation
regulation of DCN (2.3fold).
Lastly, macrophages had little effect on the TF-specific
specific genes SCX and TNMD (Figure 4.8).
The only significant effect was a 3.2
3.2-fold decrease in TNMD caused by co--culture with M1
macrophages.
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Figure 4.5: M1 macrophages induce up-regulation of inflammation-related genes by TFs. Fold
changes in TF gene expression of inflammation-related factors relative to control after 1 day of
co-culture with M0, M1, or M2 macrophages. * p < 0.05, † p < 0.10, ANOVA, significant effect
of macrophage type for all genes, bars signify Fisher’s post-hoc comparisons, * by x-axis
signifies a significant difference compared to control TFs (N=5).
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Figure 4.6: M1 macrophages induce up-regulation of matrix degradation-related genes by TFs.
Fold changes in TF gene expression of matrix degradation-related factors relative to control after
1 day of co-culture with M0, M1, or M2 macrophages. * p < 0.05, ANOVA, significant effect of
macrophage type for all genes, bars signify Fisher’s post-hoc comparisons, * by the x-axis labels
signifies a significant difference compared to control TFs (N=5).
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Figure 4.7:

M1 macrophages induce down-regulation of tendon ECM as evidenced by

decreased expression of COL1, COL3, and BGN and increased expression of DCN. Fold
changes in TF gene expression of extracellular matrix-related factors relative to control after 1
day of co-culture with M0, M1, or M2 macrophages. * p < 0.05, ANOVA, significant effect of
macrophage type for all genes, bars signify Fisher’s post-hoc comparisons, * by x-axis signifies a
significant difference compared to control TFs (N=5).

Figure 4.8: M1 macrophages induce down-regulation of the TF-specific gene, TNMD, by TFs.
Fold changes in TF gene expression of TF-specific factors relative to control after 1 day of coculture with M0, M1, or M2 macrophages.

* p < 0.05, ANOVA, significant effect of

macrophage type for all genes, bars signify Fisher’s post-hoc comparisons, * by x-axis signifies a
significant difference compared to control TFs, (N=5).
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Furthermore, co-cultures of M1 macrophages with TFs led to higher levels of IL-1β and PGE2
protein secretion compared to M1 macrophages alone (2.9- and 1.8-fold, respectively). NO was
down-regulated 1.6-fold in the M1 group when co-cultured with TFs, but this difference was not
statistically significant (Figure 4.9).
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Figure 4.9: M1 macrophages induce the secretion of inflammatory factors by TFs. Protein
expression of IL-1β, TNFα, PGE2, and NO after 1 day of co-culture with M0, M1, or M2
macrophages in the presence and absence of TFs. Data are normalized to TF controls (i.e., levels
measured for TF controls were subtracted from paired groups). * p < 0.05, † p < 0.10, 2-way
ANOVA, significant effect of macrophage type for all proteins, significant effect of time for IL80

1β and PGE2, bars signify Fisher’s post-hoc comparisons, (N=5). Note: Data for the groups
lacking TFs were previously presented in Figure 4.4, but are presented again here to highlight the
effect of TFs.

4.4

Discussion

The in vitro co-culture model of inflammation described here improved on the simple IL-1βinduced model presented in the previous chapter. As cells of the monocyte/macrophage lineage
have been identified in various tendinopathy and tendon healing models

92,93,97,124,126,128,130

, we

sought to create a biologically relevant model of in vitro inflammation using macrophage-TF coculture. Three macrophage phenotypes were generated and their effects on TFs were
investigated. Gene expression analyses revealed that macrophages promoted up-regulation of
the pro-inflammatory factors (such as IL-1β), up-regulation of matrix degradation factors (such
as MMP1), and down-regulation of tendon ECM factors (such as collagen type I). Among the
three macrophage phenotypes examined, co-culture with M1 macrophages had the most dramatic
effect on the expression by TFs of inflammatory, matrix degradation, and tendon ECM genes.
At the protein level, increases in IL-1β and PGE2 were observed in the medium of the M1 coculture group compared to M1 macrophages in mono-culture. This suggests that exposure of
TFs to M1 macrophages leads to up-regulation of IL-1β and PGE2 synthesis and secretion by
TFs. However, it is unclear whether the increases in IL-1β and PGE2 in the M1 co-culture group
are due to increased synthesis and secretion of those factors by the TFs or whether the presence
of the TFs caused increased synthesis and secretion of those factors by the M1 macrophages.
Based on the fact that the expression levels for the corresponding genes (IL-1β and COX2) were
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similarly up-regulated by TFs, it is likely that those genes were translated into proteins and, thus,
the source of the additional IL-1β and PGE2 proteins is at least in part the TFs.

No assay for

MMP protein activity (i.e., zymography) was performed, however. Thus, it remains unknown
whether the up-regulation of matrix metalloproteinase genes translates into increased MMP
activity.

Taken together, these data suggest that the presence of IL-1β and other pro-inflammatory
cytokines may be deleterious to tendon healing in vivo. Specifically, M1 macrophages, which
produce these inflammatory factors, may induce further up-regulation of inflammatory and
matrix degradation factors by the local TFs. In vivo, up-regulation of pro-inflammatory genes
and matrix metalloproteinase factors may result in excessive matrix degradation and collateral
damage to healthy tendon tissue adjacent to the injury site, and, thus, may be detrimental to
tendon healing.

While M0 and M2 macrophages also appear to cause some up-regulation of inflammatory and
matrix-degradation genes, the effect is much less than that of M1 macrophages. Moreover,
studies by other investigators have shown that macrophage depletion or modulation may be
beneficial in a tendon-to-bone healing model. Hayes et al. report a significant improvement in
collagen fiber organization and biomechanical properties in macrophage-depleted samples (via
clodronate treatment)92.

Dagher et al. found that immobilization of the knee after ACL

reconstruction led to improved mechanical properties via a shift in macrophage phenotype.
Whereas the macrophages found in mobilized animals were of the pro-inflammatory M1
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phenotype, immobilization led to a decrease in M1 macrophages and an increase in antiinflammatory, pro-regenerative M2 macrophages.

In addition, improved tendon-to-bone

integration was achieved, as evidenced by reduced scar tissue formation, increased collagen fiber
organization, and enhanced biomechanical properties93.

Taken together, these results suggest that classically activated macrophages (M1 macrophages)
may, in fact, impede tendon healing and that modulation of the macrophage population toward a
M2 phenotype may be advantageous. Thus, treatments that aim to reduce the number of M1
macrophages at the repair site may prove beneficial for tendon healing92,93,97.

4.5

Acknowledgments

Dr. Catherine Martel, a post-doctoral fellow in Dr. Gwendalyn Randolph’s lab (Washington
University in St. Louis, Department of Pathology and Immunology) aided in the setup of the
gating strategy and the analysis of FACS.

83

Chapter 5 - Mesenchymal Stem Cell-Mediated Modulation
of In Vitro Inflammation.

5.1

Introduction

The early inflammatory response after transection and repair of intrasynovial flexor tendons is
characterized by an early influx of PMNs followed by infiltration of cells from the
monocyte/macrophage lineage (see Chapter 2). Gene expression analysis from in vivo repairs
revealed significant up-regulation of pro-inflammatory genes, presumably as a result of this
immune cell population. In vitro investigations described in Chapters 3 and 4 indicated that IL1β and other pro-inflammatory cytokines secreted by M1 macrophages may induce further upregulation of inflammatory factors by native TFs and may deter new ECM formation.

Studies by other investigators suggest that M1 macrophages may be detrimental to tendon
healing due to their secretion of pro-inflammatory cytokines and that modulation of this
inflammatory response may be advantageous to healing92–94. While a certain level of
inflammation is necessary for healing to occur90 (e.g., to provide chemotactic factors for the
recruitment of fibroblasts to the repair site), high levels of pro-inflammatory cytokines may be
detrimental to tendon healing92–94. Completely suppressing inflammation, however, is also likely
to be detrimental to healing. Traditional non-steroidal anti-inflammatory drugs (NSAIDS) and
selective COX2 inhibitors (Coxibs) inhibit cyclooxygenase (COX) activity, effectively reducing
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pro-inflammatory prostaglandin production and hyperalgesia299–303. While NSAIDS and Coxibs
are successful in reducing pain and swelling, numerous studies have cautioned against their use
following tendon-to-bone repair, citing impaired healing responses304–311.

The effects of

NSAIDS and Coxibs on tendon mid-substance healing are not as well documented. Due to the
paucicellular nature of flexor tendons, accrual of repair site strength is delayed until cells migrate
to the repair site, proliferate, and synthesize extracellular matrix. In vitro studies have reported
inhibition of tendon fibroblast proliferation and matrix glycosaminoglycan production when
treated with NSAIDS312,313. Thus, broadly shutting down inflammation with the use of agents
such as NSAIDS may impair flexor tendon healing. A balance must therefore be achieved
between too much inflammation, which would incite a catabolic tendon fibroblast response, and
too little inflammation, which would impair fibroblast recruitment, proliferation, and matrix
synthesis.

Fine control of the inflammatory environment may be achieved using MSCs. Previous reports
suggest

that

MSCs

possess

capabilities170,173,203,208,211–241,243–247,314.

anti-inflammatory

and

immunosuppressive

In vitro, MSCs have been shown to significantly

suppress the proliferation of immune cells, such as T and B lymphocytes173,203,213,215–
219,222,225,226,228,229,231,233,234,236,237,239,243–247,314

, resulting in reduced secretion of inflammatory

factors (e.g., IFNγ, TNFα) and interleukins 2 and 5. Recent evidence suggests that MSCs can
also modulate the innate immune response by promoting differentiation into anti-inflammatory
macrophages (i.e., M2 macrophages)136,140,141,244,254–257.
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MSCs can be derived from a number of tissue sources. Historically, MSCs have been derived
from bone marrow aspirates. However, recent studies have shown that MSCs derived from
adipose tissue exhibit very similar characteristics. Like bone marrow-derived MSCs (BMSCs),
adipose-derived MSCs (ASCs) have been shown to differentiate along multiple cell-lineages,
while

also

demonstrating

immunomodulatory

capabilities

comparable

to

those

of

BMSCs169,216,223,229,231. Given that adipose tissue is generally more abundant and accessible, thus
increasing the ease of isolation and the overall yield, adipose tissue is an excellent and clinically
relevant source of adult stem cells169.

The purpose of the current study was to investigate the ability of ASCs to modulate
inflammation and its effects on tendon fibroblasts either by acting directly on the inflammatory
cytokine, IL-1β, or indirectly by eliciting phenotypic changes in macrophage populations (Figure
5.1).

ASC

?
M1

Figure 5.1: Schematic of hypotheses.

?
IL-1β

TF

ASCs co-cultured with TFs in an IL-1β-induced

inflammatory environment may protect TFs from the effects of IL-1β through the uptake of IL86

1β or through the secretion of anti-inflammatory factors to counteract the effects of IL-1β
(central blocking line). ASCs co-cultured with inflammation-inducing macrophages (M1) may
prompt a phenotypic switch toward an anti-inflammatory, M2 macrophage phenotype, resulting
in decreased levels of pro-inflammatory factors, increased levels of anti-inflammatory factors,
and reduced inflammatory effects on TFs (leftmost blocking line).

ASCs were incorporated into the two in vitro inflammatory models that were established in
previous chapters (see Chapters 3, 4). We hypothesized that ASCs co-cultured with TFs in an
inflammatory environment induced by IL-1β, would either take up IL-1β, effectively reducing
the amount of IL-1β in the media, or secrete anti-inflammatory factors that would counteract the
effects of IL-1β.

We hypothesized that ASCs in co-culture with inflammation-inducing

macrophages would promote a phenotypic switch towards an anti-inflammatory, M2
macrophage phenotype, resulting in decreased levels of pro-inflammatory factors (e.g., IL-1β,
TNFα, NO), increased levels of anti-inflammatory factors (e.g. IL-10), and reduced
inflammatory effects on TFs (as evidenced by the suppression of inflammatory and matrix
degradation-related genes by TFs).
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5.2

Methods

5.2.1 IL-1β-Induced Inflammation Model

Cell Isolation and Culture: ASCs and TFs were isolated from adult Sprague Dawley rats (N=4).
ASCs were isolated from abdominal adipose tissue and TFs were isolated from tail tendons. The
tissue was digested and the cells were cultured as previously described (see Chapter 3). Rat TFs
and ASCs were used at passage 4.

Co-culture Model: To determine whether ASCs can modulate the effects of exogenous IL-1β
delivery on TFs, ASCs were co-cultured with TFs using transwell plates. Based on studies
indicating

that

pre-treatment

of

the

MSCs

with

IFNγ

is

required

for

immunosuppression209,217,237,239,248,315, ASCs were either left untreated (naïve) or pre-treated for
48 hr with 50 ng/ml IFNγ (R&D Systems, Minneapolis, MN) (activated). ASCs and TFs were
co-cultured at a 1:1 cell density ratio (2.6x104 cells/cm2) using 6 well transwell plates (Costar,
0.4 µm pore size, Fisher Scientific, Pittsburgh, PA). In general, TFs were plated in the wells and
ASCs were plated in the inserts. The cells were allowed 24 hr to attach before treatment with 10
ng/ml IL-1β (R&D Systems, Minneapolis, MN) on day 0. Experiments were run using 1% FBS
as described previously in Chapter 3. The experimental and control groups examined were:
A) TFs cultured alone (TT)
B) TFs treated with IL-1β (TT+)
C) TFs co-cultured with naïve ASCs (TA)
D) TFs co-cultured with naïve ASCs and treated with IL-1β (TA+)
E) TFs co-cultured with activated ASCs (TAa)
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F) TFs co-cultured with activated ASCs and treated with IL-1β (TAa+)
Additional TFs were added to the inserts of groups 1 and 2 to maintain equal cell numbers in all
groups (Figure 5.2).

TFs

A
Media
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+ IL-1β

TFs

nASCs

C
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+ IL-1β

TFs

Media

TFs

aASCs
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TFs

TFs

nASCs

D

aASCs

E

TFs

B

TFs

Figure 5.2: Schematic of experimental design for the IL-1β-induced inflammation model. TFs
were cultured alone or co-cultured with either naïve ASCs (nASCs) or activated ASCs (aASCs)
in the presence of IL-1β (A-C). Controls consisted of the same experimental groups, but in the
absence of IL-1β (D-F). Note: TFs were cultured in the inserts of the transwell plates for groups
A and D to keep the total number of cells uniform between all groups.

Gene Expression: Total RNA was isolated from the tendon fibroblasts on days 1, 2, and 3 and
was reverse transcribed to cDNA, as described in Chapter 3. Quantitative real-time reverse
89

transcription-polymerase chain reaction (qRT-PCR) was performed to measure the gene
expression levels of pro-inflammatory factors (IL-1β, TNFα, COX2), MMPs (-1, -3, -13), ECMrelated factors (COL1, COL3), and differentiation factors (SCX, TNMD).

The data were

analyzed using the delta Ct method, in which the results were normalized to the housekeeping
gene GAPDH. For statistical analysis, the delta Ct values were compared using a multi-factor
ANOVA for the effects of IL-1β, ASCs, and time, followed by a Fisher’s post-hoc test.
Significance was set to p < 0.05.

Protein Expression: Cell supernatants were collected on days 1, 2, and 3. Samples were stored at
-80°C until analysis. The levels of IL-1β and TNFα were assessed using commercially available
kits (ELISAs, R&D Systems, Minneapolis, MN). Data were normalized to control; specifically,
protein levels from the TFs cultured alone were subtracted from their paired groups (i.e., groups
containing TFs from the same animal). For statistical analysis, the data were compared using a
multi-factor ANOVA (for the effects of IL-1β, ASCs, and time) followed by a Fisher’s post-hoc
test. Significance was set to p < 0.05.

5.2.2 Macrophage-Induced Inflammation Model
Cell Isolation and Culture: ASCs, tendon fibroblasts, and monocytes were isolated from 6 week
old C57BL/6J mice (N=9). ASCs were isolated from adipose tissue and TFs were isolated from
tail tendons. The tissue was digested and the cells were cultured as described in Chapter 4. TFs
and ASCs were used on passage 2-3 and 2-4, respectively. Note that the ASCs were not
activated as in the IL-1β-induced model. Macrophages were generated from bone marrow
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monocytes using L929-supplemented media. Macrophages were primed to become either M1 or
M2 macrophages, as described in Chapter 4, or left untreated (M0).

Tri-culture Model:

To determine whether ASCs can modulate the effects of M0 or M1

macrophages on TFs, tri-cultures of ASCs, TFs, and either M0 or M1 macrophages were
generated using transwell plates. After 24 h of macrophage priming, the priming media was
replaced with fresh RPMI Complete media. ASCs were seeded directly on top of the preexisting macrophages at a density of 1.2x104 cells/cm2 and TFs were seeded in the inserts of the
transwell plates at a density of 2.6x104 cells/cm2. Macrophages, ASCs, and TFs were tricultured for 1 day before supernatant collection and RNA isolation was performed. To allow
more time for the ASCs to produce a phenotypic switch, a separate group was analyzed, in which
ASCs and macrophages were co-culture for 4 days before TFs were added to the culture for the
remaining day.

Additional control groups consisted of tendon fibroblasts alone, M0

macrophages alone, M1 macrophages alone, and M2 macrophages alone (Figure 5.3).
Experimental and control groups examined were:
A) M0s in mono-culture
B) M1s in mono-culture
C) M2s in mono-culture
D) M0s in co-culture with TFs
E) M1s in co-culture with TFs
F) M2s in co-culture with TFs
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G) M0s in tri-culture with TFs and ASCs
H) M1s in tri-culture with TFs and ASCs
I) TFs cultured alone

A

TFs

D
M0

B

M0

TFs

E
M1

C

G

M0+ASCs

H

M1

TFs

F
M2

TFs

TFs

M1+ASCs

I

TFs

M2

Figure 5.3: Schematic of experimental design for the macrophage-induced inflammation model.
M0, M1, and M2 macrophages were cultured alone (A-C) to verify macrophage phenotype. TFs
were co-cultured with M0, M1, or M2 macrophages (D-F) or tri-cultured with naïve ASCs and
either M0 or M1 macrophages (G-H). TFs cultured alone served as controls (I).

Flow Cytometry: To determine whether co-culture with ASCs leads to a phenotypic switch in the
macrophage population, the macrophage/ASC cell populations were collected and cell surface
markers for macrophages (CD11b, F4/80) and specifically for M2 macrophages (CD206,
CD301) were analyzed via FACS analysis, as previously described (see Chapter 4).
Macrophages alone were analyzed as controls.
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Data were expressed as geometric mean

fluorescent intensity ± standard deviation. Statistical differences were assessed using a two-way
ANOVA (for the effect of macrophage type and TF presence) followed by a Fisher’s post-hoc
test. Significance was set to p < 0.05.

Gene Expression: Total RNA was isolated from the tendon fibroblasts 1 day after TFs were
seeded and was reverse transcribed to cDNA, as described in Chapter 4.

qRT-PCR was

performed to measure the gene expression levels of pro-inflammatory factors (IL-1β, TNFα,
COX2), MMPs (-1a, -1b, -3, -13), ECM-related factors (COL1, COL3, BGN, DCN), and
differentiation factors (SCX, TNMD). The data were analyzed using the delta delta Ct method,
in which the results were normalized to the housekeeping gene GAPDH and then to the paired
control (i.e., TF control). For statistical analysis, the delta Ct values were compared using a
multi-factor ANOVA (for the effects of macrophage type, ASCs, and TFs) followed by a
Fisher’s post-hoc test and a paired t-test. Significance was set to p < 0.05.

Protein Expression: Cell supernatants were collected 1 day after TFs were seeded. Samples
were stored at -80°C until analysis. The levels of IL-1β, TNFα, IL-10, Nitric Oxide and PGE2
levels using commercially available kits (IL-1β ELISA, R&D Systems, Minneapolis, MN; TNFα
ELISA, R&D Systems, Minneapolis, MN; IL-10 ELISA, R&D Systems, Minneapolis, MN;
Nitric Oxide Colorimetric Assay, EMD Millipore Chemicals, Darmstadt, Germany;
Prostaglandin E2 Parameter Assay Kit, R&D Systems, Minneapolis, MN).

Data were

normalized to control; specifically, protein levels from the TFs cultured alone were subtracted
from their paired groups (i.e., groups containing TFs from the same animal). For statistical
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analysis, the data were compared using a multi-factor ANOVA (for the effects of macrophage
type, ASCs, and TFs) followed by a Fisher’s post-hoc test and a paired t-test. Significance was
set to p < 0.05.

5.3

Results

5.3.1 IL-1β-Induced Inflammation Model

ASCs Mildly Suppress IL-1β-induced Effects on TFs: As described in Chapter 3, significant
increases in the expression of genes related to inflammation (TNFα, IL-1β, COX2) and matrix
degradation (MMP1, 3, 13) were observed 1 day after TFs were exposed to IL-1β (Figure 5.4).
Conversely, tendon-related genes (i.e., COL1, COL3, SCX) were down-regulated 1 day after
IL1-β exposure when compared to control (i.e., untreated TFs) (Figure 5.4). However, only the
decrease in COL1 was statistically significant.
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Figure 5.4: ASCs failed to suppress the IL-1β-induced effects on TF gene expression. TFs cocultured with naïve ASCs (TA), activated ASCs (TAa), or cultured alone (TT) in the presence
(+) and absence of IL-1β for 1 day. Data was normalized to a housekeeping gene (GAPDH) and
is presented as group means ± SD. * p < 0.05, † p < 0.10, multi-factor ANOVA with a Fisher’s
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post-hoc test. Significant effects of IL-1β are indicated by bars over the groups with and without
IL-1β. No significant effect of ASCs was observed.

Co-culture with naïve ASCs did not have a significant effect at the gene expression level or at
the protein level (Figure 5.5). Co-culture with activated ASCs led to a 3.1-, 1.8-, and 1.4-fold
down-regulation of TNFα, IL-1β, and MMP1 mRNA, respectively, on day 1; however, these
reductions failed to reach statistical significance (Figure 5.5). The effects of IL1β were generally
diminished with time (i.e., 2 and 3 days after IL-1β exposure) (Figure 5.6).

IL-1β
60
50

pg/ml

40
TT+

30

TA+

20

TAi+

10
0
DAY 1

DAY 2

*

Figure 5.5: ASCs failed to reduce IL-1β levels.
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DAY 3

The effect of ASCs on IL-1β-induced

inflammation is shown in terms of expression of matrix degradation-related genes 1 day after IL1β treatment. Cumulative IL-1β produced by TFs co-cultured with naïve ASCs (TA), activated
ASCs (TAa), or cultured alone (TT) in the presence (+) and absence of IL-1β on days 1, 2, and 3.
Data are presented as group means ± SD. * p < 0.05 compared to paired groups on day 1.
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Multi-factor ANOVA with a Fisher’s post-hoc test. There was a significant effect of time.
There was no effect of ASC treatment (N=4).
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Figure 5.6: Effect of IL-1β on TFs is greatest 1 day after treatment. Gene expression of TFs
treated with 10 ng/ml IL-1β normalized to control (untreated TFs). Data are presented as group
means ± SD. * p < 0.05, † p < 0.10, 2-way ANOVA with a Fisher’s post-hoc test. Significant
effects of IL-1β are indicated by stars on the x-axis. Significant effect of time was observed for
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IL-1β, MMP13, COL3, and SCX. Results of the post-hoc test are indicated by bars across the
timepoints that differ significantly.

5.3.2 Macrophage-Induced Inflammation Model

ASCs Suppress the Negative Effects of M1 Macrophages on TFs: ASCs had a significant effect
on M1 macrophages. As described in Chapter 4, M1 macrophages induced significant upregulation of pro-inflammatory and matrix degradation-related genes by TFs, while concurrently
down-regulating TF expression of ECM-related and TF-specific genes. ASC co-culture with M1
macrophages significantly altered the expression by TFs of many of those factors towards
baseline values (Figure 5.7). TNFα gene expression by TFs was down-regulated 2.4- and 2.1fold after 1 and 5 day of ASC co-culture, respectively (Figures 5.7, 5.8). While changes failed to
reach statistical significance at the gene expression level for the 5 day timepoint, significant
reductions were observed at the protein level (Figure 5.10). IL-1β gene and protein expression
were not affected after a single day of co-culture (Figures 5.7, 5.9). 5 days of ASC co-culture
with M1 macrophages, however, led to a 7.1-fold down-regulation of IL-1β by TFs (Figure 5.8).
While this change was not statistically significant, a corresponding reduction in IL-1β was seen
at the protein level (Figure 5.10). COX2 was also unaffected after only 1 day of co-culture
(Figures 5.7, 5.9), but a significant down-regulation (11.3-fold) was observed after 5 days of coculture. No significant effects were seen at the protein level, however (Figure 5.10).
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Figure 5.7: ASCss suppress the effects of M0 and M1 macrophages on TFs after 1 day of coculture. TF gene expression after 1 day of co
co-culture with macrophages (M0, M1, M2) or tritri
culture with macrophages and ASCs (M0+ASC, M1+ASC). Data are normalized to normal (i.e.
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untreated TFs) and presented as group means ± SD. * p < 0.05, multi-factor ANOVA with
Fisher’s post-hoc test. Significant effects of ASCs were observed for TNFα, MMP1a, MMP3,
COL1, SCX, TNMD, bars signify Fisher’s post-hoc comparisons, * by the x-axis labels signifies
a significant difference compared to control, (N=5). Note: Control group data (M0, M1, M2) are
the same data as presented in Figures 4.6-4.8.

MMP gene expression was also suppressed by ASC co-culture with M1 macrophages. MMP1a
expression by TFs was down-regulated 2.3- and 11.3-fold after 1 and 5 days of ASC co-culture,
respectively (Figures 5.7, 5.8). MMP1b was unaffected by a single day of ASC co-culture, but
after 5 days of ASC co-culture, a 2.1-fold decrease in MMP1b gene expression by TFs was
observed. Similarly, a small, but statistically significant reduction in MMP3 was observed after
1 day of ASC co-culture (Figure 5.7), and increased to a 7-fold down-regulation after 5 days of
ASC co-culture (Figure 5.8).

No effects on MMP13 expression were observed at either

timepoint (Figures 5.7, 5.8). ECM-related gene expression (COL1 and COL3) by TFs was
unaffected after 1 day of ASC co-culture, but was up-regulated 1.8-fold towards baseline after 5
days of co-culture. However, this change failed to reach statistical significance (Figure 5.8). No
significant effects on tendon fibroblast-specific genes were observed at either timepoint (Figures
5.7, 5.8).
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Figure 5.8: ASCss suppress the effects of M
M1 macrophages on TFs after 5 days of co-culture.
Gene expression of TFs after 1 day of co
co-culture with macrophages (M0, M1, M2) or 5 days of

101

tri-culture
culture with macrophages and ASCs (M0+ASC, M1+ASC). Data are normalized to control
(i.e., untreated TFs) and presented as group means ± SD. * p < 0.05, multi
multi-factor
factor ANOVA with
Fisher’s post-hoc
hoc test. Significant effect of macrophage type for all inflammation and matrix
remodeling genes (but not ECM or tendon fibroblast differentiation genes), significant effect of
ASCs for COX2, MMP1a, MMP3, COL3, bars signify Fisher’s post
post-hoc
hoc comparisons, * by the
x-axis labels signifies a significant difference compared to control TFs ((N=4).

Figure 5.9: ASCss fail to suppress the effects of M0 and M1 macrophages on the secretion of
pro-inflammatory factors after 1 day of co-culture. Protein expression of inflammatory factors
after 1 day of co-culture with macrophages (M0, M1, M2) or tri
tri-culture
culture with macrophages and
ASCs (M0+ASC, M1+ASC). Data w
were normalized to control (i.e., protein levels from the TFs
cultured alone were subtracted from their paired groups) and presented as group means ± SD. *
p < 0.05, multi-factor ANOVA with Fisher’s post-hoc
hoc test. Significant effect of macrophage
102

type for all genes, significant effect of ASCs for IL-1β and PGE2, bars signify Fisher’s post-hoc
comparisons, * by the x-axis labels signifies a significant difference compared to control TFs.
UND = Undetected, (N=5). Note: Control group data (M0, M1, M2) is the same data as
presented in Figure 4.9.
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ASCs suppress the effects of M1 macrophages on the secretion of pro-

inflammatory factors after 5 days of co-culture. Protein expression of inflammatory factors after
1 day of co-culture with TFs and macrophages (M0, M1, M2) or 5 days of tri-culture with TFs,
macrophages and ASCs (M0+ASC, M1+ASC). Data were normalized to control (i.e., protein
levels from the TFs cultured alone were subtracted from their paired groups) and presented as
group means ± SD. * p < 0.05, multi-factor ANOVA with Fisher’s post-hoc test. Significant
effect of macrophage type for both factors, significant effect of ASCs for both factors, bars
signify Fisher’s post-hoc comparisons, * by the x-axis labels signifies a significant difference
compared to control TFs. UND = Undetected, (N=4).

ASCs Demonstrate Limited Ability to Suppress the Effects of M0 Macrophages on TFs: As
described in Chapter 4, M0 macrophages induced up-regulation of various inflammation- and
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matrix degradation-related genes (TNFα, IL-1β, MMP1b, MMP13) and down-regulation of
tendon ECM-related genes (COL1, COL3) by TFs, but not to the extent of M1 macrophage
induction (Figure 5.7).

ASC co-culture with M0 macrophages for 1 or 5 days did not

significantly affect the expression of inflammation-related genes by TFs (Figures 5.7, 5.8).
Similarly, the secretion of pro-inflammatory factors by TFs was also unaffected (Figures 5.9,
5.10).

ASC co-culture with M0 macrophages for 1 day significantly down-regulated the

expression of certain metalloproteinase genes (i.e., MMP1a and MMP3, 2.1-fold each) by TFs
(Figure 5.7), but no effect was observed after 5 days of co-culture (Figure 5.8). However, we
note that MMP1a and MMP3 were not among the genes that were significantly up-regulated by
TF exposure to M0 macrophages (see Chapter 4). When examining ECM- and tendon fibroblastspecific factors, ASC co-culture with M0 macrophages for 1 day led to significant up-regulation
of COL1 and down-regulation of SCX and TNMD (Figure 5.7), but no effect was observed after
5 days of co-culture (Figure 5.8).

ASCs Shift Macrophages Toward an M2 Phenotype: To examine a potential mechanism by
which ASCs co-culture suppressed the negative effects of M0 and M1 macrophages on TFs, the
phenotype of the co-cultured macrophages was determined using flow cytometry. CD11b and
F480 are expressed by all macrophages. In contrast, CD206 and CD301 are cell surface markers
specific to M2 macrophages. ASCs co-cultured with M0 macrophages for a single day led to a 2fold increase in CD301 expression, surpassing the levels of M2 macrophage controls; however,
no shift in CD206 expression was observed (Figure 5.11). The addition of TFs to the co-culture
systems did not alter these trends (Figure 5.11). No apparent phenotypic changes were evident
with ASC co-culture of M1 macrophages (Figure 5.11) after a single day. Increasing the ASC
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co-culture period to 5 days, however, led to significant phenotypic changes in both M0 and M1
macrophages.

M0 macrophages co-cultured with ASCs for 5 days expressed significantly

greater levels of both CD206 and CD301 compared to M0 macrophage controls (1.3- and 4.1fold, respectively). Similarly, M1 macrophages co-cultured with ASCs for 5 days led to a
significant 2-fold increase in the expression of CD206 compared to M1 macrophage controls
(Figure 5.11).
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Figure 5.11: ASC co-culture shifts M0 macrophages toward a M2 phenotype. Mean fluorescent
intensity of M2 macrophage-specific surface markers, CD206 and CD301, after 1 or 5 days of
co-culture. Macrophages (M0, M1, M2 groups) were either co-cultured with TFs for 1 day or
tri-cultured with TFs and ASCs for 1 or 5 days (TFs were only added for the last 24 h). Data are
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presented as group means ± SD. * p < 0.05, † p < 0.10, 2-way ANOVA with Fisher’s post-hoc
test. Significant effects of macrophage type for CD206 and CD301, significant effect of ASCs
for CD301 on day 1 and day 5, significant effect of ASCs for CD206 on day 5. Bars signify
Fisher’s post-hoc comparisons, */† by the x-axis labels signifies a significant difference
compared to control TFs.

5.4

Discussion

In the previous chapters, we characterized the early inflammatory response in vivo after flexor
tendon injury and repair and established two in vitro models to mimic the in vivo environment.
We found that IL-1β and other inflammatory cytokines secreted by macrophages induce upregulation of IL-1β and other pro-inflammatory factors by TFs at both the gene and protein level.
Exposure of TFs to these inflammatory environments also led to up-regulation of factors related
to matrix remodeling and down-regulation of factors related to tendon extra cellular matrix by
the TFs.

Based on studies by other investigators that demonstrate MSC-mediated

immunosuppression170,173,202–247, we sought to investigate the ability of ASCs to modulate
inflammation and its effects on tendon fibroblasts either by acting directly on the inflammatory
cytokine IL-1β, or indirectly by influencing macrophage activity.
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5.4.1 IL-1β-Induced Inflammation Model

To determine whether ASCs could act directly on IL-1β, ASCs and TFs were co-cultured using
transwell plates in the presence or absence of IL-1β. Transwell plates separate the two cell types
with a porous membrane, inhibiting cell-cell contact, but allowing for the diffusion of soluble
factors.

Naïve ASCs did not appear to significantly alter the gene expression or protein

expression of TFs exposed to the inflammatory environment. ASCs that were activated with
IFNγ were also examined for potential protective effects. Co-culture with activated ASCs led to
reductions in the expression of the inflammatory cytokines TNFα and IL-1β and in the matrix
degradation enzyme MMP1; however, these reductions failed to reach statistical significance.
No significant effect of the activated ASCs was seen at the protein level either.

It is well established that MSCs exhibit immunomodulatory effects on lymphocytes through the
secretion of soluble factors173,203,213,215–219,222,225,226,228,229,231,233,234,236,237,239,243–247,314.

Among

other factors, secretion of the anti-inflammatory factor, IL-10, by MSCs has been
reported227,242,316,317. Given that ASCs have been shown to have similar immunomodulatory
capabilities as MSCs173,216,229,231223, we hypothesized that ASCs may have similar effects on our
IL-1β-induced inflammation model. We hypothesized that ASCs would either secrete antiinflammatory factors that would counteract the effects of IL-1β or take up the IL-1β themselves,
effectively reducing the amount of IL-1β in the media.

However, ASCs (both naïve and

activated) failed to suppress the negative effects of IL-1β on TFs.
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The lack of significant ASC-mediated effects observed in this model may be attributed to several
factors. First, the small sample size used in this study, coupled with large variability, may have
resulted in an underpowered statistical analysis. Second, it is possible that the dosage of IL-1β
used in this study was too high for ASCs to overcome. The criterion for the dosage selection
was the lowest dosage that reproducibly elicited significant up-regulation of all of the genes of
interest. Based on this criterion, 10 ng/ml was chosen. However, all genes except TNFα were
significantly up-regulated with only 1 ng/ml of IL-1β, and COX2 and the MMPs were all
significantly up-regulated with as little as 0.01 ng/ml. It remains unclear what dose is the most
physiologically relevant for flexor tendon healing. Third, the number of ASCs and/or the ratio of
ASCs to TFs may influence the outcomes. A 1:1 ASC to TF ratio was chosen based on the MSC
immunosuppression literature, which suggests that a 1:1 ratio is the most effective for the
suppression of lymphocyte proliferation315243202,211,212,214,234,238,315,318,319. These studies, however,
tested ratios up to and including 1:1, but not greater than 1:1. A higher ratio of ASCs to TFs may
prove beneficial. Lastly, the proposed hypothesis may have been incorrect. We sought to
determine whether ASCs could act directly on inflammatory factors (such as IL-1β) to protect
TFs from a harmful inflammatory environment (Figure 5.1). Based on the literature, however, it
is more likely that the suppression of inflammatory factors observed by other investigators was a
result of ASC-mediated inhibition of the immune cells that secrete such factors (e.g.,
lymphocytes).
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5.4.2 Macrophage-Induced Inflammation Model

The ability of MSCs to alter inflammation indirectly through the modulation of immune cells has
high clinical relevance for tendon repair. We previously demonstrated that monocytes infiltrate
the repair by day 3 (see Chapter 2). Studies by other investigators have indicated that M1
macrophages (which share the same lineage as monocytes) are present during tendon-to-bone
healing and that suppression of M1 macrophages may be advantageous for healing92,93,97,320.
Other studies suggest that MSCs can reprogram inflammatory, M1 macrophages into antiinflammatory, M2 macrophages136,138,139,141,143,220,245,255,257,271. Thus, we established a tri-culture
model to test the ability of ASCs to modulate the inflammatory environment by altering
macrophage phenotype.

ASCs were cultured in direct cell-cell contact with M0 or M1

macrophages and in indirect contact with TFs using a transwell system.

Previously, we found that M1 macrophages significantly increase TF expression of proinflammatory and matrix degradation-related genes, while concurrently down-regulating
expression of extracellular matrix- and tendon fibroblast differentiation genes (see Chapter 4). In
the current study, we found that ASCs significantly suppress these negative effects when cocultured with M1 macrophages for 1 day. ASCs co-cultured with M1 macrophages for 1 day led
to a significant down-regulation of pro-inflammatory and matrix degradation genes (TNFα,
MMP1a, MMP3) toward, but not reaching, baseline values. However, the reduction of TNFα at
the gene expression level was not observed at the protein level. Moreover, while no changes
were observed in the TF gene expression of IL-1β or COX2, a significant increase in the
associated proteins were observed (1.5- and 1.6-fold, respectively).
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Differences in gene

expression and protein expression can be explained by several factors. First, changes in gene
expression occur prior to changes in protein expression due to the time required for translation of
the gene into a protein. Moreover, genes can be differentially expressed, but never translated.
Second, whereas the source of the gene expression can be isolated to a single cell type in this
model (i.e., TFs), the source of the protein expression cannot. Due to the co-culture system,
protein levels measured in the supernatant are a combination of proteins secreted by all cell types
(i.e., TFs, macrophages, ASCs). However, this is similar to the source of proteins in the in vivo
repair setting. Of note, IL-1β was increased only in the presence of TFs, indicating that the TFs
are involved in producing the additional IL-1β, either directly or indirectly through feedback to
the macrophages or ASCs. PGE2, on the other hand, was increased in the absence of TFs, but
not in the presence of TFs.

Increased durations of ASC exposure led to further down-regulation of pro-inflammatory and
matrix degradation genes towards baseline. ASC co-culture of M1 macrophages for 5 days
resulted in an additional 6.2-fold down-regulation of MMP3 compared to only 1 day of ASC coculture. Moreover, inflammation- and matrix-remodeling genes that were not differentially
regulated after 1 day of co-culture were differentially regulated after 5 days. For example,
COX2 was down-regulated 11.3-fold compared to control after 5 days (i.e., M1 macrophages
alone).

This large reduction in COX2 gene expression parallels the significant reduction

observed in PGE2 production (a product of COX2). Similarly, TNFα and IL-1β gene expression
were down-regulated 2.4- and 7.1-fold at the gene expression level. While these changes were
not statistically significant, parallel, statistically significant reductions of TNFα and IL-1β were
observed at the protein level. 5 days of ASC co-culture also led to the suppression of the matrix
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degradation gene, MMP1b (7-fold), and the up-regulation of the ECM-related gene, COL1 (1.8fold, not statistically significant).

To determine the mechanism by which ASC co-culture suppressed the negative effects of M1
macrophages on TFs, the co-cultured macrophages were examined using flow cytometry.
Analysis of the cell surface markers revealed a shift in phenotype from M1 to M2 with ASC coculture. Whereas the surface markers CD11b and F480 are expressed by all macrophages;
CD206 and CD301 are specific to M2 macrophages. No apparent phenotypic changes were
evident with ASC co-culture of M1 macrophages after a single day; however, 5 days of coculture led to a significant 2-fold increase in the expression of CD206 compared to M1
macrophage controls. Moreover, flow cytometry revealed an increased ability of ASCs to push
M0 macrophages toward a M2 phenotype (compared to M1 macrophages). ASC co-culture with
M0 macrophages for 1 day led to a 2-fold increase in CD301 expression, surpassing the levels of
M2 macrophage controls. By day 5, an additional 2.1-fold increase in CD301 expression was
observed (for a total 4.1-fold increase compared to control) and a small, but statistically
significant increase in CD206 was evident (1.3-fold).

These results are in agreement with those of Kim et al. demonstrated a shift in macrophage
phenotype when co-cultured with bone marrow-derived MSCs in vitro 255,257. In addition, Kim et
al. observed increased levels of the anti-inflammatory cytokine IL-10 and decreased levels of the
pro-inflammatory cytokine TNF-α compared after 5 days of co-culture.

However, the

mechanisms by which this phenotypic switch occurs remains unclear. Francois et al. suggest that
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MSC-secreted IDO (an intracellular enzyme that catalyzes tryptophan into kynurenine249) is
responsible for this phenomenon220 (Figure 1.11).

When IDO was inhibited using a

pharmacological inhibitor (1-MT), IL-10 production was suppressed, indicating a possible
involvement of IDO in the differentiation of monocytes into anti-inflammatory M2
macrophages220,261.

While ASC appear to have a limited ability to suppress the negative effects of M0 macrophages
on TF gene expression, their ability to push M0 macrophages toward an M2 phenotype remains
attractive. As seen in Chapter 4, the effects of M0 and M2 macrophages on TFs are significantly
less than those induced by M1 macrophages (see Chapter 4).

Since the vast majority of

macrophages at the site of wound repair are recruited from the bone-marrow as undifferentiated
monocytes, this is an attractive target for improved tendon healing. Thus, early treatment with
ASCs could potentially promote differentiation of the infiltrating monocytes towards the antiinflammatory M2 macrophage lineage as opposed to the pro-inflammatory M1 macrophage
lineage. Without such treatment, the monocytes would typically revert to an M1 macrophage
phenotype due to the abundance of inflammatory factors (including IFNγ) at the repair site.
However, our results suggest that ASCs may be able to suppress the negative effects of M1
macrophages even if the treatment is delayed until after monocytes have differentiated into M1
macrophages. Since M2 macrophages are unlikely during the early period after surgical repair
and differentiation of monocytes in M2 macrophages is the ultimate goal, no M2+ASC group
was examined in this study.
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These results are in agreement with those of other investigators. Kim et al. revealed increased
expression of CD206 by non-polarized macrophages (i.e., M0 macrophages) after 4-5 days of
direct or indirect co-culture with MSCs255. However, the authors did not compare these levels to
those of M2 macrophage controls. In the current study, we found that CD206 expression was
increased in both M0 and M1 macrophages after 5 days of ASC co-culture. However, these
levels were significantly lower than those of M2 macrophage controls. Moreover, we also
examined a second M2-specific surface marker, CD301. We found that CD301 expression was
increased in M0 macrophages after 5 days of ASC co-culture to levels that surpassed those of
M2 macrophage controls. Kim et al identified altered intracellular cytokine staining after MSC
co-culture via flow cytometry255. Co-cultured macrophages exhibited increased expression of
the anti-inflammatory cytokine, IL-10, and decreased expression of pro-inflammatory cytokines,
TNFα, IL-12, and IL-6255. In the current study, we did not examine intracellular cytokine
expression, but rather the secretion of such products. Similarly, we found a significant decrease
in TNFα production after 5 days of MSC co-culture with M0 macrophages. However, we did
not observe expression of IL-10 in any of the experimental or control groups.

In our model, ASC co-culture for a longer period led to more pronounced effects. However, the
data from the ASC co-cultured groups were obtained on day 5, whereas the data from the control
groups (M0, M1, M2) was obtained on day 1. Thus, we are unable to say with certainty whether
the enhanced effects with increased co-culture period were due to increased time for ASCs to
induce phenotypic changes in the co-cultured macrophages, or whether there were fewer viable
macrophages at the 5 day timepoint and thus fewer inflammatory factors being secreted into the
media.

To better control for this possibility, the control groups were repeated at longer
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timepoints. As with the co-culture groups, the macrophages were primed to become M1 or M2
macrophages or left untreated (M0) for 1 day. The cells were then cultured in standard medium
for an additional 4 days. Under these conditions, however, decreased macrophage viability over
time resulted in fewer macrophages present when TFs were added. While this timepoint issue is
a limitation of the gene and protein expression assays of this study, the increased expression of
CD206 and CD301 over time strongly supports the idea that longer periods of ASC exposure
will lead to further down-regulation of inflammation- and matrix remodeling-related genes and
up-regulation of tendon extracellular matrix-related genes towards baseline levels.

5.4.3 Overall Conclusions

Overall, this study supports the premise that ASCs can modulate the inflammatory environment.
While there is little evidence to support the hypothesis that ASCs can counteract the effects of
IL-1β directly, there is strong evidence to support the notion that ASCs can reprogram proinflammatory M1 macrophages into anti-inflammatory M2 macrophages, thus reducing the
amount of pro-inflammatory cytokines produced (Figure 5.12). Furthermore, if ASC treatment
is performed prior to monocyte differentiation into M1 macrophages, ASCs may be able to
further modulate the inflammatory environment by pushing the undifferentiated (M0)
macrophages towards a M2 phenotype. Studies by other investigators suggest that modulation of
the healing environment through the recruitment of anti-inflammatory M2 macrophages, as
opposed to pro-inflammatory M1 macrophages may be advantageous for tendon healing92–94.
ASCs delivered at the time of intrasynovial flexor tendon repair may enhance flexor tendon
healing by modulating the early inflammatory phase via M2 macrophage differentiation. In
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order to translate these in vitro findings, a delivery system capable of delivering and retaining
ASCs at the repair site must be developed. Such a system will be described in Chapter 6.

ASC

?
M1
Figure 5.12:

IL-1β

TF

ASCs can modulate the inflammatory environment by reprograming pro-

inflammatory, IL-1β-producing M1 macrophages into anti-inflammatory M2 macrophages.
There was little evidence to support the hypothesis that ASCs could directly counteract the
effects of IL-1β. There was strong evidence to support the hypothesis that ASCs can modulate
the amount of pro-inflammatory factors (such as IL-1β), by inducing a phenotypic switch from
pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages and by suppressing
production of factors my macrophages.
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Chapter 6 - Controlled Delivery of Adipose-Derived Mesenchymal
Stem Cells Using a Nanofiber Scaffold for Tendon Repair
6.1

Introduction

Previously, we demonstrated that the early inflammatory phase of flexor tendon healing is
characterized by a remarkable 4000-fold up-regulation of IL-1β gene expression (see Chapter 2).
IL-1β has been reported to induce negative effects on tendon fibroblasts in vitro and on ex vivo
tendon explants155,163,267,268,274,278,321. We confirmed that IL-1β exposure induces up-regulation of
pro-inflammatory factors and catabolic MMPs by TFs (see Chapter 3).

Furthermore, we

investigated the effects of M1 macrophages (a primary source of IL-1β) on TFs and found
similar up-regulation of inflammation- and matrix-degradation-related genes as well as downregulation of tendon ECM-related and TF-specific genes (see Chapter 4). Co-culture of M1
macrophages with ASCs suppressed the negative effects of M1 macrophages on TFs by inducing
a phenotypic switch from a pro-inflammatory phenotype (M1) to an anti-inflammatory
phenotype (M2). In this chapter, we aim to develop a scaffold capable of delivering ASCs in vivo
at the time of flexor tendon repairs to translate the in vitro findings for enhanced flexor tendon
healing.

Most approaches for delivering cells in vivo have not been designed for dense connective tissues
such as tendon. Therefore, a new scaffold is presented herein that combines a fibrin-based
hydrogel with an aligned electrospun nanofiber poly lactic co-glycolic acid (PLGA) backbone.
The scaffold consists of eleven alternating layers of PLGA nanofiber mats and fibrin matrices
(i.e., 6 layers of PLGA and 5 layers of fibrin). The scaffold allows for the delivery of cells in a
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controlled manner86–88,115, while the PLGA backbone provides a structure that mimics collagen
fiber diameter and alignment in tendon and enhances the surgical handling properties of the
scaffold. While natural matrices (e.g., collagen, fibrin) are advantageous in terms of
biocompatibility, polymers (e.g., PLGA) provide better control of degradation and mechanical
properties. PLGA was chosen because it is biodegradable, has the appropriate mechanical
properties, can easily be electrospun, and is FDA approved322,323. PLGA polymer nanofiber mats
are biodegradable in an aqueous environment but are resistant to enzymatic degradation. The
ratio of lactic to glycolic monomers can be varied to alter the degradation rate and mechanical
properties.

In the current study, we present a novel scaffold for use in tendon repair. The ability of the
scaffold to maintain cell viability is demonstrated in vitro. Scaffold biocompatibility, feasibility
for use in tendon repair, and post-implantation cell viability are demonstrated in vivo using a
clinically relevant large animal model of flexor tendon injury and repair. In this study, our aims
were to show that: (1) controlled delivery of ASCs can be achieved from the scaffold, (2) the
scaffold can be implanted successfully at a flexor tendon repair site in vivo, (3) the scaffold is
biocompatible in vivo, and (4) ASCs implanted at the time of flexor tendon repair suppress the
expression of pro-inflammatory and matrix degradation factors.
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6.2

Methods

6.2.1 Fibrin/nanofiber layered scaffold fabrication
The fibrin/nanofiber scaffold consisted of eleven alternating layers of aligned electrospun PLGA
nanofiber mats and fibrin matrices (i.e., 6 layers of PLGA and 5 layers of fibrin, Figure 6.1).
PLGA was chosen because of its biodegradability and mechanical properties322–324. The
electrospinning solution was prepared at a concentration of 0.25 g/mL by dissolving PLGA
(85:15, MW 50,000-75,000, Sigma Aldrich) in a mixture of dichloromethane and
dimethylformamide at a ratio of 4:1. The solution was loaded into a plastic syringe equipped
with a stainless steel needle (23-gauge) connected to a high-voltage supply (ES30P-5W, Gamma
High Voltage Research). The feed rate was set at 0.5 mL/h, controlled by a syringe pump (KDS200, Stoelting). Fibers with diameters of 400-700 nm (similar in size to collagen fibrils in
tendon) were collected on a custom-made rotating mandrel to create a uniaxial array of
nanofibers designed to mimic the anisotropic ECM of tendon tissue (Figure 6.1, B inset)

325,326

.

After 2.5 h of electrospinning, the polymer nanofiber mat (~100 micrometers) was released from
the collector and freeze-dried for 72 hr to remove residual solvents. Scanning electron
microscope images (SEM, FEI Nova 200 Nanolab, accelerating voltage 5kV, 3500X) of
representative scaffolds were used to calculate the approximate diameter and orientation of the
fibers. The nanofiber mats were then sterilized with ultraviolet light for 30 min (Thermo
Scientific, model 1375, wavelength 253.7nm, power 40W) and cut into 3x7 mm pieces (with the
fibers aligned in the 7 mm direction).
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PLGA Nanofibers
Fibrin
Cell Nuceli

Figure 6.1: A representative fibrin/nanofiber scaffold with eleven alternating layers of aligned
electrospun PLGA nanofiber mats separated by fibrin containing 1x106 ASCs is shown. (A-D)
Micrograph showing the fibrin/nanofiber scaffold in vitro; the PLGA was labeled with FITC
(green), the fibrin was labeled with Alexa Fluor 546 (red), and the ASC nuclei were labeled with
Hoescht 33258 (blue) (scale bar = 200 µm). (B inset) SEM image of the scaffold showing
PLGA nanofiber alignment. (E) Micrograph showing the fibrin/nanofiber scaffold in vivo 9 days
after implantation in a tendon repair. Eleven alternating layers of PLGA and fibrin can be seen
(i.e., 6 layers of PLGA and 5 layers of fibrin); the PLGA was labeled with FITC (green) (scale
bar = 100 µm). (F) A schematic of the layered scaffold is shown.

Fibrin matrices (30 µl total) were made with the following final component concentrations: 10
mg/mL of human fibrinogen concentration (20 mg/ml stock solution, EMD Bio), 6.9 mM of
CaCl2 (50mM stock solution), and 12.5 units/mL of thrombin (1000U/ml stock solution) in Tris-
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buffered saline (137 mM NaCl, 2.7 mM KCl, 33 mM Tris; pH, 7.4). The fibrin was polymerized
directly onto the PLGA nanofiber mats (one layer at a time, 6 µL per layer), effectively serving
as a bond between layers. Once fibrin and thrombin were mixed together, the fibrin layer began
to polymerize within 30 s and reached a gel-like consistency within 1-2 min. The nanofiber mat
was placed on top of the fibrin after the fibrin reached a gel-like consistency. This process was
repeated to build a scaffold with the appropriate number of layers. The assembly of each
scaffold in this study was completed in ~15 minutes. The assembled scaffold was then left in the
incubator (37ºC, 5%CO2, 95% humidity) for ~1 hr to allow for complete fibrin polymerization
and full adherence between the fibrin and the nanofiber mat layers. For cellular scaffolds, 1x106
ASCs (per scaffold, 3.3x104 cells/µL) were incorporated into the fibrinogen solution prior to
polymerization. The final dimensions of the scaffolds were 7x3x1 mm (Figure 6.1, E).

6.2.2 Cell isolation and culture
ASCs were isolated 1-2 weeks prior to use. Adipose tissue from the abdominal cavity of canines
(N=8) was removed surgically. To harvest adipose tissue, dogs were sedated and a 2-4 cm skin
incision was made in the caudal abdomen just below the umbilicus exposing the subcutaneous fat
lying lateral to the midline. A 10-15 g sample of adipose tissue was isolated and excised
bilaterally and the skin wound was closed. The adipose tissue was minced and digested in 0.2%
Collagenase A in PBS for 2 h, collected, and centrifuged for 10 minutes at 12,000 rpm. The
digested tissue was filtered using a cell strainer and pelleted by centrifugation. The supernatant
was aspirated and the pelleted cells were resuspended in alpha-MEM with 10% FBS and 1 % P/S
and cultured for 1-2 weeks (37°C, 5% CO2, 100% humidity). The cells were used between
passages 2-4. Numerous investigators, using similar isolation methods, have described the
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resultant cell population as mesenchymal stem cells based on surface markers (via FACS) and
pluripotency229,327–329.

The cells in the current study demonstrated pluripotency based on

standard adipogenic, osteogenic, chonodrogenic, and tenogenic protocols (data not shown).

6.2.3 In vitro experiments
Cell culture: A set of scaffolds was fabricated for in vitro time-zero imaging in order to
visualize the different components of the constructs (Figure 6.1A-D). These scaffolds contained
fluorescein isothiocyanate (FITC)-labeled PLGA, Alexa Fluor 546-labeled fibrinogen
(Invitrogen Corporation, CA), and ASCs labeled with Hoechst 33258 (Invitrogen Corporation,
CA). A series of in vitro experiments were also performed to assess the viability and
proliferation of ASCs within the fibrin/nanofiber scaffold.

Cell viability: To assess the viability and proliferation of ASCs within the scaffold, a set of
fibrin/nanofiber scaffolds containing 1x106 ASCs were fabricated (N=4 cell isolations, 20
scaffolds total) and cultured in 24 well plates for up to 14 days. The scaffolds were given fresh
phenol-free alpha-MEM containing 10% FBS and 1% P/S daily. At each sacrificial time point (0,
3, 7, 11, and 14 days) the scaffolds were delaminated with forceps (i.e., the individual layers of
the scaffold were separated from each other) and a Vybrant 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) Cell Proliferation Assay (Invitrogen Corporation, CA) was
performed according to the manufacturer’s instructions. Live cells reduced the MTT solution to a
purple formazan product, which was solubilized with 200µl of 2-Propanol. The absorbance of the
solubilized formazan was measured using a microplate reader at 470 nm. The relative number of
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live cells within the scaffold was determined by averaging the absorbance values of four
different cell isolations at each timepoint and normalizing to the day 0 samples (which contained
1x106 ASCs).

6.2.4 In vivo experiments
Flexor tendon animal model: All procedures were approved by the Washington University
Animal Studies Committee. A series of surgeries were performed in order to: (1) ensure that the
scaffold did not elicit a negative inflammatory response, (2) determine cell viability, and (3)
determine the early degradation of the scaffold after implantation. Prior to cell seeding and
assembly of the scaffolds, ASCs were labeled with a fluorescent membrane dye (Di-I,
Invitrogen) according to the manufacturer’s instructions. Flexor tendon injury and repair was
performed in the clinically relevant canine animal model (N=26) using surgical techniques
identical to those used in humans7,8,86,99,263,330. Eleven-layer scaffolds (dimensions: 7x3x1 mm),
either containing 1x106 autologous ASCs (isolated 7 day prior) or left acellular, were implanted
into the intrasynovial flexor tendons of adult mongrel dogs (20-30kg, Covance, Denver,
Pennsylvania) at the time of repair as follows (Figure 6.2). The sheaths of the second and fifth
digits of the right forelimb in the region between the annular pulleys proximal and distal to the
proximal interphalangeal joint were exposed through midlateral incisions. The sheaths were
entered and the flexor digitorum profundus tendons were transected sharply. Longitudinally
oriented horizontal slits were created in the center of each tendon stump for scaffold
implantation. The fibrin/nanofiber scaffold was secured within the repair site using a core suture
(4-0 Supramid) and sealed in that location using a running epitenon suture (6-0 Proline). Each
canine received one cellular and one acellular scaffold or one acellular and one repair without
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any additional treatment in either the second or fifth digit. After surgery, the operated-on right
forelimb was immobilized using a fiberglass shoulder spica cast with the elbow flexed to 90° and
the wrist flexed to 70°. To mimic the typical clinical post-operative rehabilitation protocol,
controlled passive motion was applied to the digits during two five-minute rehabilitation sessions
performed five days a week starting on the first postoperative day3,25. The dogs were euthanized
at 3 or 9 days post-operatively. The operated tendons were removed by dissection and prepped
for either gene expression analysis at 3 days (N=3-11), histologic analysis at 9 days (N=6; 3 for
immunofluorescent imaging and 3 for evaluation of biocompatibility), and total DNA analysis at
9 days (N=5). Adhesion formation between the tendon and its sheath was qualitatively evaluated
at the time of dissection. Tendons from the contralateral paw were also dissected to serve as
normal/uninjured controls. A subset of scaffolds (N=3) was prepared with a small amount of
fluorescein isothiocyanate (FITC, 1.85 µg per scaffold) incorporated into the PLGA during
fabrication. These scaffolds were prepared in order to identify the scaffold 9 days postoperatively using fluorescent imaging of histologic sections. A “time-zero” control was also
performed on a cadaver animal to assess the scaffold structure and cellularity at the time of
implantation.

123

Figure 6.2: A depiction of the surgical technique. (A, D) Flexor tendons were transected sharply
and longitudinally oriented horizontal slits were created in the center of each tendon stump. (B,
E) A fibrin/nanofiber scaffold was grasped by a core suture. (C, F) The scaffold was secured
within the repair site.

Histology: Upon dissection, adhesion formation was assessed qualitatively. It was noted whether
any adhesions were present, and if so, whether they were mild or severe. Tendons allocated for
histology were fixed in 4% paraformaldehyde overnight, frozen in Optimal Cutting Temperature
Compound (Tissue-Tek CRYO-OCT, Fisher Scientific), and cut into 5 µm sections. The
residence time of the scaffold and the viability of the implanted cells were examined using a
fluorescent microscope equipped with the appropriate filters. To examine the immune response
at the periphery of the scaffold, sections were stained with H&E and assessed for various
immune cells (i.e., PMNs and monocytes) by an independent certified pathologist, blinded to
group. However, we note that the scaffold was apparent in some sections. Fibroblasts were
characterized as spindle-shaped cells with an elliptic nucleus and thin cytoplasm. PMNs were
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identified as cells containing nuclei with two to four lobules and a granulated cytoplasm while
cells with a single-lobed or kidney-shaped nucleus were classified as monocytes. Apoptotic cells
were characterized by nuclear fragmentation and condensation. A standard scoring system was
used to determine the levels of each outcome (- no prevalence, + mild prevalence, ++ moderate
prevalence, +++ marked prevalence). For overall cellularity and the prevalence of certain cell
types, the number of cells per high powered field (HPF, 20x) was counted and assigned a score
as follows: + <50 per HPF, ++ 51-100 per HPF, +++ 101-150 per HPF, ++++ >150 per HPF.
Apoptosis and vascularity were measured on the following scale: + <5 per HPF, ++ 6-10 per
HPF, +++ > 10 per HPF. All assessments were done using a 20x objective and 5-8 fields of view
were averaged. Sections were also stained with Picrosirius Red for collagen alignment and
viewed under polarized light. The analysis focused on the tissue adjacent to the scaffold.

Quantitative Real-time PCR: Tendons allocated for gene expression were dissected and 10 mm
sections (5 mm on each side of the repair) were isolated and immediately flash frozen in liquid
nitrogen. RNA was extracted from the tendons using the RNeasy mini kit (Qiagen, CA)
following the manufacturer’s protocol. RNA yield was quantified using a NanoDrop
spectrophotometer (Thermo Scientific, DE) and 500 ng of RNA was reverse transcribed to
cDNA using the Superscript VILO cDNA synthesis kit (Invitrogen Corporation, CA) following
manufacturer’s instructions. Real time PCR reactions were performed using SYBR Green
chemistry on a StepOnePlus Real-Time PCR System (Applied Biosystems, CA). All primers for
real-time PCR were purchased (Qiagen, CA). Gene expression changes were measured for the
inflammation-related genes (TNFα, IL-1β, and COX-2) and matrix degradation-related genes
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(MMPs -1, -3, -13). Results were expressed as fold change relative to the housekeeping gene
(GAPDH).

Total DNA Content: Tendons allocated for Total DNA Content (N=5) were dissected and 10 mm
sections (5 mm on each side of the repair) were isolated. The tendon samples were digested with
papain and DNA content was determined fluorometrically with use of a PicoGreen assay kit
(Invitrogen, CA). The results were normalized to the dry weight of the tendon sample.

6.2.4 Statistics
Cell viability within the scaffolds over time was assessed using paired t-tests to compare
absorbance values at each timepoint and the values obtained on day 0. To determine the effect of
the fibrin/nanofiber scaffold on inflammation- and matrix remodeling-related gene expression,
mean Ct values were compared using an ANOVA (groups: cellular, acellular, repair-only,
normal) followed by a least squared differences post-hoc test when the ANOVA showed a
significant effect. A paired t-test was also performed on the Ct values of GAPDH to ensure the
consistency of our housekeeping gene (p > 0.05). Samples from the same animal were treated in
a paired fashion to account for animal-to-animal variances. The total DNA content was
compared between cellular, acellular, and uninjured groups using a multi-factor ANOVA.
Significance for all statistical analyses was set to p <0.05.
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6.3

Results

6.3.1 Cells remain viable in the fibrin/nanofiber scaffold in vitro
The number of cells within the scaffolds remained approximately constant for up to 14 days in
vitro, with no statistically significant changes over time (Figure 6.3). The percentage of viable
cells on day 14 compared to day 0 was approximately 81%. Stable cell numbers over time could
result from maintenance of non-proliferating cells or a balance between proliferating, migrating,
and apoptotic cells, resulting in a zero-sum outcome. Migration of cells out of the scaffold and
onto the plastic of the wells was indeed observed. Migration of cells out of the scaffold in the in
vivo setting may allow the cells to incorporate into the adjacent tendon tissue and produce new
extracellular matrix. A type II statistical error cannot be ruled out for the non-significant cell
number outcome; a post hoc power analysis revealed that 14-18 samples would be required to
detect a statistically significant difference for the effect size seen (i.e., a 15% increase in viability
at day 1 or 13-26% decreases in viability at days 3 – 14).

Change from Day 0 (%)

Cell Viability
160
120
80
40
0
1

3

4
Time (Days)

11

14

Figure 6.3: Cells remain viable within the fibrin/nanofiber scaffold for up to 14 days in vitro.
Data are presented as a percent change in cell viability compared to day 0. No significant
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decreases in cell viability were observed at any timepoint (1-14 days) compared to day 0,
p ≥ 0.05, paired t-tests (N=4).

6.3.2 The fibrin/nanofiber scaffolds were well-tolerated in the in vivo flexor tendon repair
setting
Based on gross observations at the time of dissection, the fibrin/nanofiber scaffold did not elicit
any negative responses. The tendons were intact and had minimal adhesions at the repair site
(Figure 4D). Out of 7 repair-only samples, 5 had no adhesions, 2 had mild adhesions, and 0 had
severe adhesions. Out of 7 repairs that received scaffolds, 5 had no adhesions, 1 had mild
adhesions, and 1 had severe adhesions. Histological analysis showed a mild influx of immune
cells (i.e., PMNs and monocytes) around the implanted scaffolds 9 days post-operatively (Figure
6.4, Table 6.1). Overall cellularity was increased in the group that received the scaffold,
including increases in PMNs and monocytes. A small increase in apoptotic cells was also
observed and was related to the increased presence of PMNs. No significant difference was
noted for vascular profiles between the two groups.
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Figure 6.4: No significant immune response was elicited by the fibrin/nanofiber scaffolds when
implanted in vivo at the site of flexor tendon repair. (A-C) Representative histologic sections of
a tendon that was repaired using an acellular fibrin/nanofiber scaffold. The sections were stained
with either H&E and viewed under brightfield for cell identification (A and C) or stained with
Picrosirius Red and viewed with polarized light for collagen alignment (B). No obvious
inflammatory response was observed with the implantation of the scaffold 9 day postoperatively. Only a small number of immune cells infiltrated the scaffold (black arrows in C).
The image in C corresponds to the black box in A. (A, B: 4x objective, 1 mm scale bar; C: 40x
objective, 100 µm scale bar) (D) Gross observations of repaired tendons show no gapping at the
repair site. A representative sample shown here demonstrates no gap (black arrow) and no
adhesions between the tendon and the sheath (white arrows) 9 days post-operatively.
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Normal

Repair-Only

Scaffold

Cellularity

-

++

+

Vascularity

-

-/+

-

FB

-

+

++

PMN

-

+

++

Mono

-

++

++

Apoptosis

-

-

+

Table 6.1: The fibrin/nanofiber scaffolds elicited only a mild immune response in the in vivo
flexor tendon repair setting. Histological analysis of the immune response to the fibrin/nanofiber
scaffold was assessed 9 days post-operatively. The number and type of immune cells present in
tendons after implantation of an acellular scaffold was compared to those present in the repaironly and the normal/uninjured groups. A standard scoring system was used to determine the
levels of each outcome (- no prevalence, + mild prevalence, ++ moderate prevalence, +++
marked prevalence). FB = foreign body, PMN = polymorphonuclear cells, Mono = monocytes,
(N=3).

Similarly, there were no statistically significant changes when comparing qRT-PCR results for
tendons that received acellular scaffolds to those that were repaired without any additional
treatment (Figure 6.5). For certain genes, a type II statistical error was possible when comparing
expression in the acellular scaffold group to expression in the naïve repair group. Based on a
post-study power analysis: N=24 would be required to show that TNFα was significantly higher
130

in the repair-only group, N=28 would be required to show that COX2 was significantly higher in
the scaffold group, N=39 would be required to show that MMP3 was significantly higher in the
scaffold group, and N=14 would be required to show that MMP3 was significantly higher in the
scaffold group. As expected both repair groups showed a significant up-regulation in gene
expression relative to uninjured controls (Figure 6.5). Using fluorescent labeling and imaging
techniques, the scaffold was identifiable at the repair site 9 days post-operatively, indicating a
slow degradation rate relative to the time-course of tendon healing (Figure 6.1E).
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The fibrin/nanofiber scaffolds did not significantly alter the expression of

inflammation- and matrix degradation-related genes. Genes related to inflammation (top row)
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and genes related to matrix remodeling (bottom row) were significantly up-regulated in the
repair setting (i.e., acellular scaffold and naïve repair groups) relative to uninjured control. There
were no significant differences in gene expression when comparing the acellular scaffold and
naïve repair groups. (* p < 0.05 compared to uninjured group).

6.3.3

Successful delivery of ASCs was achieved in vivo using the fibrin/nanofiber scaffolds

Fluorescent imaging verified the viability of the implanted cells 9 days post-operatively. Colocalization of the membrane dye (Di-I) and the nuclear stain (Hoescht 33258) were evident in
the time zero and 9 day cellular groups, but not in the 9 day acellular group (Figure 6.6A-C). In
support of the qualitative fluorescent imaging, there was a significant increase in total DNA
content in the cellular group compared to the acellular group and normal/uninjured controls
(Figure 6.6D). While there is a significant increase in the total DNA of the cellular group, the
DNA assay does not distinguish between cell types. We cannot determine, therefore, whether
that increase was due to the implanted ASCs or infiltration of additional cells (via a chemotactic
mechanism initiated by the ASCs). Moreover, the comparison between the uninjured group and
acellular group indicates that the scaffold alone attracts host cells, however, neither the origin nor
phenotype of these cells could be determined (e.g., inflammatory vs. fibroblastic).
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Figure 6.6: Cells remained viable after in vivo implantation using the fibrin/nanofiber scaffolds.
(A-C) Micrographs
ographs showing the fibrin/nanofiber
/nanofiber scaffolds at implantation (day 0) and 9 days
after implantation. ASCs were labeled with the fluorescent membrane dye Di-I
Di (red) prior to
seeding and PLGA was labeled with FITC (green). Sections were stained with Hoescht 33258
(blue) to label all cell nuclei. Co
Co-localization
localization of the membrane dye (red) and the nuclear stain
(blue) was apparent at day 0 and 9 days after repair, indicating cell viability. An acellular
scaffold is shown 9 days post-operatively
operatively for comparison. Scale bars = 200 µm for main images
and 50 µm for insets. (D) Total DNA content in uninjured tendons, repaired tendons that
received acellular scaffolds, and repaired tendons that re
received
ceived cellular scaffolds. Bars signify
p < 0.05, (N=5).
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6.3.4

ASC delivery did not significantly suppress the early inflammatory response after

flexor tendon healing
Preliminary results show minimal effects of ASC delivery on the expression of inflammationand matrix degradation-related genes. As seen previously, expression of inflammatory genes
(TNFα, IL-1β, COX2) and matrix degradation genes (MMP1, MMP3, MMP13) were all upregulated in the repair setting (i.e., repair only vs. uninjured, acellular scaffold vs. uninjured)
(Figure 6.7). The addition of 1 million ASCs to the scaffolds did not significantly suppress the
expression of these factors.

While the expression of IL-1β 3 days post-operatively was

decreased (2.1-fold) in the cellular scaffold group compared to the acellular scaffold group, this
change failed to reach statistical significance (Figure 6.7). Similarly, MMP1 and MMP3 were
also down-regulated (2.0- and 1.3- fold, respectively) with ASC treatment (i.e., cellular vs.
acellular), but statistical significance was not achieved (Figure 6.7). Moreover, on day 9, there
was a statistical trend towards down-regulation of MMP1 (1.2-fold) with ASC treatment;
however, this change did not reach statistical significance (p < 0.10). The lack of significance in
this pilot study may have been due to the small sample size (N=3). A type II statistical error was
possible when comparing expression in the acellular scaffold group to expression in the cellular
scaffold group. Based on a post-study power analysis (80% power, 95% confidence): N=12
would be required to show that IL-1β was significantly lower in the cellular group, N=6 would
be required to show that MMP1 was significantly lower in the cellular group, and N=31 would
be required to show that MMP3 was significantly lower in the cellular group. For a sample size
of N=9, the small increase in MMP13 in the cellular group (compared to the acellular group)
would become significant.
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Figure 6.7: Implanted ASCs had a limited effect on the in vivo expression of inflammation- and
matrix degradation-related genes. ASC treatment did not have a statistically significant effect on
genes related to inflammation (top row) or genes related to matrix remodeling (bottom row) 3 or
9 days post-operatively.

There were no significant differences in gene expression when

comparing the acellular and cellular scaffolds. A significant effect of group (i.e., uninjured,
repair only, acellular scaffold, cellular scaffold) was observed for all genes. A significant effect
of time (i.e., 3d vs. 9d) was observed for all genes except for MMP1 and MMP3. * p < 0.05, † p
< 0.10. Star by the x-axis indicates a significant difference compared to the uninjured group.
Note: The data from the uninjured, 3 day repair, and 3 day acellular groups were previously
presented in Figure 6.5, but are presented here again to examine the effect of ASC treatment.
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6.4

Discussion

In the current study, we presented an innovative, layered scaffold design that combined the cell
delivery capabilities of fibrin and the structural integrity of a PLGA nanofiber mat. The layered
design allows for modularity; the size of the scaffold can be tailored to the specific tendon
application, and the cell delivery can be controlled. Importantly, in vivo studies in a clinically
relevant large animal study demonstrated that the delivered ASCs remained viable for at least 9
days post-operatively. Furthermore, histological and gene expression outcomes from the animal
model demonstrated that the scaffold was biocompatible up to 9 days in the relevant tendon
healing setting.

A number of questions must be resolved before the scaffold presented here can be used
clinically. First, although data in the current study indicate that the scaffold is well tolerated in
vivo, there is a chance that the PLGA will incite a negative reaction under some conditions. The
scaffold did attract a small number of PMNs and monocytes, which led to a mild increase in
apoptosis. Moreover, MMP and COX-2 gene expression in the scaffold group were increased, on
average, in the current study compared to the naïve repair group. These increases, however, were
not statistically significant. Second, we tracked implanted ASCs using a membrane dye.
Although this dye will label cells, it does not indicate whether the cells are alive. The same
limitation applies to the total DNA assay, which will label DNA regardless of cell viability. Colocalization of the membrane dye with a nuclear dye (see inset of figure 7B) provides evidence
that the implanted ASCs were viable at 9 days. However, further analyses (e.g., using a TUNEL
assay) are needed to conclusively show that implanted cells remain viable throughout the tendon
healing process.
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The relatively small sample size and the high variability in our gene expression data may have
resulted in a type II statistical error (i.e., a false negative). Importantly, in terms of the
inflammatory response to the scaffold itself, TNFα was decreased and IL-1β was unchanged in
the scaffold group compared to the naïve repair group. As with the other genes, the differences
between the repair only and the acellular scaffold groups were not statistically significant. Due to
ethical and cost consideration associated with a large animal model, we determined that it would
be inappropriate to increase the sample size such that a power of 80% was achieved; this would
require N=14-39 for the four genes where a type II error was likeliest. In the case that a negative
response is seen with the current scaffold materials, alternative polymer formulations can be
electrospun to form the nanofiber mat layers of the scaffold (e.g., collagen, poly(ε-caprolactone)
(PCL), poly(L-lactic) acid (PLA)).

While successfully delivery of ASCs was achieved using the fibrin/nanofiber scaffold,
preliminary results show minimal immunosuppressive effects of ASCs. With the current sample
size, no significant suppression of inflammation- or matrix-degradation-related genes was
observed. On average, however, the pro-inflammatory factor, IL-1β, and the matrix degradations
factors, MMP1 and MMP3, were down-regulated in the cellular group compared to the acellular
group 3 days post-operatively. On day 9, there was a statistical trend towards down-regulation
of MMP1 (p < 0.10). While the current sample size was too low to identify any statistical effects
of the ASC treatment, a post-study power analysis showed that N=6 and N=12 would be required
to show that ASCs suppress the expression of IL-1β and MMP1 on day 3, respectively. N=31
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would be required to show suppression of MMP3, however. Thus, future studies may aim to
increase the sample size of this study to N=6-12. Immunohistochemistry is also warranted to
determine whether ASC treatment had an effect on the phenotype of the macrophage population
present at the repair site.

This study was also limited to gene expression effects.

Immunohistochemistry would have been useful in determining whether ASC treatment
suppresses the production of pro-inflammatory cytokines and matrix degradation enzymes.
Western blotting or zymography may also prove useful for the assessment of protein levels;
however, this would require additional animals.

In conclusion, a novel scaffold was developed to deliver ASCs in a controlled manner to the site
of tendon repair. In vitro studies verified that the cells were contained at the repair site and
remained viable. In vivo studies in a large animal tendon model verified that the approach was
clinically relevant and that the cells remained viable in the tendon repair environment.
Specifically, no negative reaction was seen grossly at dissection or at the mRNA level; only a
mild immune response was detected histologically, viable ASCs were found at the repair site 9
days post-operatively; and increased total DNA was demonstrated in ASC-treated tendons. The
novel layered scaffold has the potential for improving tendon healing due to its ability to deliver
immunomodulatory ASCs in a surgically convenient manner.

Due to the preliminary nature of the study, however, there is not enough data to conclusively
determine whether delivery of ASCs to the site of flexor tendon repair suppresses the postoperative inflammatory response. There was some promising pilot data (i.e., down-regulation of
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IL-1β and MMP1), but additional animals and assays are required to fully evaluate the effect of
ASCs in vivo. Thus, further studies are warranted to determine the long-term effects of this
scaffold on tendon healing, and the potential for ASCs to suppress the early inflammatory
response and enhance the biomechanical properties of repaired flexor tendons in vivo.
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Chapter 7 - Conclusions and Future Directions
7.1

Summary of the Dissertation

Clinical outcomes for flexor tendon injuries remain poor despite advances in surgical techniques
over the past three decades1–4. Flexor tendons are particularly prone to gap formation and
rupture due to failure of the repair site to accrue strength within the first 3 weeks postoperatively4,6–11. Flexor tendon repairs are also susceptible to adhesion formation between the
tendon and its surrounding sheath, resulting in an inability of the tendon to glide within the
sheath and loss of motion of the repaired digit5,6,10,12–15. While passive motion rehabilitation
protocols have successfully reduced adhesion formation within the digital sheath1–4,22,24,25,
tendons remain at risk of rupture. Growth factor therapies have been investigated to accelerate
the accrual of repair site strength via cell proliferation and matrix deposition, but has had limited
success7,8,15,27,28,60–66,86.

Previous attempts to improve flexor tendon healing have focused on the later stages of healing
(i.e., proliferation and matrix synthesis). The early inflammatory phase of tendon healing,
however, remains poorly understood and its modulation during healing has not yet been studied.
Thus, the inflammatory response after flexor tendon injury and repair was characterized for the
first time to help identify targets for future treatments. Temporal changes in immune cell
population and gene expression of inflammation-, matrix degradation-, and extracellular matrix
(ECM)-related factors were examined 1, 3, and 9 days post-operatively.

We found that

intrasynovial flexor tendon injuries induce a rapid local inflammatory response characterized by
early infiltration of inflammatory cells (e.g., monocytes, macrophages, and PMNs) and a
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significant up-regulation of pro-inflammatory (e.g., IL-1β, TNFα, COX2) and matrix degradation
genes (e.g., MMP-1, -3, -13) within 1 to 9 days post injury and repair. Furthermore, a significant
down-regulation of genes related to flexor tendon extracellular matrix (e.g., COL1, COL3, LUB)
and tendon fibroblast differentiation (e.g., SCX, TNMD) were observed. The most striking
outcome, however, was the greater than 4000-fold up-regulation in the expression of the proinflammatory factor, IL-1β, as early as 1 day post-operatively.

A certain level of inflammation is essential for proper wound healing. Immune cells (i.e.,
monocytes, macrophages, and PMNs) play a critical role in the clearance of dead cells and
tissues through phagocytosis and the production of MMPs112,156–160. Macrophages also play a
pivotal role in fibroblast chemo-attraction.

Secretion of numerous growth factors by

macrophages promote cell proliferation and synthesis of extracellular matrix112,156–162.
Macrophages may also play a role in angiogenesis through the secretion of VEGF112,156–162.
Several studies have shown that macrophage-depletion is detrimental to proper wound
healing90,91,162,270

While some inflammation is essential for healing to occur, numerous studies suggest that
excessive levels of pro-inflammatory cytokines may be detrimental to tendon healing. Thus, we
sought to determine whether the high levels of IL-1β seen during tendon healing in vivo might be
harmful to the native TFs. Using an in vitro model of inflammation via exogenous delivery of
IL-1β, we found that exposure of TFs to IL-1β caused significant up-regulation of various genes
related to inflammation and matrix degradation in a dose-dependent manner. IL-1β also led to
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significant down-regulation of tendon specific factors (including those related to extracellular
matrix) and decreased cell viability. While this model suggested that the IL-1β produced in vivo
after tendon injury and repair may impair tendon healing (via increased matrix degradation and
decreased matrix formation), it is unclear whether the dosages examined in this study were
biologically relevant. Another limitation of this model was the use of only one exogenous factor
to simulate inflammation, whereas the in vivo environment includes a milieu of different
cytokines at the repair site.

Due to the limitations of the IL-1β-induced model of inflammation, a second, more biologically
relevant in vitro model was established in which inflammation was induced by macrophages. In
vivo, monocytes infiltrate the wound within the first few days after injury and differentiate into
macrophages, which become the dominant immune cell-type at the repair. Depending on the
wound environment, monocytes can differentiate into various types of macrophages.

The

presence of bacterial products (e.g., lipopolysaccharides) and inflammatory cytokines (e.g.,
IFNγ) during the early stages of wound healing promote differentiation of monocytes into proinflammatory M1 macrophages136,138,139,141,156,271, which themselves secrete high levels of proinflammatory factors (including IL-1β). As seen with the IL-1β-induced inflammation model,
co-culture of TFs with M1 macrophages also led to up-regulation of inflammation- and matrix
degradation-related genes and down-regulation of tendon-specific and tendon ECM-related
genes by TFs. The effects of other macrophage phenotypes (i.e., non-polarized M0 macrophages
and anti-inflammatory M2 macrophages) were also assessed. While M0 and M2 macrophages
also caused some up-regulation of inflammatory and matrix degradation genes, the effect was
much less than that of M1 macrophages. These results, combined with studies by Rodeo et al.92–
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, suggest that M1 macrophages may be detrimental to tendon healing due to their secretion of

pro-inflammatory cytokines.

Based on these results, it is expected that modulation of the inflammatory environment may be
advantageous to tendon healing.

Studies in the transplant literature suggest that the

inflammatory environment can be controlled using MSCs136,140,141,173,230,244,254–257,318. Therefore,
adipose-derived MSCs (i.e., ASCs) were incorporated into the two in vitro models and their
ability to modulate the inflammatory effects on TFs was investigated. While ASCs were unable
to counteract the effects of IL-1β directly, ASC co-culture with M1 macrophages successfully
suppressed the negative effects of M1 macrophages on tendon fibroblasts. FACS analysis
revealed that ASCs induced a phenotypic switch from a pro-inflammatory macrophage
phenotype (M1) to an anti-inflammatory macrophage phenotype (M2), thus resulting in exposure
of TFs to fewer pro-inflammatory cytokines.

Lastly, to translate these in vitro findings in vivo, a surgically manageable scaffold capable of
delivering and retaining ASCs at the repair site was developed. The scaffold combined a fibrin
based delivery system (containing 1x106 ASCs) and an electrospun PLGA backbone (to add
mechanical strength). A series of in vitro and in vivo studies were performed to 1) verify the
viability of the ASCs within the scaffold, 2) assess the biocompatibility of the scaffold in vivo,
and 3) examine the ability of the ASCs to modulate the inflammatory response after flexor
tendon injury and repair. The fibrin/nanofiber scaffolds were well tolerated in the in vivo flexor
tendon repair setting and successful delivery of ASCs was achieved. There was not enough data,
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however, to conclusively determine whether delivery of ASCs to the site of flexor tendon repair
suppressed the post-operative inflammatory response. In terms of gene expression, there was
some promising pilot data (i.e., down-regulation of IL-1β and MMP1), but additional animals
and assays are required to fully evaluate the effect of ASCs in vivo.

7.1

Limitations and Future Directions

These studies suggest that the high levels of pro-inflammatory cytokines present during the
inflammatory phase of flexor tendon healing may cause collateral damage to the native tendon
fibroblasts, and fine modulation of the inflammatory response may be advantageous for tendon
healing. However, due to a number of limitations, additional studies are necessary before
definitive conclusions can be made.

First, the in vivo characterization of the inflammatory response after flexor tendon injury and
repair (see Chapter 2) did not include immunohistochemical staining to determine which cell
type was the major source of the pro-inflammatory factor, IL-1β. According to the literature,
monocytes/macrophages are the main cellular source of IL-1β161; however, an assessment of
histological sections showed no monocytes/macrophages at the repair site on day 1, yet IL-1β
gene expression spiked on day 1. It is likely that PMNs that infiltrated the wound on day 1 were
the initial source of IL-1β and as the PMNs began to apoptose and monocytes/macrophages
infiltrated the repair, the monocytes/macrophages became the primary source. Future studies
should include immunohistochemical analysis to help elucidate the source(s) of IL-1β and verify
the translation of the up-regulated gene into protein. Moreover, immunohistochemistry would
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help to determine whether the high IL-1β levels at the repair site induced further up-regulation of
IL-1β by the local TFs. However, the appropriate canine antibodies are not yet commercially
available.

In vitro, gene expression analysis showed IL-1β dose-dependent up-regulation of inflammationand matrix degradation-related genes. However, assessment of resulting protein production was
not fully analyzed. Only IL-1β, TNFα, and MMP3 were assessed at the protein level using
ELISAs. TNFα was undetected in all groups. MMP3 was increased in the IL-1β treated
samples, but the activity level of the MMP enzymes was not verified using zymography. Lastly,
due to a technical issue, we were unable to determine whether the increases in IL-1β in the
treated samples were solely due to the exogenous IL-1β added to the media or whether the TFs
themselves contributed to those increased levels.

Additional protein assays (e.g., ELISAs,

Western blots, immunohistochemistry) should be performed to further assess the up-regulation of
pro-inflammatory cytokines and matrix degradation enzymes induced by IL-1β.

The second in vitro model, in which inflammation was induced by macrophage co-culture,
suggested that TFs do, in fact, up-regulate their own production of IL-1β and other proinflammatory factors in response to an inflammatory environment.

Co-cultures of M1

macrophages and TFs produced increased levels of IL-1β and PGE2 compared to M1
macrophages cultured alone. This suggests that the additional proteins are secreted by the TFs;
however, due to the co-culture system, we cannot rule out the possibility that the macrophages
secreted additional pro-inflammatory proteins in response to co-culture with TFs. Based on the
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gene expression data showing that TFs up-regulate their expression of the corresponding genes,
it is likely that the TFs are producing pro-inflammatory cytokines in response to the
inflammatory environment.

To further investigate whether or not TFs up-regulate their

production of pro-inflammatory cytokines in response to inflammation, the inserts of the
transwells (containing the TFs) could be removed and placed in fresh media for a day or more
and the supernatant could be tested for inflammatory cytokines. However, using the current
experimental setup, the number of TFs obtained was only enough to perform the gene expression
analysis on day 1. There were not enough cells to assess protein expression in this way on day 2.
Future studies, however, should be performed to address this possibility.

An additional limitation of the macrophage-induced inflammation model is the biologic
relevancy of the macrophage to TF ratio. The ratio of TFs to macrophages in vivo after flexor
tendon repair is unknown.

Thus, it is not clear whether the amount of pro-inflammatory

cytokines that the TFs were exposed to in this in vitro model was biologically relevant.

Future

studies can address this concern. First, histologic sections from the in vivo studies can be
analyzed to determine the ratio of macrophages to fibroblasts during the early inflammatory
phase of tendon healing. The ratio of TFs to macrophages in the in vitro model can then be
adjusted accordingly.

While the macrophage-induced inflammation model improved upon the IL-1β-induced
inflammation model, further modifications can be made to make the model more biologically
relevant. As seen in vivo, PMNs were the primary immune cell type at the repair on day 1. Gene
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expression showed peak levels of IL-1β on day 1 before monocytes and macrophages infiltrated
the wound. This suggests that the PMNs are an additional early source of IL-1β. Thus, addition
of PMNs into the in vitro model may improve the relevancy of this model. Temporal changes in
the immune cell population seen in vivo may be mimicked in vitro using multiple transwell
plates. TFs can be cultured in the inserts of the wells and co-cultured with PMNs (in the wells)
for 1-2 days.

The inserts containing the TFs can then be removed and co-cultured with

macrophages. The effect of delayed ASC treatment could also be addressed by adding the ASCs
at different times.

Tri-culture of ASCs with macrophages and TFs suggested that ASCs suppressed the negative
effects of M1 macrophages on TFs. However, only gene expression effects were evident on day
1. Protein levels of pro-inflammatory cytokines were unaffected by ASC co-culture on day 1. A
longer co-culture period (i.e., 5 days) further suppressed the effects of M1 macrophages in terms
of both TF gene expression and protein expression. However, the data from the ASC co-cultured
groups were obtained on day 5, whereas the data from the control groups (M0, M1, M2) was
obtained on day 1. Thus, we are unable to say with certainty whether the enhanced effects with
increased co-culture period were due to increased time for ASCs to induce phenotypic changes in
the co-cultured macrophages, or whether there were fewer viable macrophages at the 5 day
timepoint and, thus, fewer inflammatory factors being secreted into the media. To better control
for this possibility, the control groups were repeated at longer timepoints. As with the co-culture
groups, the macrophages were primed to become M1 or M2 macrophages or left untreated (M0)
for 1 day. The cells were then cultured in standard medium for an additional 4 days. However,
due to decreased macrophage viability at the later timepoints, it is a possibility that the observed
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changes in TF gene expression may be a result of fewer macrophages present when TFs were
added to the system.

Increased expression of anti-inflammatory, M2 macrophage specific

markers (CD206 and CD301) over time strongly supports the idea that longer periods of ASC
exposure will lead to further down-regulation of inflammation- and matrix remodeling-related
genes and up-regulation of tendon ECM-related genes towards baseline levels. Future studies
can examine the effect of various ASC:Macrophage ratios to determine whether additional ASCs
would enhance the effect at an earlier timepoint where the experiment can be better controlled.

The molecular mechanism for the ASC-mediated macrophage phenotypic switch remains
unknown, however. Studies by other investigators suggest that an intracellular enzyme that
catalyzes tryptophan into kynurenine (IDO) is responsible for this phenomenon220,249. The use of
a pharmacological inhibitor of IDO (1-MT) resulted in a loss of MSC-mediated suppression,
indicating a possible involvement of IDO in the differentiation of monocytes into antiinflammatory M2 macrophages220,261. Similar studies have not yet been performed in adipose
derived MSCs. Assessment of the cytokines secreted by ASCs and inhibition of those factors
may help to elucidate the mechanism involved in the ASC-mediated macrophage phenotypic
switch.

A further limitation is that the ability of ASCs to modulate the in vivo inflammatory response
after flexor tendon injury and repair remains unknown. A pilot study with a sample size of 3 per
group showed some promise in terms of suppression of certain inflammation and matrix
degradation genes. However, additional animals and assays are required in order to form stronger
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conclusions as to the effectiveness of this approach.

According to a post-study power analysis,

a sample size of 12 per group would be required to reach statistical significance in terms of
down-regulation of inflammation- and matrix degradation-related genes. Furthermore, protein
levels were not assessed in vivo.

Future studies should examine cytokine levels via

immunohistochemistry or Western blotting and matrix degradation enzyme activity should be
assessed

using

zymography.

Macrophage

phenotype

should

be

explored

using

immunohistochemistry to determine whether ASC treatment promotes a phenotypic switch from
a pro-inflammatory M1 macrophage population to an anti-inflammatory M2 macrophage
population, as was seen in the in vitro studies.

Due to the limited availability of canine

antibodies, it may not be possible to address all of these concerns.

Finally, the in vivo model used was an acute injury model in which the injury was created and
then immediately surgically repaired. Clinically, a delay of hours to weeks may occur between
injury and repair; this has important implications for the inflammatory process, which only
dominates in the first 3 days. While the repair process may induce a second wave of
inflammation, it is unclear how much damage may have already taken place prior to surgical
repair and potential ASC treatment. Future studies can address this concern by inducing a
tendon injury and leaving it unrepaired for a period of time. A second surgery hours or weeks
later can then be performed to repair the injury using ASC-seeded scaffolds. The outcomes of
these repairs can be compared to those that are repaired and treated (with ASCs) immediately
upon injury.
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7.3

Alternative Approaches

In addition to resolving some of the limitations mentioned above, alternative approaches can
further explore the role of inflammation and its modulation during tendon healing. The ability of
IL-1Ra, an IL-1 receptor antagonist, to suppress inflammation can be evaluated in vitro and in
vivo. IL-1Ra binds to the same receptor as IL-1β (IL-1R)

285,332

. However, bound IL-1Ra does

not provoke a biological response285,332. Instead, IL-1Ra acts as an inhibitor by decreasing the
number of available binding site for IL-1β285,332. Similar to the in vitro study described in
Chapter 3, TFs can be exposed to exogenous IL-1β and its effect can be examined using gene
and protein assays.

IL-1β can then be inhibited in vivo during flexor tendon healing via

sustained delivery of IL-1Ra. The delivery system used to deliver ASCs may be useful for
sustained delivery of IL-1Ra. Delivery kinetics will depend on the binding affinity of IL-1Ra to
heparin. The effect of IL-1β inhibition in vivo after flexor tendon injury and repair can then be
examined using gene expression and histological assays at early timepoints to observe changes in
the early inflammatory phase of healing.
biomechanical properties.

Later timepoints can be analyzed for effects on

Reducing IL-1β levels in vivo may be advantageous for tendon

healing. However, some level of inflammation is essential for clearance of dead cells and tissues
from the wound and for chemotaxis of fibroblasts to the repair site. Therefore, it is important to
make sure that the IL-1Ra dosage is not too high so that IL-1β is not completely inhibited.

Genetically modified mouse models can also be used to examine the effect of inflammation on
tendon healing. Mouse models in which Iκκβ (a regulator of inflammation down-stream of IL1β) is constitutively active or deleted in tendon cells can be used to determine the effect of
inflammation on tendon healing333–335.

Tendon cells can be specifically targeted by crossing
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these Floxed mice with scleraxis (a tendon-specific transcription factor) Cre mice. An acute
model of flexor tendon injury and repair (as used in the canine model) is not possible in mice due
to their small size. Therefore, an overuse or collagenase-induced tendon injury model can be
induced to incite tendon injury. These studies will allow for examining the contribution of
tendon fibroblasts vs. inflammatory cells on the production of inflammatory cytokines. It is
possible that the majority of inflammatory factors during tendon healing are produced by the
inflammatory cells (which would be unaffected in these mice). However, our in vitro studies
have shown that TFs up-regulate their own expression of inflammatory factors in response to an
inflammatory environment.

Thus, it is possible that the TFs continue to up-regulate pro-

inflammatory factors after the inflammatory phase is resolved and immune cells are no longer
producing large amounts of pro-inflammatory factors at the repair site, which could be
detrimental to tendon healing. This model may be useful in answering some of these questions.

7.4

Conclusions

This dissertation elucidates the role of inflammation in flexor tendon healing. Until now, the
early inflammatory phase of healing was not well understood and its modulation had not been
attempted. Through careful characterization of the early inflammatory phase of flexor tendon
healing, we found remarkable increases in the expression of pro-inflammatory genes and
identified potential cellular sources for these cytokines. The striking increases in genes related to
inflammation and matrix degradation led us to consider what impact these factors have on the
native TFs and, ultimately, on tendon healing.

Using two in vitro models of tendon

inflammation (included a novel macrophage-induced model), we verified that pro-inflammatory
factors (such as those produced by macrophages) negatively impact tendon fibroblasts and, thus,
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may impede tendon healing. In an attempt to suppress those negative effects, ASC-mediated
modulation of tendon inflammation was attempted for the first time. In vitro results suggest that
ASCs are capable of suppressing the negative effects of macrophages on TFs.

Preliminary in

vivo studies further supported the premise that ASCs can modulate the inflammatory
environment, but further studies are necessary to demonstrate efficacy. The potential for ASCs
to tune the inflammatory environment and enhance tendon healing holds great promise for
clinical translation.
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Appendix - Sustained Delivery of Transforming Growth
Factor Beta Three Enhances Tendon-to-Bone Healing in a
Rat Model.

A.1

Introduction

Surgically repaired rotator cuff tears are prone to recurrent tears, with a failure rate reaching 94%
for large tears16,336. Studies in the clinically relevant rat rotator cuff model show that this high
rate of failure is due to the fact that the healing process of tendon to bone is reparative (i.e., scar
mediated) and not regenerative. The composition and structural organization of the repaired
tissue does not mimic the original uninjured tissue. Whereas most uninjured tendon-to-bone
insertions have a fibrocartilage transition zone between tendon and bone337,338 repaired tendons
lack a transition zone. Instead, the interface between repaired tendon and bone is filled with
disorganized fibrovascular connective tissue whose mechanical properties are inferior to that of
the uninjured tissue (i.e. the repair is filled with “scar” tissue)320,339–341. Although the large
quantity of this fibrovascular tissue leads to a significant increase in the cross-sectional area
relative to that of the normal insertion, the mechanical properties (i.e., properties normalized to
cross-sectional area, indicative of the “quality” of the tissue) of the repaired tendon are
considerably inferior339.

It has been well established in skin that fetal wounds heal in a regenerative manner (i.e., the
repaired tissue is identical to the original tissue) while adult wounds heal in a reparative manner
(i.e., via a scar mediated process)152,154,342. Several studies have compared the healing properties
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of adult tissues to fetal tissues and have identified a pattern of growth factor expression that is
unique to development152,154,343. For transforming growth factor β (TGF-β) isoforms, fetal wound
healing is characterized by low expression of TGF-β1 and TGF-β2, high expression of TGF-β3
and no scar tissue. Adult wound healing, on the other hand, is characterized by high levels of
TGF-β1 and TGF-β2, low levels of TGF-β3 and extensive amounts of scar152,154,342,343. Injections
of exogenous TGF-β3 to the site of a nascent dermal wound reduce scar formation, thus
implicating TGF-β3 in scar-less fetal and adult wound healing152,154,342. Similar temporal
expression patterns are seen at the developing and healing tendon-to-bone insertions341,344.

Based on these studies, we hypothesized that sustained delivery of TGF-β3 would promote
regenerative healing over reparative healing at the healing adult tendon-to-bone insertion site.
This would be evident as reduced fibrovascular scar tissue formation, improved structural
organization, and improved mechanical properties in TGF-β3-treated repairs compared to
controls that received surgical repair alone. To test this hypothesis, we delivered TGF-β3 using a
heparin-binding delivery system to the supraspinatus tendon-to-bone repair sites in rat shoulders
and evaluated repairs using histological and biomechanical outcomes.

A.2

Methods

A.2.1 Growth Factor Delivery System
Bolus application of growth factors typically leads to clearance of the growth factor from the
wound site within 48 hours.10 Given that fibroblast cells begin to infiltrate the wound after 2-4
days, acute delivery of TGF-β3 would have limited effectiveness. We previously used fibrin
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matrices containing a heparin-based delivery system (HBDS) to control the release of heparinbinding growth factors115,345. Release occurs through “passive” dissociation from the delivery
system and diffusion from the matrix as well as through “active” cell-mediated degradation of
the fibrin matrix. Both mechanisms were evaluated in vitro in the studies described below.

A.2.1 In Vitro Growth Factor Release Studies
TGF-β3 Passive Release Kinetics - Acellular Study: To determine the passive (i.e., acellular)
release kinetics of TGF-β3 from the delivery system, 400µl fibrin matrices were made in
quadruplicate (N=4) in 24 well tissue culture plates as described previously345. The matrices
consisted of 50 ng TGF-β3 (R&D Systems, MN), 20 mg/ml fibrinogen (EMD Biosciences, CA),
25 mg/ml peptide (0.16 mM – dLNQEQVSPK[βA]FAKLAARLYRKA-NH2, where dL denotes
dansyl leucine), 45 mg/ml heparin, 50 mM CaCl2, 12.5 units/ml thrombin, and Tris-buffered
saline (TBS; 33 mM Tris, 137 mM NaCl, 2.7 mM KCl, pH 7.4). The heparin concentration in
the fibrin matrices varied from 0 to 4mM to yield the desired growth factor to heparin molar
ratios (1:0, 1:100, 1:1,000, and 1:10,000). The heparin to peptide ratio remained constant at
1:10. To examine growth factor release into the media, a series of washes with TBS were
performed over the course of 10 days, as described previously345. An enzyme-linked
immunosorbent assay (ELISA) for TGF-β3 (R&D Systems, MN) was then performed on all
wash volumes as well as on the fibrin remaining at the end of 10 days. To compare the passive
release kinetics of the matrices with and without the delivery system, the ratio of TGF-β3
released into the buffer per day from the HBDS group to the amount released from the no HDBS
group (i.e. HBDS group : no HBDS group) was calculated.
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TGF-β3 Active Release Kinetics – Cellular Study: To examine cell-mediated release, fibroblasts
were isolated from the supraspinatus and infraspinatus tendons of Sprague Dawley rats (N=8 cell
isolations) as described previously345. Fibrin matrices were then seeded with the fibroblasts and
the active release rate of TGF-β3 was determined. The procedure was identical to that of the
acellular study methods described above with the following exceptions: 1) gels were seeded with
50,000 cells in culture medium (1% FBS DMEM) after the first day of washes, 2) daily washes
were performed using 1% FBS DMEM to maintain cell viability, and 3) experimental groups
included matrices containing the delivery system at a factor to heparin molar ratio of 1:1000
(delivery system group) and matrices lacking the delivery system (i.e. ratio of 1:0) (no delivery
system group). Matrices were made in triplicate for all experimental groups. The experiment
was repeated for 8 cell isolations. To compare the passive release kinetics of the matrices with
and without the delivery system, the ratio of TGF-β3 released into the buffer per day from the
HBDS group to the amount released from the no HDBS group was calculated.

Statistical analysis: A one-way ANOVA with planned polynomial contrasts was used to
compare the TGF-β3 ratios over time. Paired t-tests were used to compare the release of TGFβ3 from gels with and without the HBDS at each timepoint. P < 0.05 was considered significant.

A.2.2 In Vivo Studies
Animal Model: All animal procedures were approved by the institutional Animal Studies
Committee. Supraspinatus tendons in bilateral shoulders of 76 adult male Sprague-Dawley rats
(375-400g) were transected and repaired to the humeral head using 5-0 proline suture, as
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described previously339,341. In one group of rats, fibrin matrices with the HBDS (+/(+/ TGF-β3)
(30µl)
l) were incorporated bilaterally at the supraspinatus tendon
tendon-to-bone
bone repair sites by passing
the suture through the matrix before completing the repair. The left shoulders received matrices
that were loaded with 100ng of TGF
TGF-β3 (100µg/ml,
g/ml, 1:1000 growth factor to heparin molar ratio),
while the right shoulders received matrices lacking the growth factor and served as contralateral
controls (i.e., carrier controls) (Figure A.1).

A second group of rats was used to control for

potential systemic effects of the growth factor as well as to serve as a comparison group to
conventional treatment (i.e., surgical repair only). The left shoulders of these rats were repaired
surgically but did not receive any matrices. The right shoulders received matrices lacking the
growth factor (i.e., carrier controls). Animals were sacrificed 28 and 56 days post-operatively
post
(N=11-16
16 per group) for biomechanical testing. Animals were sacrificed at 14, 28, and 56 days
post-operatively
operatively for histological analysis (N=4 per group) (Figure A.1). A separate group of
uninjured age-matched rats (N=8)
=8) was used as normal controls.
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Figure A.1: Study Design. The left shoulders received matrices loaded with 100ng of TGF-β3
and the right shoulders received matrices lacking the growth factor. A second group of control
rats was used to examine potential systemic effects of the growth factor as well for comparison
group to surgical repair only. Animals were sacrificed at 14 days for histology and at 28 and 56
days for histology and biomechanical testing.

Histology-based assays: Four specimens from each group were examined histologically.
Specimens were fixed, decalcified, embedded in paraffin, and sectioned at 5 µm in the coronal
plane. Sections were stained with toluidine blue to examine fibrocartilage, hematoxylin and eosin
to examine cell morphology, and Masson’s trichrome to examine fibrous tissue. Proliferating
cell nuclear antigen (PCNA) immunohistochemistry was done in accordance with the
manufacturer’s protocol (Zymed Laboratories, San Francisco, CA) as a measure of cell
proliferation. The antibody was visualized by incubation with diaminobenzidine (DAB). Three
independent observers (Necat Havlioglu – pathologist, Leesa Galatz – orthopaedic surgeon, and
Cionne Manning – graduate student), blinded to group and timepoint, evaluated the tissue
sections for cellularity, cell proliferation, vascularity, inflammation, fibrosis (i.e., scar tissue
formation), and fibrocartilage formation339,341. A standard scoring system was used to determine
the levels of each outcome (- no prevalence, + minimal prevalence, ++ mild prevalence, +++
moderate prevalence, ++++ high prevalence) Our analysis was focused solely on the tissue
adjacent to bone (i.e., the healing tendon-to-bone interface).
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Geometry and biomechanics: Biomechanical testing of the supraspinatus tendon-to-bone
insertions was performed as previously described339. The thickness of each insertion was
measured using a laser displacement sensor (Keyence LK-081, NJ) and the width was measured
using optical methods. The cross-sectional area was calculated by assuming an elliptical crosssection. In order to determine the mechanical properties of the healing tendon-to-bone insertion
without the confounding effect of the suture repair strength, sutures were cut at the entrance of
humeral head bone tunnel prior to biomechanical testing. To control hydration, temperature, and
pH during biomechanical testing, tendons were immersed in a physiologic saline bath at 39°C
(rat body temperature) during testing. A servo-hydraulic materials testing system (Instron Corp.,
Model 8841) was then used to perform the mechanical test (i.e., pre-conditioning, followed by
stress relaxation, followed by constant ramp at a strain rate of 0.1%/sec until failure).
Engineering stress was calculated by dividing the tensile force by the initial cross-sectional area
of the tendon. Strain was measured optically by tracking two surface stain lines using customwritten software (Matlab, Natick, MA)339. Ultimate load, stiffness (i.e., the slope of the linear
portion of the load-deformation curve), toughness (i.e., the area under the load-deformation
curve), ultimate stress, and tangent modulus (i.e., the slope of the linear portion of the stressstrain curve) were determined.

Statistical analysis: For geometric and biomechanical outcomes, groups were compared using a
two-factor analysis of variance for time and treatment followed by a Fisher least-squares
differences post-hoc test. Paired data (i.e. TGF-β3 group vs. experimental group carriers or
repair-only group vs. control group carriers) were compared using paired t-tests. P < 0.05 was
considered significant.
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A.3

Results

A.3.1 In Vitro Studies
Sustained growth factor release was achieved in the absence of cells via the HBDS (Figure A.2,
A). The percent change of TGF-β3 released from the gels containing the HBDS to those lacking
the delivery system was initially negative, indicating that more growth factor was being released
from the no-HBDS gels at the early timepoints. Over time, however, the percent change was
positive, indicating that the HBDS gels were releasing more growth factor than the no-HBDS
gels. The amount of TGF-β3 released from the two groups (HBDS vs. no-HBDS groups) were
significantly different at days 0, 1, 2, 5, 7, and 9. Similarly, the amount of growth factor
remaining in the HBDS gels at the end of the 10 day experiment was significantly more than the
amount remaining in the no-HBDS gels. Moreover, the ratios of TGF-β3 released from the gels
with and without the HBDS significantly increase over time. Gels without the HBDS (1:0)
released nearly all (99%) of the growth factor by day 10, whereas the gels with the HBDS at
ratios of 1:100, 1:1000, and 1:10,000 released 88%, 74%, and 52%, respectively. The same
trends were seen in tendon fibroblast seeded gels (Figure A.2, B), although the rate of release
was accelerated in the presence of cells. The amount of TGF-β3 released from the no-HBDS
group was greater than the amount released from the HBDS group at the early timepoints. At the
later timepoints, however, the opposite trend was observed. TGF-β3 release from the HBDS was
significantly increased compared to the no HBDS group at days 7, 8, and 9. A significant linear
increase in these ratios (HBDS : no-HBDS) was observed over time.
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Figure A.2: In vitro Release Kinetics. In both the acellular environment (A) and the cellular
environment (B), the ratios significantly increased with time, indicating sustained released of
TGF-β33 from the gels containing the delivery system. Differences in the amount of TGF-β3
TGF
released from the two groups (i.e. HBDS vs. no HBDS) are signified by stars and crosses (* p <
0.05, † p < 0.1). R: TGF-β33 remaining in the gels at the end of the 10 day ex
experiment.
periment.
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A.3.2 In Vivo Studies

Histology: There was good agreement among the blinded investigators made by the three
observers. Large discrepancies in grades were resolved by re-evaluating the slide as a group.
Blind evaluation revealed increased cellularity and increased cell proliferation (as demonstrated
by PCNA labeling) at the repair site in the TGF-β3 group at 14 days (Table A.1, Figure A.3).
Group

Fibrosis Inflammation Cellularity Proliferation Vascularity

14

TGF-β3

+++

+++

+++/++++

+++

+++

day

Exp Carrier

+

++

++/+++

+/++

++

Ctl Carrier

++

+

++/+++

++

++

Repair Only

++

++

++

++/+++

++

28

TGF-β3

++

+

++

-/+

++

day

Exp Carrier

++

-/+

++

-/+

+

Ctl Carrier

+

-/+

+/++

+

+

Repair Only

+

+

++

+/++

+/++

56

TGF-β3

++

-/+

++

-/+

++

day

Exp Carrier

+/++

-/+

+

-/+

+

Ctl Carrier

+

-/+

+

-/+

+

Repair Only

+/++

-/+

+

-/+

+

Table A.1: Histological Assessment. Grading scheme: - no prevalence, + minimal prevalence,
++ mild prevalence, +++ moderate prevalence, ++++ high prevalence. Average grades are
shown.
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The number of blood vessels (i.e. vascularity) and the amount of fibrous tissue (i.e. scar) was
also substantially
ubstantially increased in TGF
TGF-β3
3 group at the earliest timepoint (i.e., day 14) (Table 1,
Figure A.3).
3). An increased immune response (as evidenced by an increase in lymphocytes) was
also apparent in the TGF-β3-treated
treated tendons compared to all other groups at
a 14 days. The
amount of fibrovascular scar tissue and the number of cells and blood vessels remained high at
all timepoints in the TGF-β3-treated
treated tendons, whereas differences in lymphocytes and cell
proliferation were no longer evident at 28 and 56 days. No evidence of fibrocartilage
regeneration was seen in any of the groups at any timepoint (Table A.1).

Figure A.3: Histology. Sections stained with PCNA (top panels; cells in the proliferative stage
of the cell cycle stain dark brown) and hematoxylin and
d eosin (middle and bottom panels) at 14
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days. The tendons treated with TGF
TGF-β3
3 exhibited increases in cell proliferation, cellularity, and
vascularity compared to controls (i.e., experimental group carriers). [Scale bars = 200µm].
Geometry: At 28 days, the cross
cross-sectional
sectional area of the tendons treated with TGF-β3
TGF
was
significantly greater than that of any other group (Figure 44.A).
). At 56 days, however, the TGFTGF
β3-treated
treated tendons had the smallest cross
cross-sectional
sectional area. The cross sectional area of the tendons
in the control group (i.e. control group carriers and repair
repair-only
only group) increased significantly
over time, whereas the tendons in the experimental group (i.e. TGF
TGF-β3-treated
treated and experimental
group carriers) did not. Cross-sectional
sectional areas ooff all repaired tendons were significantly increased
compared to normal/uninjured tendons at both timepoints.

Figure A.4: Geometry. Cross-sectional
sectional area of TGF-β3-treated
treated tendons was increased at 28 days
compared to control group carriers and repair
repair-only tendons. At 56 days, cross--sectional area of
TGF-β3-treated
treated tendons was decreased compared to control group carriers and repair-only
repair
tendons.

Cross-sectional
sectional areas of repaired

insertions were increased

normal/uninjured insertions (normal = 2.
2.6 ±0.4 mm2). * p < 0.05, (N=10).
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compared to

Biomechanics: At 28 days, the structural property ultimate load of the TGF-β3-treated tendons
was significantly increased compared to the contralateral control tendons (p = 0.04, 30%
increase, Figure A.5, A). There was also a trend towards increased ultimate load in the TGF-β3treated group compared to the repair-only group (p = 0.08, 28% increase). The stiffness and the
toughness of the TGF-β3-treated tendons were also increased compared to carrier controls
(stiffness: p = 0.04, 50% increase compared to experimental group carrier; toughness: p = 0.007,
34% decrease compared to control group carrier, Figure A.5, B & E). There were no differences
in the mechanical properties (i.e., ultimate stress and modulus) when comparing the TGF-β3treated tendons to all other groups at this early timepoint. At 56 days, the tendons in the TGFβ3-treated group had increased ultimate stress compared to tendons in the carrier-only groups,
but these differences were not statistically significant (p = 0.08, 48% increase compared to
control group carrier; p = 0.12, 41% increase compared to experimental group carrier, Figure
A.5, C). A statistically significant increase was seen for modulus when comparing the TGF-β3treated group to the experimental group carriers (p = 0.01, 37% increase, Figure A.5, D). The
toughness of the TGF-β3-treated group was also significantly increased over the repair-only
group (p = 0.03, 36% increase, Figure A.5, E). Changes over time were observed in ultimate load
and toughness. The ultimate load of tendons increased over time in all groups (p = 0.07, 22%
increase for TGF-β3 group, p < 0.05, 31% - 46% increases for all other groups). Similar
statistically significant trends were seen for toughness over time (p = 0.001). Stiffness, ultimate
stress, modulus, and toughness were significantly lower in all injury and repair groups at 28 and
56 days compared to the normal/uninjured group (p < 0.01 for all groups). Ultimate load,
however, was not significantly different when comparing the normal/uninjured group to most
injury and repair groups at 56 days (p = 0.68, 4% decrease for TGF-β3 group; p = 0.22, 12%
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decrease for experimental group carrier; p = 0.37, 9% decrease for control group carrier). The
one exception was the repair-only group, in which ultimate load remained significantly lower
than normal at 56 days (p = 0.05, 20% decrease).

Figure A.5: Biomechanics. At 28 days, the structural properties (ultimate load (A), stiffness (B),
and toughness (E)) of the TGF-β3-treated insertions were increased compared to carrier controls
(i.e. experimental group carriers and control group carriers). Ultimate load increased in all
groups over time, approaching normal/uninjured values (normal = 28.8 ± 6.0 N). At 56 days, the
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mechanical properties (ultimate stress (C) and modulus (D)) of the TGF-β3-treated insertions
were increased compared to carrier controls. Stiffness, ultimate stress, modulus, and toughness of
injury and repair groups did not reach normal values by 56 days (normal values: stiffness = 37.8
± 8.8 N/mm, ultimate stress = 11.1 ± 2.7 MPa, modulus = 128.3 ± 40.6 MPa, toughness = 43.1
± 12.9 N mm). * p < 0.05, † p < 0.1. (N=10).

A.4

Discussion

Although current rotator cuff repair techniques are successful in alleviating pain, they are prone
to recurrent ruptures16,336. Failure rates after surgical repair range from 20-94% depending on the
size of the initial tear16,336. Studies in the rat rotator cuff model indicate that this high failure rate
is at least in part due to the fact that the repaired tendons do not mimic the original tendon: the
healing process is reparative (i.e., scar mediated), not regenerative320,339–341. The healing tendonto-bone insertion is characterized by disorganized fibrovascular tissue formation and a lack of a
fibrocartilage transition zone at the interface. Differences in growth factor expression have been
noted between fetal development and adult healing. During these two processes, the cytokine
TGF-β is found in different isoforms. TGF-β3 expression is elevated during tendon development
and low during adult tendon healing. In contrast, TGF-β1 expression is low during development
but high during adult tendon healing341,344. Dermal wound healing studies in mice have revealed
similar trends. TGF-β3 is abundant during development and is also elevated during fetal wound
healing, which occurs through a regenerative (i.e., scarless) process. Furthermore, a shift in
expression from TGF-β3 to TGF-β1 occurs 16-18 days post-conception, a critical timepoint
known to coincide with the end of regenerative fetal healing of skin342.
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Based on these results, we expected that sustained delivery of TGF-β3 would reduce the amount
of fibrovascular scar tissue formed during adult tendon-to-bone healing, thus leading to an
improvement in the structural and material properties of the healing tendon-to-bone insertion
compared to untreated controls. Contrary to our hypothesis, delivery of TGF-β3 did not lead to a
reduction in scar tissue formation. Instead of promoting regeneration of a fibrocartilaginous
transition between tendon and bone, TGF-β3, led to an increase in disorganized fibrovascular
tissue. The lack of regenerative healing with TGF-β3 may have been due to differences between
adult and post-natal environments. For example, the cell types present (and their pluripotency)
are quite different prenatally compared to postnatally. The response of a mesenchymal stem cell
to TGF-β3 will be much different than the response of a primary fibroblast to TGF-β3. Further
studies are required in order to determine why TGF-β3 did not have the desired effect in an adult
tendon-to-bone healing environment.

As seen by the increase in cross sectional area at the early timepoint studied, TGF-β3 promoted
an increase in extracellular matrix formation during tendon-to-bone healing. Although TGF-β3
delivery did not lead to a reduction in scar formation, it did lead to a significant improvement in
the structural and mechanical properties of the healing tendon-to-bone insertions. At the early
timepoint, the structural properties ultimate force and stiffness were increased in the TGF-β3treated insertions compared to the untreated control insertions.

At the later timepoint, the

mechanical properties ultimate stress and modulus were increased in the TGF-β3-treated
insertions compared to untreated control insertions. These results indicate that TGF-β3 treatment
accelerated all phases of the healing process: inflammation was enhanced at early timepoints (as
seen histologically), cell proliferation and matrix synthesis were increased at early timepoints (as
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seen histologically, geometrically, and structurally), and extracellular matrix remodeling was
increased at later timepoints (as seen histologically and in mechanical properties). In summary,
treatment with TGF-β3 led to increases in cross-sectional area and a resultant increase in
structural properties at early timepoints. With time, remodeling of the tissue led to a decrease in
cross-sectional area and a resultant increase in the mechanical properties (i.e., a better “quality”
tissue). These results were most apparent for toughness, but improvements were also seen in
modulus and failure stress.

Implantation of the delivery system alone (i.e. without growth factor) had no significant effect on
tendon healing. The biomechanical and histological properties of the insertions that received the
carrier alone (i.e. experimental group carriers and control group carriers) did not differ
significantly from the insertions that received surgical repair only. Thus, differences seen in the
TGF-β3-treated group can be attributed to TGF-β3 itself and not to any components of the
delivery system. Some differences between the two carrier groups (i.e. experimental group
carriers and control group carriers) were evident in some biomechanical properties, however.
For example, at 28 days ultimate stress and modulus were significantly higher in the control
group carriers compared to the experimental group carriers. The only difference between these
two groups was the treatment in the contralateral shoulders. For the control group carriers, the
contralateral shoulder received surgical repair only. For the experimental group carriers, the
contralateral shoulder received TGF-β3 treatment. It is possible that some systemic effects may
have resulted from the local delivery of TGF-β3.

169

The rat is an appropriate animal model for studying the rotator cuff based on anatomic
considerations346. Rats have a coraco-acromial arch similar to that of humans, under which the
supraspinatus tendon passes repeatedly during shoulder motion. This arch in notably missing in
most non-primate larger animal species. Moreover, the rat rotator cuff is sufficiently large to
perform a repair that is technically similar to what is used clinically. However, larger animals are
better suited to reproduce the more complex surgical techniques currently used clinically. A
limitation of the injury and repair model used in this study is that it approximates an acute rotator
cuff injury and does not represent the chronic degenerative rotator cuff tears seen in the majority
of clinical patients. However, while our results cannot be applied to the scenario of chronically
degenerated rotator cuff, they are relevant to the human shoulder and to acute tendon injuries
specifically. A possible limitation in this study is the use of bilateral surgeries. However, our
experience with bilateral surgeries in past studies has shown no differences in left vs. right
shoulder activity based on behavioral observations.

Two additional limitations apply to our study. First, although sustained release of TGF-β3 from
the HBDS was demonstrated in vitro, the in vivo release kinetics are unknown and likely differ
from that of the in vitro environment in absolute terms. Second, the mechanism behind the
improved mechanical properties we observed in the TGF-β3-treated tendons remains unknown.
Improvements in the biomechanics of the tissue may have resulted from differences in matrix
production (e.g., collagen III : collagen I ratio), collagen crosslinking, collagen orientation,
growth factor expression, cell migration, and/or cell recruitment.
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In this study we demonstrated that TGF-β3 can be delivered at a sustained rate using a fibrin
matrix containing a heparin-based delivery system and that use of this delivery system in vivo
enhances tendon-to-bone healing in a rat model. Although TGF-β3 treatment led to improved
toughness relative to repairs that received the conventional treatment (i.e. surgical repair only),
the biomechanical properties of TGF-β3-treated tendons were still significantly inferior to those
of normal (i.e., uninjured) tendon-to-bone insertions.

Thus, while delivery of TGF-β3 for

enhanced tendon-to-bone healing holds promise, further studies are necessary to optimize the
delivery methods and the choice of biological factors for improved tendon-to-bone healing.
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